

GLUCOSE-6- PHOSPHATE DEHYDROGENASE DEFICIENCY

A 3-in-1 Medical Reference

A Bibliography and Dictionary
for Physicians, Patients,
and Genome Researchers

TO INTERNET REFERENCES

ICON Group
International, Inc.

GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY

A BIBLIOGRAPHY AND
DICTIONARY

FOR PHYSICIANS, PATIENTS,
AND GENOME RESEARCHERS



JAMES N. PARKER, M.D.
AND PHILIP M. PARKER, PH.D., EDITORS

ICON Health Publications
ICON Group International, Inc.
7404 Trade Street
San Diego, CA 92121 USA

Copyright ©2007 by ICON Group International, Inc.

Copyright ©2007 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher.

Printed in the United States of America.

Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1

Publisher, Health Care: Philip Parker, Ph.D.
Editor(s): James Parker, M.D., Philip Parker, Ph.D.

Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments.

Cataloging-in-Publication Data

Parker, James N., 1961-
Parker, Philip M., 1960-

Glucose-6-Phosphate Dehydrogenase Deficiency: A Bibliography and Dictionary for Physicians, Patients, and Genome Researchers/ James N. Parker and Philip M. Parker, editors

p. cm.

Includes bibliographical references, glossary, and index.

ISBN: 0-497-11222-1

1. Glucose-6-Phosphate Dehydrogenase Deficiency-Popular works.I. Title.

Disclaimer

This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services.

References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.

Copyright Notice

If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail: iconedit@san.rr.com). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International, Inc. **The disclaimer above must accompany all reproductions, in whole or in part, of this book.**

Acknowledgements

The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on glucose-6-phosphate dehydrogenase deficiency. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.

About the Editors

James N. Parker, M.D.

Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications.

Philip M. Parker, Ph.D.

Philip M. Parker is the Chaired Professor of Management Science at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.

About ICON Health Publications

To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes&Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts:

ICON Group International, Inc.
7404 Trade Street
San Diego, CA 92121 USA
Fax: 858-635-9414
Web site: www.icongrouponline.com/health

Table of Contents

FORWARD	1
CHAPTER 1. STUDIES ON GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY	3
<i>Overview</i>	3
<i>Genetics Home Reference</i>	3
<i>What Is Glucose-6-Phosphate Dehydrogenase Deficiency?</i>	3
<i>How Common Is Glucose-6-Phosphate Dehydrogenase Deficiency?</i>	4
<i>What Genes Are Related to Glucose-6-Phosphate Dehydrogenase Deficiency?</i>	4
<i>How Do People Inherit Glucose-6-Phosphate Dehydrogenase Deficiency?</i>	5
<i>Where Can I Find Additional Information about Glucose-6-Phosphate Dehydrogenase Deficiency?</i>	5
<i>References</i>	6
<i>What Is the Official Name of the G6PD Gene?</i>	7
<i>What Is the Normal Function of the G6PD Gene?</i>	7
<i>What Conditions Are Related to the G6PD Gene?</i>	8
<i>Where Is the G6PD Gene Located?</i>	8
<i>References</i>	8
<i>Federally Funded Research on Glucose-6-Phosphate Dehydrogenase Deficiency</i>	9
<i>The National Library of Medicine: PubMed</i>	10
CHAPTER 2. ALTERNATIVE MEDICINE AND GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY	54
<i>Overview</i>	54
<i>National Center for Complementary and Alternative Medicine</i>	54
<i>Additional Web Resources</i>	60
<i>General References</i>	60
CHAPTER 3. BOOKS ON GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY	61
<i>Overview</i>	61
<i>Book Summaries: Online Booksellers</i>	61
APPENDIX A. HELP ME UNDERSTAND GENETICS	64
<i>Overview</i>	64
<i>The Basics: Genes and How They Work</i>	64
<i>Genetic Mutations and Health</i>	75
<i>Inheriting Genetic Conditions</i>	81
<i>Genetic Consultation</i>	89
<i>Genetic Testing</i>	91
<i>Gene Therapy</i>	97
<i>The Human Genome Project and Genomic Research</i>	100
APPENDIX B. PHYSICIAN RESOURCES	103
<i>Overview</i>	103
<i>NIH Guidelines</i>	103
<i>NIH Databases</i>	104
<i>Other Commercial Databases</i>	107
APPENDIX C. PATIENT RESOURCES	108
<i>Overview</i>	108
<i>Patient Guideline Sources</i>	108
<i>Finding Associations</i>	110
<i>Resources for Patients and Families</i>	111
ONLINE GLOSSARIES	113
<i>Online Dictionary Directories</i>	115
GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY DICTIONARY	116

INDEX **152**

FORWARD

In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."¹ Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with glucose-6-phosphate dehydrogenase deficiency is indexed in search engines, such as **www.google.com** or others, a non-systematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about glucose-6-phosphate dehydrogenase deficiency, using the most advanced research tools available and spending the least amount of time doing so.

In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to glucose-6-phosphate dehydrogenase deficiency, from the essentials to the most advanced areas of research. Special attention has been paid to present the genetic basis and pattern of inheritance of glucose-6-phosphate dehydrogenase deficiency. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on glucose-6-phosphate dehydrogenase deficiency. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. **While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to glucose-6-phosphate dehydrogenase deficiency, these are noted in the text.**

E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. **NOTE:** At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet.

For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. We hope these resources will prove useful to the widest possible audience seeking information on glucose-6-phosphate dehydrogenase deficiency.

The Editors

¹ From the NIH, National Cancer Institute (NCI): <http://www.cancer.gov/>.

CHAPTER 1. STUDIES ON GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY

Overview

In this chapter, we will show you how to locate peer-reviewed references and studies on glucose-6-phosphate dehydrogenase deficiency. For those interested in basic information about glucose-6-phosphate dehydrogenase deficiency, we begin with a condition summary published by the National Library of Medicine.

Genetics Home Reference

Genetics Home Reference (GHR) is the National Library of Medicine's Web site for consumer information about genetic conditions and the genes or chromosomes responsible for those conditions. Here you can find a condition summary on glucose-6-phosphate dehydrogenase deficiency that describes the major features of the condition, provides information about the condition's genetic basis, and explains its pattern of inheritance. In addition, a summary of the gene or chromosome related to glucose-6-phosphate dehydrogenase deficiency is provided.²

The Genetics Home Reference has recently published the following summary for glucose-6-phosphate dehydrogenase deficiency:

What Is Glucose-6-Phosphate Dehydrogenase Deficiency?³

Glucose-6-phosphate dehydrogenase deficiency is a genetic disorder that occurs most often in males. This condition mainly affects red blood cells, which carry oxygen from the lungs to tissues throughout the body. In affected individuals, a defect in an enzyme called glucose-6-phosphate dehydrogenase causes red blood cells to break down prematurely. This destruction of red blood cells is called hemolysis.

² This section has been adapted from the National Library of Medicine: <http://ghr.nlm.nih.gov/>.

³ Adapted from the Genetics Home Reference of the National Library of Medicine: <http://ghr.nlm.nih.gov/condition=glucose6phosphatedehydrogenasedeficiency>.

The most common medical problem associated with glucose-6-phosphate dehydrogenase deficiency is hemolytic anemia, which occurs when red blood cells are destroyed faster than the body can replace them. This type of anemia leads to paleness, yellowing of the skin and whites of the eyes (jaundice), dark urine, fatigue, shortness of breath, and a rapid heart rate. In people with glucose-6-dehydrogenase deficiency, hemolytic anemia is most often triggered by bacterial or viral infections or by certain drugs (such as some antibiotics and medications used to treat malaria). Hemolytic anemia can also occur after eating fava beans or inhaling pollen from fava plants (a reaction called favism).

Glucose-6-dehydrogenase deficiency is also a significant cause of mild to severe jaundice in newborns. Many people with this disorder, however, never experience any signs or symptoms.

How Common Is Glucose-6-Phosphate Dehydrogenase Deficiency?

An estimated 400 million people worldwide have glucose-6-phosphate dehydrogenase deficiency. This condition occurs most frequently in certain parts of Africa, Asia, and the Mediterranean. It affects about 1 in 10 African-American males in the United States.

What Genes Are Related to Glucose-6-Phosphate Dehydrogenase Deficiency?

Mutations in the **G6PD** (<http://ghr.nlm.nih.gov/gene=g6pd>) gene cause glucose-6-phosphate dehydrogenase deficiency.

The G6PD gene provides instructions for making an enzyme called glucose-6-phosphate dehydrogenase. This enzyme is involved in the normal processing of carbohydrates. It also protects red blood cells from the effects of potentially harmful molecules called reactive oxygen species. Reactive oxygen species are byproducts of normal cellular functions. Chemical reactions involving glucose-6-phosphate dehydrogenase produce compounds that prevent reactive oxygen species from building up to toxic levels within red blood cells.

If mutations in the G6PD gene reduce the amount of glucose-6-phosphate dehydrogenase or alter its structure, this enzyme can no longer play its protective role. As a result, reactive oxygen species can accumulate and damage red blood cells. Factors such as infections, certain drugs, or ingesting fava beans can increase the levels of reactive oxygen species, causing red blood cells to be destroyed faster than the body can replace them. A reduction in the amount of red blood cells causes the signs and symptoms of hemolytic anemia.

Researchers believe that carriers of a G6PD mutation may be partially protected against malaria, an infectious disease carried by a certain type of mosquito. A reduction in the amount of functional glucose-6-dehydrogenase appears to make it more difficult for this parasite to invade red blood cells. Glucose-6-phosphate dehydrogenase deficiency occurs most frequently in areas of the world where malaria is common.

How Do People Inherit Glucose-6-Phosphate Dehydrogenase Deficiency?

This condition is inherited in an X-linked recessive pattern. A condition is considered X-linked if the mutated gene that causes the disorder is located on the X chromosome, one of the two sex chromosomes. In males (who have only one X chromosome), one altered copy of the gene in each cell is sufficient to cause the condition. In females (who have two X chromosomes), a mutation must be present in both copies of the gene to cause the disorder. Males are affected by X-linked recessive disorders much more frequently than females. A striking characteristic of X-linked inheritance is that fathers cannot pass X-linked traits to their sons.

Where Can I Find Additional Information about Glucose-6-Phosphate Dehydrogenase Deficiency?

You may find the following resources about glucose-6-phosphate dehydrogenase deficiency helpful. These materials are written for the general public.

MedlinePlus - Health Information

- Encyclopedia: Glucose-6-phosphate dehydrogenase deficiency:
<http://www.nlm.nih.gov/medlineplus/ency/article/000528.htm>
- Encyclopedia: Glucose-6-phosphate dehydrogenase test:
<http://www.nlm.nih.gov/medlineplus/ency/article/003671.htm>
- Encyclopedia: Hemolytic anemia:
<http://www.nlm.nih.gov/medlineplus/ency/article/000571.htm>
- Encyclopedia: Newborn jaundice:
<http://www.nlm.nih.gov/medlineplus/ency/article/001559.htm>
- Health Topic: Anemia:
<http://www.nlm.nih.gov/medlineplus/anemia.html>
- Health Topic: Metabolic Disorders:
<http://www.nlm.nih.gov/medlineplus/metabolicdisorders.html>
- Health Topic: Newborn Screening:
<http://www.nlm.nih.gov/medlineplus/newbornscreening.html>

Educational Resources - Information Pages

- Ask the Geneticist: Glucose-6-phosphate dehydrogenase deficiency:
http://www.askthegen.org/question.php?question_id=534
- Great Ormond Street Hospital for Children:
<http://www.gosh.nhs.uk/factsheets/families/F040269/index.html>
- KidsHealth from the Nemours Foundation:
<http://kidshealth.org/parent/general/aches/g6pd.html>

- Madisons Foundation:
<http://www.madisonsfoundation.org/content/3/1/display.asp?did=243>
- New York Online Access to Health (NOAH):
<http://www.noah-health.org/en/blood/anemia/types/g6pd.html>
- Orphanet:
http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=GB&Expert=362
- Save Babies Through Screening Foundation, Inc.:
<http://www.savebabies.org/diseasedescriptions/g6pd.php>
- University of Virginia Health System:
http://www.healthsystem.virginia.edu/uvahealth/adult_blood/glucose.cfm

Patient Support - for Patients and Families

- Children Living With Inherited Metabolic Diseases (CLIMB) (UK):
<http://www.climb.org.uk/>
- National Organization for Rare Disorders:
http://www.rarediseases.org/search/rdbdetail_abstract.html?disname=Glucose-6-Phosphate+Dehydrogenase+Deficiency
- Resource list from the University of Kansas Medical Center:
<http://www.kumc.edu/gec/support/metaboli.html>

Professional Resources

You may also be interested in these resources, which are designed for healthcare professionals and researchers.

- Gene Tests - DNA tests ordered by healthcare professionals:
<http://www.genetests.org/query?testid=2339>
- ClinicalTrials.gov - Linking patients to medical research:
<http://clinicaltrials.gov/search/condition=%22glucose-6-phosphate+dehydrogenase+deficiency%22?recruiting=false>
- PubMed - Recent literature:
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=PubMed&term=\(Glucosephosphate+Dehydrogenase+Deficiency\[MAJR\]\)+AND+\(glucose-6-phosphate+dehydrogenase+deficiency\[TIAB\]\)+AND+english\[la\]+AND+human\[mh\]&orig_db=PubMed&filters=ON&pmfilter_EDatLimit=1440+Days](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=PubMed&term=(Glucosephosphate+Dehydrogenase+Deficiency[MAJR])+AND+(glucose-6-phosphate+dehydrogenase+deficiency[TIAB])+AND+english[la]+AND+human[mh]&orig_db=PubMed&filters=ON&pmfilter_EDatLimit=1440+Days)
- OMIM - Genetic disorder catalog:
<http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=305900>

References

These sources were used to develop the Genetics Home Reference condition summary on glucose-6-phosphate dehydrogenase deficiency.

- Beutler E. G6PD deficiency. *Blood*. 1994 Dec 1;84(11):3613-36. Review. No abstract available. PubMed citation

- Dhaliwal G, Cornett PA, Tierney LM Jr. Hemolytic anemia. *Am Fam Physician*. 2004 Jun 1;69(11):2599-606. Review. PubMed citation
- Frank JE. Diagnosis and management of G6PD deficiency. *Am Fam Physician*. 2005 Oct 1;72(7):1277-82. Review. PubMed citation
- Kaplan M, Hammerman C. Glucose-6-phosphate dehydrogenase deficiency: a potential source of severe neonatal hyperbilirubinaemia and kernicterus. *Semin Neonatol*. 2002 Apr;7(2):121-8. Review. PubMed citation
- Mehta A, Mason PJ, Vulliamy TJ. Glucose-6-phosphate dehydrogenase deficiency. *Baillieres Best Pract Res Clin Haematol*. 2000 Mar;13(1):21-38. Review. PubMed citation
- Ruwende C, Hill A. Glucose-6-phosphate dehydrogenase deficiency and malaria. *J Mol Med*. 1998 Jul;76(8):581-8. Review. PubMed citation
- Scriver, Charles R; *The metabolic & molecular bases of inherited disease*; 8th ed.; New York : McGraw-Hill, c2001. p4517-4540. NLM Catalog
- Verrelli BC, McDonald JH, Argyropoulos G, Destro-Bisol G, Froment A, Drousiotou A, Lefranc G, Helal AN, Loiselet J, Tishkoff SA. Evidence for balancing selection from nucleotide sequence analyses of human G6PD. *Am J Hum Genet*. 2002 Nov;71(5):1112-28. Epub 2002 Oct 11. PubMed citation

A summary of the gene related to glucose-6-phosphate dehydrogenase deficiency is provided below:

What Is the Official Name of the G6PD Gene?⁴

The official name of this gene is “glucose-6-phosphate dehydrogenase.”

G6PD is the gene's official symbol. The G6PD gene is also known by other names, listed below.

What Is the Normal Function of the G6PD Gene?

The G6PD gene provides instructions for making an enzyme called glucose-6-phosphate dehydrogenase. This enzyme, which is active in virtually all types of cells, is involved in the normal processing of carbohydrates. It plays a critical role in red blood cells, which carry oxygen from the lungs to tissues throughout the body. This enzyme helps protect red blood cells from damage and premature destruction.

Glucose-6-dehydrogenase is responsible for the first step in a chemical pathway that converts glucose (a type of sugar found in most carbohydrates) to ribose-5-phosphate. Ribose-5-phosphate is an important component of nucleotides, which are the building blocks of DNA and its chemical cousin RNA. This chemical reaction produces a molecule called NADPH, which plays a role in protecting cells from potentially harmful molecules called reactive oxygen species. These molecules are byproducts of normal cellular functions.

⁴ Adapted from the Genetics Home Reference of the National Library of Medicine:
<http://ghr.nlm.nih.gov/gene=g6pd;jsessionid=51F75F8CB8BA8D1489740BBCD911AB24>.

Reactions involving NADPH produce compounds that prevent reactive oxygen species from building up to toxic levels within cells. The production of NADPH by glucose-6-dehydrogenase is essential in red blood cells, which are particularly susceptible to damage by reactive oxygen species because they lack other NADPH-producing enzymes.

What Conditions Are Related to the G6PD Gene?


Glucose-6-Phosphate Dehydrogenase Deficiency - Caused by Mutations in the G6PD Gene

More than 140 mutations that cause glucose-6-phosphate dehydrogenase deficiency have been identified in the G6PD gene. Almost all of these mutations lead to changes in single building blocks (amino acids) that make up the glucose-6-phosphate dehydrogenase enzyme. These changes disrupt the normal structure and function of the enzyme or reduce the amount of the enzyme in cells.

Where Is the G6PD Gene Located?

Cytogenetic Location: Xq28

Molecular Location on the X chromosome: base pairs 153,412,799 to 153,428,662



The G6PD gene is located on the long (q) arm of the X chromosome at position 28.

More precisely, the G6PD gene is located from base pair 153,412,799 to base pair 153,428,662 on the X chromosome.

References

These sources were used to develop the Genetics Home Reference gene summary on the G6PD gene.

- Beutler E. G6PD deficiency. *Blood*. 1994 Dec 1;84(11):3613-36. Review. No abstract available. PubMed citation
- Chapter 20.5: Glucose 6-Phosphate Dehydrogenase Plays a Key Role in Protection Against Reactive Oxygen Species (*Biochemistry*, fifth edition, 2002)

- Efferth T, Schwarzl SM, Smith J, Osieka R. Role of glucose-6-phosphate dehydrogenase for oxidative stress and apoptosis. *Cell Death Differ.* 2006 Mar;13(3):527-8; author reply 529-30. No abstract available. PubMed citation
- Kwok CJ, Martin AC, Au SW, Lam VM. G6PDdb, an integrated database of glucose-6-phosphate dehydrogenase (G6PD) mutations. *Hum Mutat.* 2002 Mar;19(3):217-24. PubMed citation
- Mehta A, Mason PJ, Vulliamy TJ. Glucose-6-phosphate dehydrogenase deficiency. *Baillieres Best Pract Res Clin Haematol.* 2000 Mar;13(1):21-38. Review. PubMed citation
- Scriver, Charles R; *The metabolic & molecular bases of inherited disease*; 8th ed.; New York : McGraw-Hill, c2001. p4517-4530. NLM Catalog
- Verrelli BC, McDonald JH, Argyropoulos G, Destro-Bisol G, Froment A, Drousiotou A, Lefranc G, Helal AN, Loiselet J, Tishkoff SA. Evidence for balancing selection from nucleotide sequence analyses of human G6PD. *Am J Hum Genet.* 2002 Nov;71(5):1112-28. Epub 2002 Oct 11. PubMed citation

Federally Funded Research on Glucose-6-Phosphate Dehydrogenase Deficiency

The U.S. Government supports a variety of research studies relating to glucose-6-phosphate dehydrogenase deficiency. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.⁵

NTIS (National Technical Information Service)

The NTIS (www.ntis.gov), a service of the U.S. Department of Commerce, has published the following information on sponsored studies related to glucose-6-phosphate dehydrogenase deficiency:

- **"Dissimilar Deficiency of glucose-6-phosphate dehydrogenase (G-6-PD) among the AFARS and the Somalis of Djibouti,"** published in 1991.

Sponsored by: Naval Medical Research Unit No. 3, FPO New York 09527.

Written by: W. Sidrak, E. Fox, D. Polycarpe, J. G. Olson and S. O. Shakib.

Abstract: In order to determine the prevalence of deficient activity of the enzyme glucose-6-phosphate dehydrogenase (G-6-PD) among the inhabitants of the east African Republic of Djibouti, we analyzed by the methemoglobin reduction test the blood of 170 Djiboutian males, 81 Afars and 89 Somalis. Eight subjects were found to be G-6-PD deficient, 1 Afar and 7 Somalis (1,2% versus 8%; $P = 0.02$). We conclude that in Djibouti, health care providers should consider the presence of potential G-6-PD deficiency in their patients, especially in males of the Somali ethnic group. Indeed, many medications are contraindicated in the G-6-PD deficient subjects, and primaquine and pyrimethamine-sulfadoxine (FANSIDAR) have to be considered dangerous anti-

⁵ Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).

malarial drugs for Somali males as long as their level of G-6-PD activity has not been determined. Since in Djibouti many acute falciparum cases are presenting with severe icteric anaemia, we hypothesize that some of these hemolytic anaemias might not be caused by the parasitic infection alone, but that some malaria patients might become aggravated through the administration of hemolytic drugs in case they are G-6-PD deficient. Finally, we propose that our study should be expanded to include the systematic determination of the variants of the enzyme in all subjects found G-6-PD deficient, since the clinical manifestations of G-6-PD deficiency are directly related to the type of variant present. Malarial drugs; G-6-PD deficiency; Drug contraindication; Patients; Djibouti.

The National Library of Medicine: PubMed

One of the quickest and most comprehensive ways to find academic studies in both English and other languages is to use PubMed, maintained by the National Library of Medicine.⁶ The advantage of PubMed over previously mentioned sources is that it covers a greater number of domestic and foreign references. It is also free to use. If the publisher has a Web site that offers full text of its journals, PubMed will provide links to that site, as well as to sites offering other related data. User registration, a subscription fee, or some other type of fee may be required to access the full text of articles in some journals.

To generate your own bibliography of studies dealing with glucose-6-phosphate dehydrogenase deficiency, simply go to <http://www.ncbi.nlm.nih.gov/pubmed>. Type **glucose-6-phosphate dehydrogenase deficiency** (or synonyms) into the search box, and click **Go**. The following is the type of output you can expect from PubMed for glucose-6-phosphate dehydrogenase deficiency (hyperlinks lead to article summaries):

- **A correlative study of A B O blood groups, sickle cell haemoglobin and glucose-6-phosphate dehydrogenase deficiency as genetic marker in Mahar community of rural population of Wardha District in Maharashtra.**
Author(s): Khan N, Gupta SG, Sharma SM, Ingole NS, Moghe KV, Agrawal RV.
Source: Indian J Pathol Microbiol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=3869575&query_hl=24&itool=pubmed_docsum
- **Acute episodic hemolysis in the African black rhinoceros as an analogue of human glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Paglia DE.
Source: American Journal of Hematology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8416295&query_hl=24&itool=pubmed_docsum

⁶ PubMed was developed by the National Center for Biotechnology Information (NCBI) at the National Library of Medicine (NLM) at the National Institutes of Health (NIH). The PubMed database was developed in conjunction with publishers of biomedical literature as a search tool for accessing literature citations and linking to full-text journal articles at Web sites of participating publishers. Publishers that participate in PubMed supply NLM with their citations electronically prior to or at the time of publication.

- **Acute hemolytic anemia induced by a pyrazolonic drug in a child with glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Sansone G, Reali S, Sansone R, Allegranza F.
 Source: Acta Haematologica.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6438997&query_hl=24&itool=pubmed_docsum
- **Acute intravascular haemolysis in glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Sarkar S, Prakash D, Marwaha RK, Garewal G, Kumar L, Singhi S, Walia BN.
 Source: Annals of Tropical Paediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7506889&query_hl=24&itool=pubmed_docsum
- **Acute viral hepatitis with severe hyperbilirubinemia and massive hemolysis in glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Mert A, Tabak F, Ozturk R, Aktuglu Y, Ozaras R, Kanat M.
 Source: Journal of Clinical Gastroenterology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11319332&query_hl=24&itool=pubmed_docsum
- **Acute viral hepatitis, glucose-6-phosphate dehydrogenase deficiency and prolonged acute renal failure: a case report.**
 Author(s): al-Rasheed SA, al-Mugeiren MM, al-Salloum AA, al-Fawaz IM, al-Sohaibani MO.
 Source: Annals of Tropical Paediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8534046&query_hl=24&itool=pubmed_docsum
- **Alternative DNA-based newborn screening for glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Lin Z, Fontaine JM, Freer DE, Naylor EW.
 Source: Molecular Genetics and Metabolism.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15996498&query_hl=24&itool=pubmed_docsum
- **An improved, simple screening method for detection of glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Tantular IS, Kawamoto F.
 Source: Tropical Medicine & International Health : Tm & Ih.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12791063&query_hl=24&itool=pubmed_docsum
- **An unusual distribution of glucose-6-phosphate dehydrogenase deficiency of south Indian newborn population.**
 Author(s): Ramadevi R, Savithri HS, Devi AR, Bittles AH, Rao NA.
 Source: Indian J Biochem Biophys.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8002021&query_hl=24&itool=pubmed_docsum

- **An update on the prevalence of glucose-6-phosphate dehydrogenase deficiency and neonatal jaundice in Tehran neonates.**
Author(s): Abolghasemi H, Mehrani H, Amid A.
Source: Clinical Biochemistry.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=14972648&query_hl=24&itool=pubmed_docsum
- **Analysis of common mutations and associated haplotypes in Chinese patients with glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Li P, Thompson JN, Wang X, Song L.
Source: Biochem Mol Biol Int.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9891846&query_hl=24&itool=pubmed_docsum
- **Aortic valve replacement for a patient with glucose-6-phosphate dehydrogenase deficiency and autoimmune hemolytic anemia.**
Author(s): Tas S, Donmez AA, Kirali K, Alp MH, Yakut C.
Source: Journal of Cardiac Surgery.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15985145&query_hl=24&itool=pubmed_docsum
- **Apert syndrome with glucose-6-phosphate dehydrogenase deficiency: a case report.**
Author(s): Tosun G, Sener Y.
Source: International Journal of Paediatric Dentistry / the British Paedodontic Society [and] the International Association of Dentistry for Children.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16643545&query_hl=24&itool=pubmed_docsum
- **Aspects of sickle cell gene in Saudi Arabia--interaction with glucose-6-phosphate dehydrogenase deficiency.**
Author(s): el-Hazmi MA, Warsy AS.
Source: Human Genetics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6510911&query_hl=24&itool=pubmed_docsum
- **Aspirin and glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Colonna P.
Source: British Medical Journal (Clinical Research Ed.).
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6794814&query_hl=24&itool=pubmed_docsum
- **Association of glucose-6-phosphate dehydrogenase deficiency and X-linked chronic granulomatous disease in a child with anemia and recurrent infections.**
Author(s): Agudelo-Florez P, Costa-Carvalho BT, Lopez JA, Redher J, Newburger PE, Olalla-Saad ST, Condino-Neto A.
Source: American Journal of Hematology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=14978696&query_hl=24&itool=pubmed_docsum

- **Association of glucose-6-phosphate dehydrogenase deficiency with diabetes mellitus.**
 Author(s): Saeed TK, Hamamy HA, Alwan AA.
 Source: Diabetic Medicine : a Journal of the British Diabetic Association.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2952393&query_hl=24&itool=pubmed_docsum
- **At least five polymorphic mutants account for the prevalence of glucose-6-phosphate dehydrogenase deficiency in Algeria.**
 Author(s): Nafa K, Reghis A, Osmani N, Baghli L, Ait-Abbes H, Benabadji M, Kaplan JC, Vulliamy T, Luzzatto L.
 Source: Human Genetics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7959686&query_hl=24&itool=pubmed_docsum
- **Bacterial infections in children with glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Mallouh AA, Abu-Osba YK.
 Source: The Journal of Pediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=3681550&query_hl=24&itool=pubmed_docsum
- **Bilateral pulmonary edema after endoscopic sympathectomy in a patient with glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Lan CJ, Luk HN, Wu CT, Chang WK, Tsou MY, Lui PW, Lee TY.
 Source: Acta Anaesthesiologica Scandinavica.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11152024&query_hl=24&itool=pubmed_docsum
- **Bimodal distribution of erythrocytes in heterozygotes for strong Mediterranean glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Sartori E, Panizon F, Zacchello F.
 Source: Journal of Medical Genetics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=5911829&query_hl=24&itool=pubmed_docsum
- **Biochemical and cytochemical evaluation of heterozygote individuals with glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Gurbuz N, Aksu TA, Van Noorden CJ.
 Source: Acta Histochemica.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16139339&query_hl=24&itool=pubmed_docsum
- **Biochemical mechanisms of glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Morelli A, Benatti U, Gaetani GF, De Flora A.
 Source: Proceedings of the National Academy of Sciences of the United States of America.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=273924&query_hl=24&itool=pubmed_docsum

- **Biogenetical studies of Nagas: glucose-6-phosphate dehydrogenase deficiency in Angami Nagas.**
Author(s): Seth PK, Seth S.
Source: Human Biology; an International Record of Research.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=5148008&query_hl=24&itool=pubmed_docsum
- **Blood pressure and other cardiovascular disease risk factors in black adults with sickle cell trait or glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Nwankwo MU, Bunker CH, Ukoli FA, Omene JA, Freeman DT, Vergis EN, Yeh LL, Kuller LH.
Source: Genetic Epidemiology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2369999&query_hl=24&itool=pubmed_docsum
- **Calcium activated neutral protease & calcium ATPase in glucose-6-phosphate dehydrogenase deficiency hemizygotes.**
Author(s): Devi CV, Anandaraj MP.
Source: The Indian Journal of Medical Research.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7883283&query_hl=24&itool=pubmed_docsum
- **Can glucose-6-phosphate dehydrogenase deficiency be correlated with ABO blood type?**
Author(s): Lesho EP.
Source: Military Medicine.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7870327&query_hl=24&itool=pubmed_docsum
- **Can severe neonatal jaundice be prevented by neonatal screening for glucose-6-phosphate dehydrogenase deficiency?--a review of evidence.**
Author(s): Chuu WM, Lin DT, Lin KH, Chen BW, Chen RL, Lin KS.
Source: Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8942026&query_hl=24&itool=pubmed_docsum
- **Cataracts in glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Assaf AA, Tabbara KF, el-Hazmi MA.
Source: Ophthalmic Paediatr Genet.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8233357&query_hl=24&itool=pubmed_docsum
- **Chronic granulomatous disease with leukocytic glucose-6-phosphate dehydrogenase deficiency in a 28-month-old girl.**
Author(s): Corberand J, De Larrard B, Vergnes H, Carriere JP.
Source: American Journal of Clinical Pathology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=696690&query_hl=24&itool=pubmed_docsum

- **Clinical implications of sickle-cell trait and glucose-6-phosphate dehydrogenase deficiency in hospitalized black male patients.**
 Author(s): Heller P, Best WR, Nelson RB, Becktel J.
 Source: The New England Journal of Medicine.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=431593&query_hl=24&itool=pubmed_docsum
- **Clinical significance of glucose-6-phosphate dehydrogenase deficiency in Nigerian patients with sickle cell disease.**
 Author(s): Ahmed SG, Ibrahim UA.
 Source: Niger Postgrad Med J.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12690675&query_hl=24&itool=pubmed_docsum
- **Co-evolution of glucose-6-phosphate dehydrogenase deficiency and quinine taste sensitivity.**
 Author(s): Greene LS, McMahon L, DiIorio J.
 Source: Annals of Human Biology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8215232&query_hl=24&itool=pubmed_docsum
- **Coinheritance of variant UDP-glucuronosyl transferase 1A1 gene and glucose-6-phosphate dehydrogenase deficiency in adults with hyperbilirubinemia.**
 Author(s): Huang MJ, Yang YC, Yang SS, Lin MS, Chen ES, Huang CS.
 Source: Pharmacogenetics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12439228&query_hl=24&itool=pubmed_docsum
- **Combination of ABO blood group incompatibility and glucose-6-phosphate dehydrogenase deficiency: effect on hemolysis and neonatal hyperbilirubinemia.**
 Author(s): Kaplan M, Vreman HJ, Hammerman C, Leiter C, Rudensky B, MacDonald MG, Stevenson DK.
 Source: Acta Paediatrica (Oslo, Norway : 1992).
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9628306&query_hl=24&itool=pubmed_docsum
- **Combined glucose phosphate isomerase and glucose-6-phosphate dehydrogenase deficiency of erythrocytes.**
 Author(s): Steiman I, Kaufman S, Zaidman JL, Leiba H.
 Source: Isr J Med Sci.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=750548&query_hl=24&itool=pubmed_docsum
- **Comparison between the chromate inhibition test and a cytochemical method for the determination of glucose-6-phosphate dehydrogenase deficiency in erythrocytes.**
 Author(s): Jonges GN, Hagen H, Van Noorden CJ, Weening RS, Roos D.
 Source: Clinica Chimica Acta; International Journal of Clinical Chemistry.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2472236&query_hl=24&itool=pubmed_docsum

- **Comparison of commercial screening tests for glucose-6-phosphate dehydrogenase deficiency in the neonatal period.**
Author(s): Kaplan M, Leiter C, Hammerman C, Rudensky B.
Source: Clinical Chemistry.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9216462&query_hl=24&itool=pubmed_docsum
- **Conjugated bilirubin in neonates with glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Kaplan M, Rubaltelli FF, Hammerman C, Vilei MT, Leiter C, Abramov A, Muraca M.
Source: The Journal of Pediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8627445&query_hl=24&itool=pubmed_docsum
- **Control of glucose-6-phosphate dehydrogenase deficiency on the formation of mutagenic and carcinogenic metabolites derived from benzo(a)pyrene.**
Author(s): Pirisi L, Garcea R, Pascale R, Ruggiu ME, Feo F.
Source: Toxicologic Pathology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=3576073&query_hl=24&itool=pubmed_docsum
- **Cortisol levels in glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Saad MJ, Monte-Alegre S, Saad ST.
Source: Hormone Research.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1655604&query_hl=24&itool=pubmed_docsum
- **Co-trimoxazole in the treatment of typhoid fever in children with glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Lexomboon U, Unkurapiana N.
Source: Southeast Asian J Trop Med Public Health.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=751223&query_hl=24&itool=pubmed_docsum
- **Cytochemical determination of heterozygous glucose-6-phosphate dehydrogenase deficiency in erythrocytes.**
Author(s): Vogels IM, Van Noorden CJ, Wolf BH, Saelman DE, Tromp A, Schutgens RB, Weening RS.
Source: British Journal of Haematology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=3521715&query_hl=24&itool=pubmed_docsum
- **Cytomegalovirus infection and aplastic crisis in glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Garcia S, Linares M, Colomina P, Miguel A, Miguel A.
Source: Lancet.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2885558&query_hl=24&itool=pubmed_docsum

- **Cytomegalovirus infection and hemolytic anemia due to glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Rosenbloom BE, Rosenfelt FP, Ullman H, Weinstein IM.
 Source: The Mount Sinai Journal of Medicine, New York.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2989679&query_hl=24&itool=pubmed_docsum
- **Detection of glucose-6-phosphate dehydrogenase deficiency in erythrocytes: a spectrophotometric assay and a fluorescent spot test compared with a cytochemical method.**
 Author(s): Wolf BH, Weening RS, Schutgens RB, van Noorden CJ, Vogels IM, Nagelkerke NJ.
 Source: Clinica Chimica Acta; International Journal of Clinical Chemistry.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=3677412&query_hl=24&itool=pubmed_docsum
- **Detection of glucose-6-phosphate dehydrogenase deficiency in the newborn using blood specimens dried on filter paper.**
 Author(s): Szeinberg A, Peled N.
 Source: Isr J Med Sci.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=4775116&query_hl=24&itool=pubmed_docsum
- **D-Glucuric acid excretion in newborns with severe jaundice of unknown etiology and due to glucose-6-phosphate dehydrogenase deficiency in Greece.**
 Author(s): Malaka-Zafiriou K, Tsiures J, Cassimos C.
 Source: Helv Paediatr Acta.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=807541&query_hl=24&itool=pubmed_docsum
- **Diabetic ketoacidosis does not precipitate haemolysis in patients with the Mediterranean variant of glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Shalev O, Wollner A, Menczel J.
 Source: British Medical Journal (Clinical Research Ed.).
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6419846&query_hl=24&itool=pubmed_docsum
- **Diagnosis of erythrocyte glucose-6-phosphate dehydrogenase deficiency in the negro male despite hemolytic crisis.**
 Author(s): Herz F, Kaplan E, Scheye ES.
 Source: Blood.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=5412679&query_hl=24&itool=pubmed_docsum

- **Differentiation of hair growth cycle from scalp hair roots for the diagnosis of glucose-6-phosphate dehydrogenase deficiency in neonates.**
Author(s): Lin SY, Niu DM, Li MJ, Tu CP, Lin HL.
Source: Journal of Inherited Metabolic Disease.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11117431&query_hl=24&itool=pubmed_docsum
- **Disorders in the metabolism of erythrocytes in a case of congenital nonspherocytic hemolytic anemia with glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Koj A, Frendo J, Urasinski I.
Source: Acta Med Pol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=5918725&query_hl=24&itool=pubmed_docsum
- **Distribution of beta-thalassemia trait and erythrocyte glucose-6-phosphate dehydrogenase deficiency in the Markham River Valley of New Guinea.**
Author(s): Giles E, Curtain CC, Baumgarten A.
Source: American Journal of Physical Anthropology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6058057&query_hl=24&itool=pubmed_docsum
- **Diversity in expression of glucose-6-phosphate dehydrogenase deficiency in females.**
Author(s): Abdulrazzaq YM, Micallef R, Qureshi M, Dawodu A, Ahmed I, Khidr A, Bastaki SM, Al-Khayat A, Bayoumi RA.
Source: Clinical Genetics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10066026&query_hl=24&itool=pubmed_docsum
- **Do tribal communities show an inverse relationship between sickle cell disorders and glucose-6-phosphate dehydrogenase deficiency in malaria endemic areas of Central-Eastern India?**
Author(s): Balgir RS.
Source: Homo : Internationale Zeitschrift Fur Die Vergleichende Forschung Am Menschen.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16603161&query_hl=24&itool=pubmed_docsum
- **Does nimesulide induce haemolysis in glucose-6-phosphate dehydrogenase deficiency?**
Author(s): Srivatsa A, Bharti B, Singhi SC.
Source: Acta Paediatrica (Oslo, Norway : 1992).
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12839301&query_hl=24&itool=pubmed_docsum
- **Double heterozygosity for glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Chan TK, Lai MC.
Source: Journal of Medical Genetics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=5096537&query_hl=24&itool=pubmed_docsum

- **Drug induced acute haemolytic anaemia in glucose-6-phosphate dehydrogenase deficiency subjects.**
 Author(s): Rajkondawar VL, Modi TH, Mishra SN.
 Source: J Assoc Physicians India.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=5711919&query_hl=24&itool=pubmed_docsum
- **Drug-induced anemia associated with glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Meister F, Endsley L, Schmidt JD.
 Source: J Iowa Med Soc.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1194724&query_hl=24&itool=pubmed_docsum
- **Drug-induced haemolysis and renal failure in children with glucose-6-phosphate dehydrogenase deficiency in Afghanistan.**
 Author(s): Choudhry VP, Ghafary A, Zaher M, Qureshi MA, Fazel I, Ghani R.
 Source: Annals of Tropical Paediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1708959&query_hl=24&itool=pubmed_docsum
- **Drug-induced haemolysis in glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Chan TK, Todd D, Tso SC.
 Source: British Medical Journal.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=990860&query_hl=24&itool=pubmed_docsum
- **Effect of ascorbic acid on copper-induced oxidative changes in erythrocytes of individuals with a glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Calabrese EJ, Moore GS, McCarthy MS.
 Source: Bulletin of Environmental Contamination and Toxicology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6850118&query_hl=24&itool=pubmed_docsum
- **Effect of desferrioxamine B on hemolysis in glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Khalifa AS, el-Alfy MS, Mokhtar G, Fakeir AA, Khazbak MA, el-Baz F, el-Kholy M.
 Source: Acta Haematologica.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2554630&query_hl=24&itool=pubmed_docsum
- **Effect of desferrioxamine in acute haemolytic anaemia of glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): al-Rimawi HS, al-Sheyyab M, Batieha A, el-Shanti H, Abuekteish F.
 Source: Acta Haematologica.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10352334&query_hl=24&itool=pubmed_docsum

- **Effect of exercise on oxidative stress in individuals with glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Jamurtas AZ, Fatouros IG, Koukousias N, Manthou E, Tofas T, Yfanti C, Nikolaidis MG, Koutedakis Y.
 Source: In Vivo.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17203782&query_hl=24&itool=pubmed_docsum
- **Effect of glucose-6-phosphate dehydrogenase deficiency on neutrophil function.**
 Author(s): Ardati KO, Bajakian KM, Tabbara KS.
 Source: Acta Haematologica.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9158663&query_hl=24&itool=pubmed_docsum
- **Effect of glucose-6-phosphate dehydrogenase deficiency on reduced and oxidized glutathione and lipid peroxide levels in the blood of African-Americans.**
 Author(s): Jain SK, Palmer M.
 Source: Clinica Chimica Acta; International Journal of Clinical Chemistry.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8879848&query_hl=24&itool=pubmed_docsum
- **Effect of glucose-6-phosphate dehydrogenase deficiency on the benz(a)pyrene toxicity for in vitro cultured human skin fibroblasts.**
 Author(s): Pirisi L, Pascale R, Daino L, Frassetto S, La Spina V, Zanetti S, Gaspa L, Ledda GM, Garcea R, Feo F.
 Source: Res Commun Chem Pathol Pharmacol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6298917&query_hl=24&itool=pubmed_docsum
- **Effect of red blood cell glucose-6-phosphate dehydrogenase deficiency on patients with dengue hemorrhagic fever.**
 Author(s): Tanphaichitr VS, Chonlasin R, Suwanto L, Pung-Amritt P, Tachavanich K, Yogsan S, Viprakasit V.
 Source: J Med Assoc Thai.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12403228&query_hl=24&itool=pubmed_docsum
- **Effects of glucose-6-phosphate dehydrogenase deficiency upon sickle cell anaemia.**
 Author(s): al-Ali AK, Ahmed MA, al-Idrissi H, al-Sibai MH, al-Mutairy AR, al-Awami M.
 Source: Annals of Clinical Biochemistry.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2482687&query_hl=24&itool=pubmed_docsum
- **Effects of glucose-6-phosphate dehydrogenase deficiency upon sickle cell anemia.**
 Author(s): Steinberg MH, West MS, Gallagher D, Mentzer W.
 Source: Blood.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=3345344&query_hl=24&itool=pubmed_docsum

- Effects of variant UDP-glucuronosyltransferase 1A1 gene, glucose-6-phosphate dehydrogenase deficiency and thalassemia on cholelithiasis.**
 Author(s): Huang YY, Huang CS, Yang SS, Lin MS, Huang MJ, Huang CS.
 Source: World Journal of Gastroenterology : Wjg.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16237771&query_hl=24&itool=pubmed_docsum
- Enhanced erythrocyte apoptosis in sickle cell anemia, thalassemia and glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Lang KS, Roll B, Myssina S, Schittenhelm M, Scheel-Walter HG, Kanz L, Fritz J, Lang F, Huber SM, Wieder T.
 Source: Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12438773&query_hl=24&itool=pubmed_docsum
- Erythrocyte glucose-6-phosphate dehydrogenase deficiency: precautions for dental treatment.**
 Author(s): Taylor MH, Peterson DS.
 Source: J Pedod.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6215477&query_hl=24&itool=pubmed_docsum
- Erythrocyte glucose-6-phosphate dehydrogenase deficiency in Poland--a study on the 563 and 1311 mutations of the G6PD gene.**
 Author(s): Jablonska-Skwieciniska E, Zimowski JG, Klopocka J, Bisko M, Hoffman-Zacharska D, Zaremba J.
 Source: European Journal of Human Genetics : Ejhg.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9156317&query_hl=24&itool=pubmed_docsum
- Erythrocyte glutathione concentrations in diabetics with cataracts, with and without glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): el Fakhri M, Sheriff DS, Chandrasena L, Gupta JD, Rai ST, Qureshi MS.
 Source: Clinical Chemistry.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=3665056&query_hl=24&itool=pubmed_docsum
- Erythrocyte glutathione determination in the diagnosis of glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Bozzi A, Parisi M, Strom R.
 Source: Biochem Mol Biol Int.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8908366&query_hl=24&itool=pubmed_docsum

- **Erythrocyte membrane abnormalities in glucose-6-phosphate dehydrogenase deficiency of the Mediterranean and A-types.**
Author(s): Rice-Evans C, Rush J, Omorphos SC, Flynn DM.
Source: Febs Letters.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7319058&query_hl=24&itool=pubmed_docsum
- **Erythrocyte superoxide dismutase, catalase and glutathione peroxidase in glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Gerli GC, Beretta L, Bianchi M, Agostoni A, Gualandri V, Orsini GB.
Source: Scand J Haematol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7134887&query_hl=24&itool=pubmed_docsum
- **Erythrocytic glucose-6-phosphate dehydrogenase deficiency in the Bania community of Punjab.**
Author(s): Handa R, Singh N, Chander J.
Source: J Assoc Physicians India.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1634454&query_hl=24&itool=pubmed_docsum
- **Erythrocytic glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Wong HB.
Source: J Singapore Paediatr Soc.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6632811&query_hl=24&itool=pubmed_docsum
- **Failure of methylene blue treatment in toxic methemoglobinemia. Association with glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Rosen PJ, Johnson C, McGehee WG, Beutler E.
Source: Annals of Internal Medicine.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=5091568&query_hl=24&itool=pubmed_docsum
- **Fast hemoglobin and glucose-6-phosphate dehydrogenase deficiency as artefacts imputable to an anticoagulant added to the blood sample.**
Author(s): Schoos-Barbette S, Dodinval-Versie J, Husquinet H, Lambotte C.
Source: Clinica Chimica Acta; International Journal of Clinical Chemistry.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7296889&query_hl=24&itool=pubmed_docsum
- **Fatal hemolysis from mafenide treatment of burns in a patient with glucose-6-phosphate dehydrogenase deficiency. Case report.**
Author(s): Marsicano AR Jr, Hutton JJ, Bryant WM.
Source: Plastic and Reconstructive Surgery.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=4722683&query_hl=24&itool=pubmed_docsum

- **Favism in the African type of glucose-6-phosphate dehydrogenase deficiency (A-).**
 Author(s): Galiano S, Gaetani GF, Barabino A, Cottafava F, Zeitlin H, Town M, Luzzatto L.
 Source: Bmj (Clinical Research Ed.).
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2106932&query_hl=24&itool=pubmed_docsum
- **Favism: looking for an autosomal gene associated with glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Mareni C, Repetto L, Forteleoni G, Meloni T, Gaetani GF.
 Source: Journal of Medical Genetics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6436490&query_hl=24&itool=pubmed_docsum
- **Flow cytofluorometric analysis of enzyme reactions based on quenching of fluorescence by the final reaction product: detection of glucose-6-phosphate dehydrogenase deficiency in human erythrocytes.**
 Author(s): Van Noorden CJ, Dolbeare F, Aten J.
 Source: The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2768805&query_hl=24&itool=pubmed_docsum
- **Fractionation of serum bilirubin conjugates in the exploration of the pathogenesis of significant neonatal bilirubinemia associated with glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Valaes T.
 Source: The Journal of Pediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9108875&query_hl=24&itool=pubmed_docsum
- **Frequencies of sickle cell trait and glucose-6-phosphate dehydrogenase deficiency differ in highland and nearby lowland malaria-endemic areas of Kenya.**
 Author(s): Moormann AM, Embury PE, Opondo J, Sumba OP, Ouma JH, Kazura JW, John CC.
 Source: Transactions of the Royal Society of Tropical Medicine and Hygiene.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15307413&query_hl=24&itool=pubmed_docsum
- **Frequency of Glucose-6-Phosphate dehydrogenase deficiency in Egyptian infants.**
 Author(s): Kamal I, Gabr M, Mohy-Eldin O, Talaat MM.
 Source: J Egypt Med Assoc.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=5955028&query_hl=24&itool=pubmed_docsum

- **Frequency of glucose-6-phosphate dehydrogenase deficiency in individuals with normal and sickle cell haemoglobin--a preliminary study.**
 Author(s): Pradhan PK, Dua HK, Kavishwar WK, Agarwal S.
 Source: Indian J Pathol Microbiol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=3833721&query_hl=24&itool=pubmed_docsum
- **Frequency of glucose-6-phosphate dehydrogenase deficiency in relation to altitude: a malaria hypothesis.**
 Author(s): Tzoneva M, Bulanov AG, Mavrudieva M, Lalchev S, Toncheva D, Tanev D.
 Source: Bulletin of the World Health Organization.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6969137&query_hl=24&itool=pubmed_docsum
- **Frequency of glucose-6-phosphate dehydrogenase deficiency in sickle-cell disease. A study in Saudi Arabia.**
 Author(s): Warsy AS.
 Source: Human Heredity.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=3997159&query_hl=24&itool=pubmed_docsum
- **Frequency of glucose-6-phosphate dehydrogenase deficiency in some ethnic groups of Pakistan.**
 Author(s): Ali N, Anwar M, Ayyub M, Bhatti FA, Nadeem M, Nadeem A.
 Source: J Coll Physicians Surg Pak.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15808089&query_hl=24&itool=pubmed_docsum
- **Frequency of glutathione reductase, pyruvate kinase and glucose-6-phosphate dehydrogenase deficiency in a Spanish population.**
 Author(s): Garcia SC, Moragon AC, Lopez-Fernandez ME.
 Source: Human Heredity.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=489031&query_hl=24&itool=pubmed_docsum
- **Frequency of haemoglobinopathies and glucose-6-phosphate dehydrogenase deficiency in Basra.**
 Author(s): Hassan MK, Taha JY, Al-Naama LM, Widad NM, Jasim SN.
 Source: East Mediterr Health J.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15562732&query_hl=24&itool=pubmed_docsum
- **Frequency of malaria and glucose-6-phosphate dehydrogenase deficiency in Tajikistan.**
 Author(s): Rebholz CE, Michel AJ, Maselli DA, Saipphudin K, Wyss K.
 Source: Malaria Journal [electronic Resource].
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16780577&query_hl=24&itool=pubmed_docsum

- **Fulminant Rocky Mountain spotted fever. Its pathologic characteristics associated with glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Walker DH, Hawkins HK, Hudson P.
 Source: Archives of Pathology & Laboratory Medicine.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6687526&query_hl=24&itool=pubmed_docsum
- **Functional analysis of polymorphonuclear leukocytes in siblings of glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Matsuura R, Kishi T, Okahata H, Kobayashi M, Tanabe A, Sakura N, Sawano K, Usui T.
 Source: Hiroshima J Med Sci.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6618900&query_hl=24&itool=pubmed_docsum
- **Further evidence for heterogeneity of glucose-6-phosphate dehydrogenase deficiency in Papua New Guinea.**
 Author(s): Chockkalingam K, Board PG.
 Source: Human Genetics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7450778&query_hl=24&itool=pubmed_docsum
- **Further studies of haemoglobin glycosylation: influence of diabetes mellitus and glucose-6-phosphate dehydrogenase deficiency in Nigerians.**
 Author(s): Mgbodile M, Onyeanusu JC.
 Source: Cent Afr J Med.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=3219715&query_hl=24&itool=pubmed_docsum
- **Glucose-6-phosphate dehydrogenase deficiency and abnormal hemoglobins in mexican newborns with jaundice.**
 Author(s): Vaca G, Ibarra B, Hernandez A, Olivares N, Medina C, Sanchez-Corona J, Wunsch C, Godinez B, Martinez-Basalo C, Cantu JM.
 Source: Revista De Investigacion Clinica; Organo Del Hospital De Enfermedades De La Nutricion.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7330495&query_hl=24&itool=pubmed_docsum
- **Glucose-6-phosphate dehydrogenase deficiency and blood groups in northern Sardinia.**
 Author(s): Martuzzi Veronesi F, Stangoni A, Cuccuru GB, Mulas G, Marogna G, Cossu G, Pettener D.
 Source: Human Heredity.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=3932186&query_hl=24&itool=pubmed_docsum

- **Glucose-6-phosphate dehydrogenase deficiency and cataracts.**
Author(s): Hatcher G Jr.
Source: J Am Osteopath Assoc.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7251411&query_hl=24&itool=pubmed_docsum
- **Glucose-6-phosphate dehydrogenase deficiency and incidence of cataract in Sicily.**
Author(s): Moro F, Gorgone G, Li Volti S, Cavallaro N, Faro S, Curreri R, Mollica F.
Source: Ophthalmic Paediatr Genet.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=4069580&query_hl=24&itool=pubmed_docsum
- **Glucose-6-phosphate dehydrogenase deficiency and Mediterranean fever in northern Sardinia.**
Author(s): Meloni T, Forteleoni G.
Source: The Journal of Infectious Diseases.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7108279&query_hl=24&itool=pubmed_docsum
- **Glucose-6-phosphate dehydrogenase deficiency and Rh factor.**
Author(s): Tzoneva M, Mavrudieva M, Toncheva D, Lalchev S.
Source: Haematologia.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6442913&query_hl=24&itool=pubmed_docsum
- **Glucose-6-phosphate dehydrogenase deficiency in a psychiatric population: a preliminary study.**
Author(s): Nasr SJ, Altman E, Pscheidt G, Meltzer HY.
Source: Biological Psychiatry.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7115841&query_hl=24&itool=pubmed_docsum
- **Glucose-6-phosphate dehydrogenase deficiency in Cukurova Province, Turkey.**
Author(s): Akoglu T, Ozer FL, Cig S, Kumi M, Erdogan A, Anil H.
Source: International Journal of Epidemiology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7239758&query_hl=24&itool=pubmed_docsum
- **Glucose-6-phosphate dehydrogenase deficiency in male patients with Mediterranean spotted fever in Sardinia.**
Author(s): Piras MA, Calia G, Saba F, Gakis C, Andreoni G.
Source: The Journal of Infectious Diseases.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6833807&query_hl=24&itool=pubmed_docsum

- **Glucose-6-phosphate dehydrogenase deficiency in Papua New Guinea. The description of 13 new variants.**
 Author(s): Chockkalingam K, Board PG, Nurse GT.
 Source: Human Genetics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7076260&query_hl=24&itool=pubmed_docsum
- **Glucose-6-phosphate dehydrogenase deficiency in Southeast Asian refugees entering the United States.**
 Author(s): Schwartz IK, Chin W, Newman J, Roberts JM.
 Source: The American Journal of Tropical Medicine and Hygiene.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6696177&query_hl=24&itool=pubmed_docsum
- **Glucose-6-phosphate dehydrogenase deficiency in the Greek population of Cape Town.**
 Author(s): Bonafede RP, Botha MC, Beighton P.
 Source: South African Medical Journal. Suid-Afrikaanse Tydskrif Vir Geneeskunde.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6710260&query_hl=24&itool=pubmed_docsum
- **Glucose-6-phosphate dehydrogenase deficiency inhibits in vitro growth of Plasmodium falciparum.**
 Author(s): Roth EF Jr, Raventos-Suarez C, Rinaldi A, Nagel RL.
 Source: Proceedings of the National Academy of Sciences of the United States of America.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6337374&query_hl=24&itool=pubmed_docsum
- **Glucose-6-phosphate dehydrogenase deficiency, thalassaemia & abnormal haemoglobins in Bohra Muslims.**
 Author(s): Jain RC, Chhapparwal JK, Bansal G, Gupta RK.
 Source: The Indian Journal of Medical Research.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6519703&query_hl=24&itool=pubmed_docsum
- **Glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Bernstein RE.
 Source: South African Medical Journal. Suid-Afrikaanse Tydskrif Vir Geneeskunde.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6463789&query_hl=24&itool=pubmed_docsum
- **Glucose-6-phosphate dehydrogenase deficiency. Part 1: Tropical Africa.**
 Author(s): Bienzle U.
 Source: Clin Haematol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7030552&query_hl=24&itool=pubmed_docsum

- **Glucose-6-phosphate dehydrogenase deficiency. Part 2. Tropical Asia.**
Author(s): Panich V.
Source: Clin Haematol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7030553&query_hl=24&itool=pubmed_docsum
- **Glucose-6-phosphate dehydrogenase deficiency: genetic heterogeneity in Sardinia.**
Author(s): Fenu MP, Finazzi G, Manoussakis C, Palomba V, Fiorelli G.
Source: Annals of Human Genetics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7114788&query_hl=24&itool=pubmed_docsum
- **Glucose-6-phosphate dehydrogenase deficiency: screening of 200 Zambian newborn.**
Author(s): Bhagwat GP, Mwisya M.
Source: Med J Zambia.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6336243&query_hl=24&itool=pubmed_docsum
- **Glucose-6-phosphate dehydrogenase deficiency-relationship with caste and ABO blood groups.**
Author(s): Bhatia R, Gupta M, Ichhpujani RL, Khanna KK, Rai Chowdhuri AN.
Source: J Commun Dis.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6512237&query_hl=24&itool=pubmed_docsum
- **Haemoglobinopathies and glucose-6-phosphate dehydrogenase deficiency in Eastern Libya.**
Author(s): Jain RC.
Source: Indian J Pathol Microbiol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7166378&query_hl=24&itool=pubmed_docsum
- **Haemoglobinuria after a single dose treatment with dapsone and pyrimethamine for falciparum malaria in a patient with glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Ponnampalam JT.
Source: Trop Geogr Med.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7342390&query_hl=24&itool=pubmed_docsum
- **Haemolysis with rickettsiosis and glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Walker DH, Radisch DL, Kirkman HN.
Source: Lancet.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6135048&query_hl=24&itool=pubmed_docsum

- **Haemolytic potential of three chemotherapeutic agents and aspirin in glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Ali NA, al-Naama LM, Khalid LO.
 Source: East Mediterr Health J.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10793824&query_hl=24&itool=pubmed_docsum
- **Hemolysis after acetaminophen overdose in a patient with glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Wright RO, Perry HE, Woolf AD, Shannon MW.
 Source: Journal of Toxicology. Clinical Toxicology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8941205&query_hl=24&itool=pubmed_docsum
- **Hemolysis and hyperbilirubinemia in an African American neonate heterozygous for glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Herschel M, Ryan M, Gelbart T, Kaplan M.
 Source: Journal of Perinatology : Official Journal of the California Perinatal Association.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12368976&query_hl=24&itool=pubmed_docsum
- **Hemolysis as a potential complication of acetaminophen overdose in a patient with glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Sklar GE.
 Source: Pharmacotherapy.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12013368&query_hl=24&itool=pubmed_docsum
- **Hemolytic anemia after acetaminophen overdose in patient with glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Ruha AM, Seldem B.
 Source: The American Journal of Medicine.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11221636&query_hl=24&itool=pubmed_docsum
- **Hemolytic crisis in a non-ketotic and euglycemic child with glucose-6-phosphate dehydrogenase deficiency and onset of type 1 diabetes mellitus.**
 Author(s): Messina MF, Lombardo F, Crisafulli G, Salzano G, Rosano M, Di Giorgio RM.
 Source: J Pediatr Endocrinol Metab.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15645702&query_hl=24&itool=pubmed_docsum
- **Henna causes life threatening haemolysis in glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Raupp P, Hassan JA, Varughese M, Kristiansson B.
 Source: Archives of Disease in Childhood.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11668106&query_hl=24&itool=pubmed_docsum

- **Hepatitis A and cytomegalovirus infection precipitating acute hemolysis in glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Siddiqui T, Khan AH.
Source: Military Medicine.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9640043&query_hl=24&itool=pubmed_docsum
- **High incidence of 3-thalassemia, hemoglobin E, and glucose-6-phosphate dehydrogenase deficiency in populations of malaria-endemic southern Shan State, Myanmar.**
Author(s): Than AM, Harano T, Harano K, Myint AA, Ogino T, Okada S.
Source: International Journal of Hematology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16146842&query_hl=24&itool=pubmed_docsum
- **High incidence of glucose-6-phosphate dehydrogenase deficiency in Croatian island isolate: example from Vis island, Croatia.**
Author(s): Markic J, Krzelj V, Markotic A, Marusic E, Stricevic L, Zanchi J, Bosnjak N, Sapunar A.
Source: Croatian Medical Journal.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16909453&query_hl=24&itool=pubmed_docsum
- **High prevalence of glucose-6-phosphate dehydrogenase deficiency without gene mutation suggests a novel genetic mechanism predisposing to ketosis-prone diabetes.**
Author(s): Sobngwi E, Gautier JF, Kevorkian JP, Villette JM, Riveline JP, Zhang S, Vexiau P, Leal SM, Vaisse C, Mauvais-Jarvis F.
Source: The Journal of Clinical Endocrinology and Metabolism.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15914531&query_hl=24&itool=pubmed_docsum
- **Homozygous germline mutation of CDKN2A/p16 and glucose-6-phosphate dehydrogenase deficiency in a multiple melanoma case.**
Author(s): Pavel S, Smit NP, van der Meulen H, Kolb RM, de Groot AJ, van der Velden PA, Gruis NA, Bergman W.
Source: Melanoma Research.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12690301&query_hl=24&itool=pubmed_docsum
- **Human hair follicles may be used for population screening of heterozygotes of glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Vermorken AJ, Markslag AM, Goos CM, Miguel A, Ramon M, Petitpierre E.
Source: Clinical Genetics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7172478&query_hl=24&itool=pubmed_docsum

- **Hyperbilirubinaemia, glucose-6-phosphate dehydrogenase deficiency and Gilbert syndrome.**
 Author(s): Kaplan M, Hammerman C, Beutler E.
 Source: European Journal of Pediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11277384&query_hl=24&itool=pubmed_docsum
- **Hyperbilirubinemia in healthy neonates with glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Weng YH, Chou YH, Lien RI.
 Source: Early Human Development.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12663150&query_hl=24&itool=pubmed_docsum
- **Hypoglycemia-induced hemolysis in glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Shalev O, Eliakim R, Lugassy GZ, Menczel J.
 Source: Acta Haematologica.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=3939066&query_hl=24&itool=pubmed_docsum
- **Impaired oxygenation and increased hemolysis after cardiopulmonary bypass in patients with glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Gerrah R, Shargal Y, Elami A.
 Source: The Annals of Thoracic Surgery.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12902098&query_hl=24&itool=pubmed_docsum
- **Imported cerebral malaria complicated with glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Chadee DD, Tilluckdharry CC, Doon R.
 Source: The West Indian Medical Journal.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8952432&query_hl=24&itool=pubmed_docsum
- **Improved erythrocyte survival with combined vitamin E and selenium therapy in children with glucose-6-phosphate dehydrogenase deficiency and mild chronic hemolysis.**
 Author(s): Hafez M, Amar ES, Zedan M, Hammad H, Sorour AH, el-Desouky ES, Gamil N.
 Source: The Journal of Pediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=3958828&query_hl=24&itool=pubmed_docsum

- **Incidence and complete molecular characterization of glucose-6-phosphate dehydrogenase deficiency in the Guangxi Zhuang autonomous region of southern China: description of four novel mutations.**
 Author(s): Yan T, Cai R, Mo O, Zhu D, Ouyang H, Huang L, Zhao M, Huang F, Li L, Liang X, Xu X.
 Source: Haematologica.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17018380&query_hl=24&itool=pubmed_docsum
- **Incidence and molecular analysis of glucose-6-phosphate dehydrogenase deficiency in the province of Denizli, Turkey.**
 Author(s): Keskin N, Ozdes I, Keskin A, Acikbas I, Bagci H.
 Source: Medical Science Monitor : International Medical Journal of Experimental and Clinical Research.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12070439&query_hl=24&itool=pubmed_docsum
- **Incidence of glucose-6-phosphate dehydrogenase deficiency and haemoglobinopathies in Bhil tribe of Udaipur District.**
 Author(s): Mogra N, Surana SS, Joshi KC, Gupta OP, Mehra SK.
 Source: J Assoc Physicians India.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7182386&query_hl=24&itool=pubmed_docsum
- **Incidence of glucose-6-phosphate dehydrogenase deficiency in a hospital population of Delhi.**
 Author(s): Madan N, Talwar N, Maheshwari A, Sood SK.
 Source: The Indian Journal of Medical Research.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7275238&query_hl=24&itool=pubmed_docsum
- **Incidence of glucose-6-phosphate dehydrogenase deficiency in Jabalpur area.**
 Author(s): Gupta JC, Yagnik U, Seth P.
 Source: Indian J Pathol Microbiol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7106910&query_hl=24&itool=pubmed_docsum
- **Incidence of glucose-6-phosphate dehydrogenase deficiency in jaundiced punjabi neonates.**
 Author(s): Bhandari A, Crowell EB, Crowell S, Khanna SD.
 Source: Indian J Pathol Microbiol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7166383&query_hl=24&itool=pubmed_docsum
- **Incidence of glucose-6-phosphate dehydrogenase deficiency in Zimbabwe.**
 Author(s): Bernstein RE.
 Source: Cent Afr J Med.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7127449&query_hl=24&itool=pubmed_docsum

- **Increased incidence of hyperbilirubinaemia in 'unchallenged' glucose-6-phosphate dehydrogenase deficiency in term Saudi newborns.**
 Author(s): Yaish HM, Niazi GA, al Shaalan M, Khan S, Ahmed GS.
 Source: Annals of Tropical Paediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1719925&query_hl=24&itool=pubmed_docsum
- **Increased morbidity following acute viral hepatitis in children with glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Choudhry VP, Bagga A, Desai N.
 Source: Journal of Tropical Pediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1507312&query_hl=24&itool=pubmed_docsum
- **Increased prevalence of glucose-6-phosphate dehydrogenase deficiency in patients with cholelithiasis.**
 Author(s): Meloni T, Forteleoni G, Noja G, Dettori G, Sale MA, Meloni GF.
 Source: Acta Haematologica.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2024558&query_hl=24&itool=pubmed_docsum
- **Index of suspicion. Case 3. Diagnosis: glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Bates S, Friedman J.
 Source: Pediatrics in Review / American Academy of Pediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9557067&query_hl=24&itool=pubmed_docsum
- **Index of suspicion. Case 3. Kernicterus in a baby girl homozygous for glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Oblender M.
 Source: Pediatrics in Review / American Academy of Pediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8493190&query_hl=24&itool=pubmed_docsum
- **Infectious hepatitis and glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Berry E, Melmed RN.
 Source: Isr J Med Sci.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=885712&query_hl=24&itool=pubmed_docsum
- **Interaction between glucose-6-phosphate dehydrogenase deficiency and sickle cell gene in Saudi Arabia.**
 Author(s): el-Hazmi MA, Warsy AS.
 Source: Trop Geogr Med.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=3474817&query_hl=24&itool=pubmed_docsum

- **Interaction of malarial infection and glucose-6-phosphate dehydrogenase deficiency in Muria gonds of district Bastar, central India.**
Author(s): Thakur A, Verma IC.
Source: Trop Geogr Med.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1455522&query_hl=24&itool=pubmed_docsum
- **Intraoperative hemolysis. The initial manifestation of glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Sazama K, Klein HG, Davey RJ, Corash L.
Source: Archives of Internal Medicine.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7387283&query_hl=24&itool=pubmed_docsum
- **Intravascular haemolysis due to glucose-6-phosphate dehydrogenase deficiency in a patient with aluminium phosphide poisoning.**
Author(s): Srinivas R, Agarwal R, Jairam A, Sakhuja V.
Source: Emergency Medicine Journal : Emj.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17183055&query_hl=24&itool=pubmed_docsum
- **Kinetic analysis in single, intact cells by microspectrophotometry: evidence for two populations of erythrocytes in an individual heterozygous for glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Ashmun RA, Hultquist DE, Schultz JS.
Source: American Journal of Hematology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=3788959&query_hl=24&itool=pubmed_docsum
- **Lack of association between glucose-6-phosphate dehydrogenase deficiency and dextromethorphan O-demethylation polymorphism.**
Author(s): Irshaid YM, al-Hadidi HF, Rawashdeh NM.
Source: European Journal of Clinical Pharmacology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8491251&query_hl=24&itool=pubmed_docsum
- **Leg ulcers in a family with both beta thalassaemia and glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Ganor S, Cohen T.
Source: The British Journal of Dermatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=952759&query_hl=24&itool=pubmed_docsum
- **Letter: Glucose-6-phosphate dehydrogenase deficiency and co-trimoxazole.**
Author(s): Chan MC, Wong HB.
Source: Lancet.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=46571&query_hl=24&itool=pubmed_docsum

- **Leucocyte glucose-6-phosphate dehydrogenase deficiency and necrotizing pneumonia.**
 Author(s): Fite E, Morell F, Zuazu J, Julia A, Morera J.
 Source: Eur J Respir Dis.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6832252&query_hl=24&itool=pubmed_docsum
- **Linkage between glucose-6-phosphate dehydrogenase deficiency and manic-depressive psychosis.**
 Author(s): Mendlewicz J, Linkowski P, Wilmotte J.
 Source: The British Journal of Psychiatry; the Journal of Mental Science.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7448473&query_hl=24&itool=pubmed_docsum
- **Linkage disequilibrium between glucose-6-phosphate dehydrogenase deficiency and congenital color blindness in Turkish population.**
 Author(s): Yucel G, Yucel I, Bagci H, Aksu G, Luleci G, Gumuslu S, Aksu TA, Duranoglu Y.
 Source: Japanese Journal of Ophthalmology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1635293&query_hl=24&itool=pubmed_docsum
- **Long-term, low-dose aspirin is safe in glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Shalev O.
 Source: Dicp.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1803794&query_hl=24&itool=pubmed_docsum
- **Loss of flaps due to glucose-6-phosphate dehydrogenase deficiency. Case report.**
 Author(s): Adamson JE, Taddeo RJ, Gwyn PP.
 Source: Plastic and Reconstructive Surgery.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=4915229&query_hl=24&itool=pubmed_docsum
- **Malignant hyperthermia and glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Younker D, DeVore M, Hartlage P.
 Source: Anesthesiology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6731919&query_hl=24&itool=pubmed_docsum
- **Mass newborn screening for glucose-6-phosphate dehydrogenase deficiency in Singapore.**
 Author(s): Joseph R, Ho LY, Gomez JM, Rajdurai VS, Sivasankaran S, Yip YY.
 Source: Southeast Asian J Trop Med Public Health.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11400790&query_hl=24&itool=pubmed_docsum

- **Massive acute haemolysis in neonates with glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Dhillon AS, Darbyshire PJ, Williams MD, Bissenden JG.
 Source: Archives of Disease in Childhood. Fetal and Neonatal Edition.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=14602706&query_hl=24&itool=pubmed_docsum
- **Metabolism of the hexose monophosphate shunt in glucose-6-phosphate dehydrogenase deficiency and closely interrelated reactions.**
 Author(s): Jacobasch G, Bleiber R, Schonian G.
 Source: Haematologia.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7186479&query_hl=24&itool=pubmed_docsum
- **Microsomal incubation test of potentially hemolytic drugs for glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Bloom KE, Brewer GJ, Magon AM, Wetterstroem N.
 Source: Clinical Pharmacology and Therapeutics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6572582&query_hl=24&itool=pubmed_docsum
- **Modulatory effect of glucose-6-phosphate dehydrogenase deficiency on benzo(a)pyrene toxicity and transforming activity for in vitro-cultured human skin fibroblasts.**
 Author(s): Feo F, Pirisi L, Pascale R, Daino L, Frassetto S, Garcea R, Gaspa L.
 Source: Cancer Research.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6331645&query_hl=24&itool=pubmed_docsum
- **Molecular basis of glucose-6-phosphate dehydrogenase deficiency among Filipinos.**
 Author(s): Silao CL, Shirakawa T, Nishiyama K, Padilla C, Matsuo M.
 Source: Pediatrics International : Official Journal of the Japan Pediatric Society.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10221015&query_hl=24&itool=pubmed_docsum
- **Molecular characterization of a German variant of glucose-6-phosphate dehydrogenase deficiency (G6PD Aachen).**
 Author(s): Efferth T, Osieka R, Beutler E.
 Source: Blood Cells, Molecules & Diseases.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10772881&query_hl=24&itool=pubmed_docsum
- **Molecular characterization of glucose-6-phosphate dehydrogenase deficiency in Brazil.**
 Author(s): Saad ST, Salles TS, Carvalho MH, Costa FF.
 Source: Human Heredity.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9017974&query_hl=24&itool=pubmed_docsum

- **Molecular characterization of glucose-6-phosphate dehydrogenase deficiency in the Eastern Province of Saudi Arabia.**
 Author(s): Al-Ali AK, Al-Mustafa ZH, Al-Madan M, Qaw F, Al-Ateeq S.
 Source: Clinical Chemistry and Laboratory Medicine : Cclm / Fesccl.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12392311&query_hl=24&itool=pubmed_docsum
- **Molecular characterization of glucose-6-phosphate dehydrogenase deficiency in the Fars province of Iran.**
 Author(s): Karimi M, Martinez di Montemuros F, Danielli MG, Farjadian S, Afrasiabi A, Fiorelli G, Cappellini MD.
 Source: Haematologica.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12651275&query_hl=24&itool=pubmed_docsum
- **Molecular characterization of glucose-6-phosphate dehydrogenase deficiency in the Kurdish population of Western Iran.**
 Author(s): Rahimi Z, Vaisi-Raygani A, Nagel RL, Muniz A.
 Source: Blood Cells, Molecules & Diseases.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16938474&query_hl=24&itool=pubmed_docsum
- **Molecular characterization of glucose-6-phosphate dehydrogenase deficiency in Turkey.**
 Author(s): Oner R, Gumruk F, Acar C, Oner C, Gurgey A, Altay C.
 Source: Haematologica.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10702825&query_hl=24&itool=pubmed_docsum
- **Molecular genetics of glucose-6-phosphate dehydrogenase deficiency in a population of newborns from Ivory Coast.**
 Author(s): Coulibaly FH, Koffi G, Toure HA, Bouanga JC, Allangba O, Tolo A, Sawadogo D, Sanogo I, Konate S, Prehu C, Sangare A, Galacteros F.
 Source: Clinical Biochemistry.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11018694&query_hl=24&itool=pubmed_docsum
- **Molecular genetics of glucose-6-phosphate dehydrogenase deficiency in Mexico.**
 Author(s): Medina MD, Vaca G, Lopez-Guido B, Westwood B, Beutler E.
 Source: Blood Cells, Molecules & Diseases.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9215753&query_hl=24&itool=pubmed_docsum
- **Molecular heterogeneity of glucose-6-phosphate dehydrogenase deficiency in Jordan.**
 Author(s): Karadsheh NS, Moses L, Ismail SI, Devaney JM, Hoffman E.
 Source: Haematologica.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16330444&query_hl=24&itool=pubmed_docsum

- **Molecular heterogeneity of glucose-6-phosphate dehydrogenase deficiency in Malays in Malaysia.**
Author(s): Yusoff NM, Shirakawa T, Nishiyama K, Ghazali S, Ee CK, Orita A, Abdullah WZ, Isa MN, Van Rostenberghe H, Matsuo M.
Source: International Journal of Hematology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12215013&query_hl=24&itool=pubmed_docsum
- **Molecular heterogeneity of glucose-6-phosphate dehydrogenase deficiency in Mexico: overall results of a 7-year project.**
Author(s): Vaca G, Arambula E, Esparza A.
Source: Blood Cells, Molecules & Diseases.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12367588&query_hl=24&itool=pubmed_docsum
- **Molecular heterogeneity of the glucose-6-phosphate dehydrogenase deficiency in the Hellenic population.**
Author(s): Menounos P, Zervas C, Garinis G, Doukas C, Kolokithopoulos D, Tegos C, Patrinos GP.
Source: Human Heredity.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10782016&query_hl=24&itool=pubmed_docsum
- **Mortality in a cohort of men expressing the glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Cocco P, Todde P, Fornera S, Manca MB, Manca P, Sias AR.
Source: Blood.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9427729&query_hl=24&itool=pubmed_docsum
- **N-acetylcysteine reduces methemoglobin in an in-vitro model of glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Wright RO, Woolf AD, Shannon MW, Magnani B.
Source: Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9523930&query_hl=24&itool=pubmed_docsum
- **Neonatal bilirubin levels and glucose-6-phosphate dehydrogenase deficiency in preterm and low-birth-weight infants in Israel.**
Author(s): Ashkenazi S, Mimouni F, Merlob P, Reisner SH.
Source: Isr J Med Sci.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6662695&query_hl=24&itool=pubmed_docsum

- **Neonatal bilirubin production-conjugation imbalance: effect of glucose-6-phosphate dehydrogenase deficiency and borderline prematurity.**
 Author(s): Kaplan M, Muraca M, Vreman HJ, Hammerman C, Vilei MT, Rubaltelli FF, Stevenson DK.
 Source: Archives of Disease in Childhood. Fetal and Neonatal Edition.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15724035&query_hl=24&itool=pubmed_docsum
- **Neonatal hyperbilirubinemia and glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Milbauer B, Peled N, Svirsky S.
 Source: Isr J Med Sci.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=4778402&query_hl=24&itool=pubmed_docsum
- **Neonatal hyperbilirubinemia associated with glucose-6-phosphate dehydrogenase deficiency in Sephardic-Jewish neonates: incidence, severity, and the effect of phototherapy.**
 Author(s): Kaplan M, Abramov A.
 Source: Pediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1518696&query_hl=24&itool=pubmed_docsum
- **Neonatal hyperbilirubinemia in African American males: the importance of glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Kaplan M, Herschel M, Hammerman C, Hoyer JD, Heller GZ, Stevenson DK.
 Source: The Journal of Pediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16860133&query_hl=24&itool=pubmed_docsum
- **Neonatal jaundice and glucose-6-phosphate dehydrogenase deficiency in Basrah.**
 Author(s): Al-Naama LM, Al-Sadoon IA, Al-Naama MM.
 Source: Annals of Tropical Paediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2441650&query_hl=24&itool=pubmed_docsum
- **Neonatal jaundice and glucose-6-phosphate dehydrogenase deficiency in Papua New Guinea.**
 Author(s): Woodfield DG, Biddulph J.
 Source: The Medical Journal of Australia.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1160703&query_hl=24&itool=pubmed_docsum
- **Neonatal jaundice and glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Sasanakul W, Hathirat P, Jeraporn K, Tejavej A, Siripoonya P, Isarangkura P.
 Source: J Med Assoc Thai.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2732634&query_hl=24&itool=pubmed_docsum

- **Neonatal jaundice and severity of glucose-6-phosphate dehydrogenase deficiency in Sardinian babies.**
Author(s): Meloni T, Cutillo S, Testa U, Luzzatto L.
Source: Early Human Development.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=3436274&query_hl=24&itool=pubmed_docsum
- **Neonatal screening for glucose-6-phosphate dehydrogenase deficiency fails to detect heterozygote females.**
Author(s): Zaffanello M, Rugolotto S, Zamboni G, Gaudino R, Tato L.
Source: European Journal of Epidemiology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15117119&query_hl=24&itool=pubmed_docsum
- **Neonatal screening for glucose-6-phosphate dehydrogenase deficiency in Taiwan.**
Author(s): Chiang SH, Wu SJ, Wu KF, Hsiao KJ.
Source: Southeast Asian J Trop Med Public Health.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11400791&query_hl=24&itool=pubmed_docsum
- **Neonatal screening for glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Pao M, Kulkarni A, Gupta V, Kaul S, Balan S.
Source: Indian J Pediatr.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16272653&query_hl=24&itool=pubmed_docsum
- **Neonatal screening for glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Piomelli S, Wolff JA.
Source: The Journal of Pediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1517934&query_hl=24&itool=pubmed_docsum
- **Neonatal screening for glucose-6-phosphate dehydrogenase deficiency: sex distribution.**
Author(s): Kaplan M, Hammerman C, Kvit R, Rudensky B, Abramov A.
Source: Archives of Disease in Childhood. Fetal and Neonatal Edition.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8092877&query_hl=24&itool=pubmed_docsum
- **Neonatal screening of glucose-6-phosphate dehydrogenase deficiency in Yanbu, Saudi Arabia.**
Author(s): Muzaffer MA.
Source: Journal of Medical Screening.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16417692&query_hl=24&itool=pubmed_docsum

- **Neutrophil dysfunction in a case of glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Costa E, Vasconcelos J, Santos E, Laranjeira A, Castro e Melo J, Barbot J.
 Source: Journal of Pediatric Hematology/Oncology : Official Journal of the American Society of Pediatric Hematology/Oncology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11990707&query_hl=24&itool=pubmed_docsum
- **New considerations on the distribution of malaria, thalassemia, and glucose-6-phosphate dehydrogenase deficiency in Sardinia.**
 Author(s): Brown PJ.
 Source: Human Biology; an International Record of Research.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7309023&query_hl=24&itool=pubmed_docsum
- **New data on glucose-6-phosphate dehydrogenase deficiency in Saudi Arabia. G6PD variants, and the association between enzyme deficiency and hemoglobins S.**
 Author(s): Gelpi AP, King MC.
 Source: Human Heredity.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=892808&query_hl=24&itool=pubmed_docsum
- **New developments in glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Luzzatto L.
 Source: Isr J Med Sci.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=4152522&query_hl=24&itool=pubmed_docsum
- **Overt hemolysis in patients with glucose-6-phosphate dehydrogenase deficiency: a survey in general practice.**
 Author(s): Herman J, Ben-Meir S.
 Source: Isr J Med Sci.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1140951&query_hl=24&itool=pubmed_docsum
- **Oxidant damage to erythrocyte membrane in glucose-6-phosphate dehydrogenase deficiency: correlation with in vivo reduced glutathione concentration and membrane protein oxidation.**
 Author(s): Johnson RM, Ravindranath Y, el-Alfy M, Goyette G Jr.
 Source: Blood.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8111051&query_hl=24&itool=pubmed_docsum
- **Partial exchange transfusion prior to treating cerebral malaria in an African child with glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Rahimy MC, Dan V, Akpona S, Massougbodji A, Falanga PB.
 Source: Transfusion.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9308649&query_hl=24&itool=pubmed_docsum

- **Parvovirus-associated aplastic crisis in a patient with red blood cell glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Goldman F, Rotbart H, Gutierrez K, Ambruso D.
Source: The Pediatric Infectious Disease Journal.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2172909&query_hl=24&itool=pubmed_docsum
- **Pathophysiology of hemolysis in glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Arese P, De Flora A.
Source: Semin Hematol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2405494&query_hl=24&itool=pubmed_docsum
- **Pathophysiology of spontaneous neonatal bilirubinemia associated with glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Valaes T.
Source: The Journal of Pediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8648552&query_hl=24&itool=pubmed_docsum
- **Patterns of sickle cell, thalassaemia and glucose-6-phosphate dehydrogenase deficiency genes in north-western Saudi Arabia.**
Author(s): El-Hazmi MA, Jabbar FA, Al-Faleh FZ, Al-Swailem AR, Warsy AS.
Source: Human Heredity.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2050379&query_hl=24&itool=pubmed_docsum
- **Pelvic pain, low blood pressure, and hemolysis after outpatient hysteroscopy in a patient with glucose-6-phosphate dehydrogenase deficiency.**
Author(s): De Angelis C, Re ME, Santoro G.
Source: Fertility and Sterility.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12798896&query_hl=24&itool=pubmed_docsum
- **Peripheral red blood cell survival invariance during pefloxacin treatment in subjects with glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Perpignano G, Mela Q, Ruggiero V, Pitzus F.
Source: Drugs Exp Clin Res.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2130006&query_hl=24&itool=pubmed_docsum
- **Peripheral red blood cell survival invariance during piroxicam treatment in subjects with glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Perpignano G, Mela Q, Ruggiero V, Pitzus F.
Source: Clin Exp Rheumatol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2397632&query_hl=24&itool=pubmed_docsum

- **Perspectives on hydrogen peroxide and drug-induced hemolytic anemia in glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Hochstein P.
 Source: Free Radical Biology & Medicine.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=3076882&query_hl=24&itool=pubmed_docsum
- **Phototherapy in newborn infants with glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Kopelman AE, Ey JL, Lee H.
 Source: The Journal of Pediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=690776&query_hl=24&itool=pubmed_docsum
- **Population screening for glucose-6-phosphate dehydrogenase deficiency on the Baleares.**
 Author(s): Miguel A, Ramon M, Petitpierre E, Goos CM, Vermeesch-Markslag AM, Vermorken AJ.
 Source: Human Genetics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6885055&query_hl=24&itool=pubmed_docsum
- **Population studies in Cameroon: hemoglobin S, glucose-6-phosphate dehydrogenase deficiency and falciparum malaria.**
 Author(s): Bernstein SC, Bowman JE, Kaptue Noche L.
 Source: Human Heredity.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6993342&query_hl=24&itool=pubmed_docsum
- **Possible potentiation of hemolytic anemia by tolbutamide. Report of a patient with erythrocyte glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Pavlic GJ.
 Source: Jama : the Journal of the American Medical Association.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=4957012&query_hl=24&itool=pubmed_docsum
- **Predictive models for human glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Horton HM, Calabrese EJ.
 Source: Drug Metabolism Reviews.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=3552540&query_hl=24&itool=pubmed_docsum
- **Prevalence and clinical presentation of glucose-6-phosphate dehydrogenase deficiency in Pakistani Pathan and Afghan refugee communities in Pakistan; implications for the use of primaquine in regional malaria control programmes.**
 Author(s): Bouma MJ, Goris M, Akhtar T, Khan N, Khan N, Kita E.
 Source: Transactions of the Royal Society of Tropical Medicine and Hygiene.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7747310&query_hl=24&itool=pubmed_docsum

- **Prevalence of abnormal hemoglobins, thalassaemia and erythrocyte glucose-6-phosphate dehydrogenase deficiency in Kashmiris: a preliminary study.**
 Author(s): Dash S, Quadri MI, Akhtar SS, Dash RJ.
 Source: J Assoc Physicians India.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7275922&query_hl=24&itool=pubmed_docsum
- **Prevalence of glucose-6-phosphate dehydrogenase deficiency in U.S. Army personnel.**
 Author(s): Chinevere TD, Murray CK, Grant E Jr, Johnson GA, Duerm F, Hospenthal DR.
 Source: Military Medicine.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17036616&query_hl=24&itool=pubmed_docsum
- **Prevalence of glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Leung AK, McLeod DR.
 Source: The Journal of Pediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=3373388&query_hl=24&itool=pubmed_docsum
- **Proceedings: Red cell cytochemistry in glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Gordon PA, Stuart J.
 Source: British Journal of Haematology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=4843681&query_hl=24&itool=pubmed_docsum
- **Quality assurance program for neonatal screening of glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Chiang SH, Wu KF, Liu TT, Wu SJ, Hsiao KJ.
 Source: Southeast Asian J Trop Med Public Health.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15906716&query_hl=24&itool=pubmed_docsum
- **Rapid epidemiologic assessment of glucose-6-phosphate dehydrogenase deficiency in malaria-endemic areas in Southeast Asia using a novel diagnostic kit.**
 Author(s): Jalloh A, Tantular IS, Pusarawati S, Kawilarang AP, Kerong H, Lin K, Ferreira MU, Matsuoka H, Arai M, Kita K, Kawamoto F.
 Source: Tropical Medicine & International Health : Tm & Ih.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15117307&query_hl=24&itool=pubmed_docsum
- **Rapid screening for glucose-6-phosphate dehydrogenase deficiency and haemoglobin polymorphisms in Africa by a simple high-throughput SSOP-ELISA method.**
 Author(s): Enevold A, Vestergaard LS, Lusingu J, Drakeley CJ, Lemnge MM, Theander TG, Bygbjerg IC, Alifrangis M.
 Source: Malaria Journal [electronic Resource].
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16356170&query_hl=24&itool=pubmed_docsum

- **Rapid, simultaneous genotyping of 10 Southeast Asian glucose-6-phosphate dehydrogenase deficiency-causing mutations and a silent polymorphism by multiplex primer extension/denaturing HPLC assay.**
 Author(s): Wu G, Liang WH, Zhu J, Ouyang H, Pearson P, Cai R, Liao C, Mo QH, Zhu DL, Xu XM.
 Source: Clinical Chemistry.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15976116&query_hl=24&itool=pubmed_docsum
- **Red blood cell disorders in Rwandese neonates: screening for sickle cell disease and glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Munyanganizi R, Cotton F, Vertongen F, Gulbis B.
 Source: Journal of Medical Screening.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17007653&query_hl=24&itool=pubmed_docsum
- **Red cell glucose-6-phosphate dehydrogenase deficiency among Andhras.**
 Author(s): Veerraju P, Busi BR, Anand NE.
 Source: American Journal of Physical Anthropology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=677293&query_hl=24&itool=pubmed_docsum
- **Red cell glucose-6-phosphate dehydrogenase deficiency and haemoglobin variants among ten endogamous groups of Maharashtra and West Bengal.**
 Author(s): Kate SL, Mukherjee BN, Malhotra KC, Phadke MA, Mutalik GS, Sainani GS.
 Source: Human Genetics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=730172&query_hl=24&itool=pubmed_docsum
- **Red cell glucose-6-phosphate dehydrogenase deficiency in ethnic groups in Israel.**
 Author(s): Zaidman JL, Leiba H, Scharf S, Steinman I.
 Source: Clinical Genetics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1248171&query_hl=24&itool=pubmed_docsum
- **Red cell glucose-6-phosphate dehydrogenase deficiency in Finland.**
 Author(s): Vuopio P, Harkonen M, Johnsson R, Nuutinen M.
 Source: Ann Clin Res.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=4749241&query_hl=24&itool=pubmed_docsum
- **Red cell glucose-6-phosphate dehydrogenase deficiency in Finland. Characterization of a new variant with severe enzyme deficiency.**
 Author(s): Vuopio P, Harkonen M, Helske T, Naveri H.
 Source: Scand J Haematol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1188317&query_hl=24&itool=pubmed_docsum

- **Red cell glucose-6-phosphate dehydrogenase deficiency in Finland. Further biochemical characterization of G-6-PD Helsinki.**
Author(s): Harkonen M, Vuopio P.
Source: Ann Clin Res.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=4154719&query_hl=24&itool=pubmed_docsum
- **Red cell glucose-6-phosphate dehydrogenase deficiency in Pakistan.**
Author(s): McCurdy PR, Mahmood L.
Source: The Journal of Laboratory and Clinical Medicine.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=5485383&query_hl=24&itool=pubmed_docsum
- **Red cell glucose-6-phosphate dehydrogenase deficiency in the Jammu region of J&K State.**
Author(s): Verma V, Saini RK, Kaul BL, Arya RK.
Source: J Assoc Physicians India.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=4093414&query_hl=24&itool=pubmed_docsum
- **Red cell membrane protein in thalassemia and glucose-6-phosphate dehydrogenase deficiency anemia.**
Author(s): Khalil M, Aziz Y, Tanios A, Moghazy M, Soliman SI, Sallam H.
Source: Gaz Egypt Paediatr Assoc.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=612474&query_hl=24&itool=pubmed_docsum
- **Red cell NADP+ and NADPH in glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Kirkman HN, Gaetani GD, Clemons EH, Mareni C.
Source: The Journal of Clinical Investigation.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=235564&query_hl=24&itool=pubmed_docsum
- **Reduced chronic hemolysis in Mediterranean glucose-6-phosphate dehydrogenase deficiency after vitamin E therapy.**
Author(s): Schulman JD, Corash L, Bartsocas C, Spielberg S, Boxer L, Sheetz M, Steinherz R, Papadatos C.
Source: Prog Clin Biol Res.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=531063&query_hl=24&itool=pubmed_docsum
- **Relationship between exposure to icterogenic agents, glucose-6-phosphate dehydrogenase deficiency and neonatal jaundice in Nigeria.**
Author(s): Owa JA.
Source: Acta Paediatr Scand.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2603709&query_hl=24&itool=pubmed_docsum

- **Reliability of three screening tests in detection of glucose-6-phosphate dehydrogenase deficiency in adults and neonates.**
 Author(s): Sood SK, Madan N, Talwar N, Maheshwari A, Jayant D, Bhargava SK.
 Source: Indian J Pathol Microbiol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7287108&query_hl=24&itool=pubmed_docsum
- **Rhabdomyolysis and hemolysis associated with sickle cell trait and glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Kimmick G, Owen J.
 Source: Southern Medical Journal.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8903296&query_hl=24&itool=pubmed_docsum
- **Screening for glucose-6-phosphate dehydrogenase deficiency as a preventive measure: prevalence among 1,286,000 Greek newborn infants.**
 Author(s): Missiou-Tsagaraki S.
 Source: The Journal of Pediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1824550&query_hl=24&itool=pubmed_docsum
- **Screening for glucose-6-phosphate dehydrogenase deficiency can prevent severe neonatal jaundice.**
 Author(s): Mallouh AA, Imseeh G, Abu-Osba YK, Hamdan JA.
 Source: Annals of Tropical Paediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1283668&query_hl=24&itool=pubmed_docsum
- **Screening for glucose-6-phosphate dehydrogenase deficiency prior to dapsone therapy.**
 Author(s): Todd P, Samaratunga IR, Pembroke A.
 Source: Clinical and Experimental Dermatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8033379&query_hl=24&itool=pubmed_docsum
- **Screening for glucose-6-phosphate dehydrogenase deficiency using a modified formazan method: a pilot study on Filipino male newborns.**
 Author(s): Padilla C, Nishiyama K, Shirakawa T, Matsuo M; Newborn Screening Study Group.
 Source: Pediatrics International : Official Journal of the Japan Pediatric Society.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12654062&query_hl=24&itool=pubmed_docsum
- **Screening for glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Sutton B.
 Source: Tex Med.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7256670&query_hl=24&itool=pubmed_docsum

- **Screening for glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Kaplan M, Abramov A, Hammerman C.
Source: The Journal of Pediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1625079&query_hl=24&itool=pubmed_docsum
- **Screening of the newborns for glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Ahmed P, Ahmad KN.
Source: Indian Pediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6629472&query_hl=24&itool=pubmed_docsum
- **Senile cataract and glucose-6-phosphate dehydrogenase deficiency in Indians.**
Author(s): Bhatia RP, Patel R, Dubey B.
Source: Trop Geogr Med.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2100077&query_hl=24&itool=pubmed_docsum
- **Serum lipoprotein profile in the Mediterranean variant of glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Muntoni S, Batetta B, Dessi S, Muntoni S, Pani P.
Source: European Journal of Epidemiology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1505653&query_hl=24&itool=pubmed_docsum
- **Severe hemolytic anemia in black children with glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Shannon K, Buchanan GR.
Source: Pediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7110809&query_hl=24&itool=pubmed_docsum
- **Severe hyperbilirubinemia due to acute hepatitis A superimposed on a chronic hepatitis B carrier with glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Huo TL, Wu JC, Chiu CF, Lee SD.
Source: The American Journal of Gastroenterology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8561121&query_hl=24&itool=pubmed_docsum
- **Severe jaundice in a gunshot casualty due to the coexistence of Dubin-Johnson and glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Zamir D, Groisman G, Zamir C, Sternberg E, Iuchtman M, Alfisi R, Weiner P.
Source: Journal of Clinical Gastroenterology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10372945&query_hl=24&itool=pubmed_docsum

- **Severe neonatal hyperbilirubinemia. A potential complication of glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Kaplan M, Hammerman C.
 Source: Clin Perinatol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9779335&query_hl=24&itool=pubmed_docsum
- **Severe neonatal jaundice associated with glucose-6-phosphate dehydrogenase deficiency: pathogenesis and global epidemiology.**
 Author(s): Valaes T.
 Source: Acta Paediatrica (Oslo, Norway : 1992). Supplement.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7919613&query_hl=24&itool=pubmed_docsum
- **Sickle cell haemoglobin and glucose-6-phosphate dehydrogenase deficiency among Dhobis of Visakhapatnam, Andhra Pradesh, India.**
 Author(s): Ramesh M, Balakrishna A, Veerraju P.
 Source: Anthropol Anz.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8333737&query_hl=24&itool=pubmed_docsum
- **Sickle cell haemoglobin and glucose-6-phosphate dehydrogenase deficiency among Rellis of Visakhapatnam, Andhra Pradesh, South India.**
 Author(s): Ramesh M, Veerraju P.
 Source: Anthropol Anz.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9468756&query_hl=24&itool=pubmed_docsum
- **Sickle cell trait and glucose-6-phosphate dehydrogenase deficiency. Effects on health and military performance in black Navy enlistees.**
 Author(s): Hoiberg A, Ernst J, Uddin DE.
 Source: Archives of Internal Medicine.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7283560&query_hl=24&itool=pubmed_docsum
- **Sickle cell trait, thalassaemia and glucose-6-phosphate dehydrogenase deficiency in the Bhil tribe of southern Rajasthan.**
 Author(s): Jain RC, Mehta J, Mehta NL, Joshi KC, Gupta OP, Andrew AM.
 Source: The Indian Journal of Medical Research.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7262926&query_hl=24&itool=pubmed_docsum
- **Sideroblastic anemia segregating with glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Brewer GJ.
 Source: American Journal of Hematology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1553960&query_hl=24&itool=pubmed_docsum

- **Spectrophotometric evaluation of results of the ascorbate and the ascorbate-cyanide screening tests for glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Rakitzis ET, Manolakou K, Papandreou P.
 Source: Clinica Chimica Acta; International Journal of Clinical Chemistry.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2317936&query_hl=24&itool=pubmed_docsum
- **The ascorbate cyanide test and the detection of females heterozygous for glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Deacon-Smith R.
 Source: Med Lab Sci.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6289033&query_hl=24&itool=pubmed_docsum
- **The coincidence of glucose-6-phosphate dehydrogenase deficiency and hemoglobin S gene in Cukurova Province, Turkey.**
 Author(s): Akoglu T, Ozer FL, Akoglu E.
 Source: American Journal of Epidemiology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=3953546&query_hl=24&itool=pubmed_docsum
- **The effect of glucose-6-phosphate dehydrogenase deficiency on the severity of neonatal jaundice in Cape Town.**
 Author(s): Roux P, Karabus CD, Hartley PS.
 Source: South African Medical Journal. Suid-Afrikaanse Tydskrif Vir Geneeskunde.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7079890&query_hl=24&itool=pubmed_docsum
- **The effects of glucose-6-phosphate dehydrogenase deficiency on the haematological parameters and clinical manifestations in patients with sickle cell anaemia.**
 Author(s): el-Hazmi MA, Warsy AS.
 Source: Trop Geogr Med.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2763347&query_hl=24&itool=pubmed_docsum
- **The erythroenzymopathies. With particular reference to glucose-6-phosphate dehydrogenase deficiency and favism.**
 Author(s): Carcassi U, Arese P, Frigerio R, Passiu G.
 Source: Ann Ital Med Int.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=3152863&query_hl=24&itool=pubmed_docsum

- **The expression of uridine diphosphate glucuronosyltransferase gene is a major determinant of bilirubin level in heterozygous beta-thalassaemia and in glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Sampietro M, Lupica L, Perrero L, Comino A, Martinez di Montemuros F, Cappellini MD, Fiorelli G.
 Source: British Journal of Haematology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9375769&query_hl=24&itool=pubmed_docsum
- **The genetics of glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Beutler E.
 Source: Semin Hematol.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2190319&query_hl=24&itool=pubmed_docsum
- **The molecular basis of glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Vulliamy T, Mason P, Luzzatto L.
 Source: Trends in Genetics : Tig.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1631957&query_hl=24&itool=pubmed_docsum
- **The ocular findings in glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Zeng LH, Mao WS, Chen YZ, Ma QY.
 Source: Yan Ke Xue Bao.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2485742&query_hl=24&itool=pubmed_docsum
- **The prevalence of hemoglobin S and glucose-6-phosphate dehydrogenase deficiency in Jordanian newborn.**
 Author(s): Talafih K, Hunaiti AA, Gharaibeh N, Gharaibeh M, Jaradat S.
 Source: The Journal of Obstetrics and Gynaecology Research.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8987321&query_hl=24&itool=pubmed_docsum
- **The relationship between glucose-6-phosphate dehydrogenase deficiency and cataracts in Sardinia. An epidemiological and biochemical study.**
 Author(s): Orzalesi N, Fossarello M, Sorcinelli R, Schlich U.
 Source: Documenta Ophthalmologica. Advances in Ophthalmology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6331998&query_hl=24&itool=pubmed_docsum
- **The role of glucose-6-phosphate dehydrogenase deficiency in blackwater fever.**
 Author(s): Houston S.
 Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9402415&query_hl=24&itool=pubmed_docsum

- **The role of the G6PD A₁376G/968C allele in glucose-6-phosphate dehydrogenase deficiency in the seerer population of Senegal.**
 Author(s): De Araujo C, Migot-Nabias F, Guitard J, Pelleau S, Vulliamy T, Ducrocq R.
 Source: Haematologica.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16461316&query_hl=24&itool=pubmed_docsum
- **The suitability of saliva for detection of glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Beamont AH, Miguel A, Goos CM, Vermeesch-Markslag AM, Hermans A, Vermorken AJ.
 Source: Molecular Biology Reports.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=3221843&query_hl=24&itool=pubmed_docsum
- **The value of screening tests for glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Abdalla SH, Phelan L, Hussein HA.
 Source: Clinical and Laboratory Haematology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2344719&query_hl=24&itool=pubmed_docsum
- **Tolerability of Peg interferon-alpha2b and Ribavirin therapy in patients with chronic hepatitis C and glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Demelia L, Civolani A, Murgia D, Murru A, Sorbello O, Rizzetto M.
 Source: Journal of Hepatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17107736&query_hl=24&itool=pubmed_docsum
- **Transient, acquired glucose-6-phosphate dehydrogenase deficiency in Thai children with typhoid fever.**
 Author(s): Tanphaichitr VS, Suvatte V, Mahasandana C, Tuchinda S.
 Source: Southeast Asian J Trop Med Public Health.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7112210&query_hl=24&itool=pubmed_docsum
- **Treatment of chronic hepatitis C in patients with glucose-6-phosphate dehydrogenase deficiency: is ribavirin harmful?**
 Author(s): Balestrieri C, Serra G, Cauli C, Chessa L, Balestrieri A, Farci P.
 Source: Blood.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16597599&query_hl=24&itool=pubmed_docsum
- **Two novel mutations (2976INSA, 4311insA) of ATP7B in a patient with Wilson's disease coexisting with glucose-6-phosphate dehydrogenase deficiency.**
 Author(s): Prasad R, Kaur G, Kumar S, Ram Thapa B.
 Source: Journal of Gastroenterology and Hepatology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15836726&query_hl=24&itool=pubmed_docsum

- **Urinary acidification in a patient with glucose-6-phosphate dehydrogenase deficiency. A reevaluation of the role of the hexose monophosphate shunt in renal acid secretion.**
Author(s): Rostand SG, Culpepper RM, Prchal JT.
Source: The American Journal of Medicine.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6247913&query_hl=24&itool=pubmed_docsum
- **Use of fosamprenavir, a sulfa-containing protease inhibitor, in HIV-infected patients with glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Torres HA, Barnett BJ, Arduino RC.
Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17304468&query_hl=24&itool=pubmed_docsum
- **Use of tolfenamic acid in febrile children with and without glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Haliotis FA, Tzortzinis AA, Papanastasiou DA.
Source: Int J Clin Pharmacol Ther.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9088998&query_hl=24&itool=pubmed_docsum
- **Viral hepatitis with haemolytic anaemia due to glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Keng CB.
Source: Singapore Med J.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=5820583&query_hl=24&itool=pubmed_docsum

CHAPTER 2. ALTERNATIVE MEDICINE AND GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY

Overview

In this chapter, we will begin by introducing you to official information sources on complementary and alternative medicine (CAM) relating to glucose-6-phosphate dehydrogenase deficiency. At the conclusion of this chapter, we will provide additional sources.

National Center for Complementary and Alternative Medicine

The National Center for Complementary and Alternative Medicine (NCCAM) of the National Institutes of Health (<http://nccam.nih.gov/>) has created a link to the National Library of Medicine's databases to facilitate research for articles that specifically relate to glucose-6-phosphate dehydrogenase deficiency and complementary medicine. To search the database, go to <http://www.nlm.nih.gov/nccam/camonpubmed.html>. Select **CAM on PubMed**. Enter **glucose-6-phosphate dehydrogenase deficiency** (or synonyms) into the search box. Click **Go**. The following references provide information on particular aspects of complementary and alternative medicine that are related to glucose-6-phosphate dehydrogenase deficiency:

- **A novel method for quantitation of favism-inducing agents in legumes.**
Author(s): Chevion M, Navok T.
Source: Analytical Biochemistry.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6846790&query_hl=1&itool=pubmed_docsum
- **A simple fluorimetric assay for pyridoxamine phosphate oxidase in erythrocyte haemolysates: effects of riboflavin supplementation and of glucose 6-phosphate dehydrogenase deficiency.**
Author(s): Bates CJ, Powers HJ.

Source: Hum Nutr Clin Nutr.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=4019261&query_hl=1&itool=pubmed_docsum

- **Acalypha indica induced haemolysis in G6PD deficiency.**
Author(s): Sellahewa K.
Source: Ceylon Med J.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7820896&query_hl=1&itool=pubmed_docsum
- **Acalypha indica induced haemolysis in G6PD deficiency.**
Author(s): Lamabadusuriya SP, Jayantha UK.
Source: Ceylon Med J.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8194149&query_hl=1&itool=pubmed_docsum
- **Acute haemolysis induced by high dose ascorbic acid in glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Rees DC, Kelsey H, Richards JD.
Source: Bmj (Clinical Research Ed.).
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8490379&query_hl=1&itool=pubmed_docsum
- **Acute haemolytic episodes & fava bean consumption in G6PD deficient Iraqis.**
Author(s): Yahya HI, al-Allawi NA.
Source: The Indian Journal of Medical Research.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8132232&query_hl=1&itool=pubmed_docsum
- **Acute hemolysis related to consumption of fava beans: a case study and medical nutrition therapy approach.**
Author(s): Hampl JS, Holland KA, Marple JT, Hutchins MR, Brockman KK.
Source: Journal of the American Dietetic Association.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9020249&query_hl=1&itool=pubmed_docsum
- **Acute intravascular haemolysis in glucose-6-phosphate dehydrogenase deficient patients following ingestion of herbal broth containing Acalypha indica.**
Author(s): Senanayake N, Sanmuganathan PS.
Source: Trop Doct.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8693563&query_hl=1&itool=pubmed_docsum
- **Acute massive haemolysis in children with glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Lau HK, Li CH, Lee AC.

Source: Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi / Hong Kong Academy of Medicine.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16603783&query_hl=1&itool=pubmed_docsum

- **Anti-nutritional and toxic factors in food legumes: a review.**
 Author(s): Gupta YP.
 Source: Plant Foods for Human Nutrition (Dordrecht, Netherlands).
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2853348&query_hl=1&itool=pubmed_docsum
- **Antioxidant effect of EGb 761 on hydrogen peroxide-induced lipoperoxidation of G-6-PD deficient erythrocytes.**
 Author(s): Sarikcioglu SB, Oner G, Tercan E.
 Source: Phytotherapy Research : Ptr.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15551377&query_hl=1&itool=pubmed_docsum
- **Association between ACP1 and favism: a possible biochemical mechanism.**
 Author(s): Bottini E, Bottini FG, Borgiani P, Businco L.
 Source: Blood.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9116311&query_hl=1&itool=pubmed_docsum
- **Biological activities of broad bean (Vicia faba L.) extracts cultivated in South Anatolia in favism sensitive subjects.**
 Author(s): Vural N, Sardas S.
 Source: Toxicology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6740693&query_hl=1&itool=pubmed_docsum
- **Child health in Singapore. Traditional practices and their effects.**
 Author(s): Boon WH.
 Source: Clinical Pediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=5344428&query_hl=1&itool=pubmed_docsum
- **Coping with toxic pulses.**
 Author(s): Brown EG.
 Source: Nature.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1285803&query_hl=1&itool=pubmed_docsum
- **Dietary rescue of a lethal "null" activity allele of 6-phosphogluconate dehydrogenase in Drosophila melanogaster.**
 Author(s): Hughes MB, Lucchesi JC.

Source: Biochemical Genetics.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=104708&query_hl=1&itool=pubmed_docsum

- **Effect of riboflavin supplementation on erythrocyte glutathione stability.**
Author(s): Flatz G.
Source: Klin Wochenschr.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=5524899&query_hl=1&itool=pubmed_docsum
- **Effects of ascorbic acid on glucose-6-phosphate dehydrogenase-deficient erythrocytes: studies in an animal model.**
Author(s): Udomratn T, Steinberg MH, Campbell GD Jr, Oelshlegel FJ Jr.
Source: Blood.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=836955&query_hl=1&itool=pubmed_docsum
- **Eight children with coexistent sickle cell anemia and plumbism.**
Author(s): Seeler RA.
Source: Clinical Pediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=4209022&query_hl=1&itool=pubmed_docsum
- **Favism by proxy in nursing glucose-6-phosphate dehydrogenase-deficient neonates.**
Author(s): Kaplan M, Vreman HJ, Hammerman C, Schimmel MS, Abrahamov A, Stevenson DK.
Source: Journal of Perinatology : Official Journal of the California Perinatal Association.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9848766&query_hl=1&itool=pubmed_docsum
- **Favism: divicine hemotoxicity in the rat.**
Author(s): McMillan DC, Jollow DJ.
Source: Toxicological Sciences : an Official Journal of the Society of Toxicology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10543033&query_hl=1&itool=pubmed_docsum
- **Favism-inducing toxins in broad beans (*Vicia faba*). Determination of vicine content and investigation of other non-protein nitrogenous compounds in different broad bean cultivars.**
Author(s): Jamalian J.
Source: J Sci Food Agric.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=642461&query_hl=1&itool=pubmed_docsum
- **G6PD deficiency and fava bean consumption do not produce hemolysis in Thailand.**
Author(s): Kitayaporn D, Charoenlarp P, Pattaraarechachai J, Pholpoti T.

Source: Southeast Asian J Trop Med Public Health.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=1948276&query_hl=1&itool=pubmed_docsum

- **G6PD-deficiency infectious haemolysis: a complement dependent innocent bystander phenomenon.**
 Author(s): Kasper ML, Miller WJ, Jacob HS.
 Source: British Journal of Haematology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=3707864&query_hl=1&itool=pubmed_docsum
- **Gall stones, G-6PD deficiency and Wilson's disease.**
 Author(s): Singh R, Sibal A, Jain SK.
 Source: Indian J Pediatr.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12173707&query_hl=1&itool=pubmed_docsum
- **Genetic and dietary adaptation to malaria in human populations.**
 Author(s): Greene LS.
 Source: Parassitologia.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10697854&query_hl=1&itool=pubmed_docsum
- **Green tea polyphenol epigallocatechin-3-gallate protects cells against peroxynitrite-induced cytotoxicity: modulatory effect of cellular G6PD status.**
 Author(s): Ho HY, Wei TT, Cheng ML, Chiu DT.
 Source: Journal of Agricultural and Food Chemistry.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16506813&query_hl=1&itool=pubmed_docsum
- **Hemolysis during BAL chelation therapy for high blood lead levels in two G6PD deficient children.**
 Author(s): Janakiraman N, Seeler RA, Royal JE, Chen MF.
 Source: Clinical Pediatrics.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=417891&query_hl=1&itool=pubmed_docsum
- **Hemolytic anemia following succimer administration in a glucose-6-phosphate dehydrogenase deficient patient.**
 Author(s): Gerr F, Frumkin H, Hodgins P.
 Source: Journal of Toxicology. Clinical Toxicology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7932916&query_hl=1&itool=pubmed_docsum
- **Henna (Lawsonia inermis Linn.) inducing haemolysis among G6PD-deficient newborns. A new clinical observation.**
 Author(s): Kandil HH, al-Ghanem MM, Sarwat MA, al-Thallab FS.

Source: Annals of Tropical Paediatrics.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8985525&query_hl=1&itool=pubmed_docsum

- **Herbal medicine precipitating massive haemolysis.**
Author(s): Baker S, Thomas PS.
Source: Lancet.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2883381&query_hl=1&itool=pubmed_docsum
- **High-dose vitamin E does not decrease the rate of chronic hemolysis in glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Johnson GJ, Vatassery GT, Finkel B, Allen DW.
Source: The New England Journal of Medicine.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6835308&query_hl=1&itool=pubmed_docsum
- **High-performance reversed-phase liquid chromatography (HPLC) of favism-inducing factors in *Vicia faba* L.**
Author(s): Lattanzio V, Bianco VV, Lafiandra D.
Source: Experientia.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7106247&query_hl=1&itool=pubmed_docsum
- **Oxidative haemolysis secondary to high-dose vitamins in a woman with glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Burton C, Kaczmarek R.
Source: British Journal of Haematology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12694240&query_hl=1&itool=pubmed_docsum
- **Prevalence of hemoglobin E, alpha-thalassemia and glucose-6-phosphate dehydrogenase deficiency in 1,000 cord bloods studied in Bangkok.**
Author(s): Tanphaichitr VS, Mahasandana C, Suvatte V, Yodthong S, Pung-amritt P, Seeloem J.
Source: Southeast Asian J Trop Med Public Health.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8629122&query_hl=1&itool=pubmed_docsum
- **Reduced chronic hemolysis during high-dose vitamin E administration in Mediterranean-type glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Corash L, Spielberg S, Bartsocas C, Boxer L, Steinherz R, Sheetz M, Egan M, Schlesselman J, Schulman JD.
Source: The New England Journal of Medicine.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7393270&query_hl=1&itool=pubmed_docsum

- **Resistance of glucose-6-phosphate dehydrogenase deficiency to malaria: effects of fava bean hydroxypyrimidine glucosides on Plasmodium falciparum growth in culture and on the phagocytosis of infected cells.**
Author(s): Ginsburg H, Atamna H, Shalmiev G, Kanaani J, Krugliak M.
Source: Parasitology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8710417&query_hl=1&itool=pubmed_docsum
- **Sporadic G6PD deficiency with haemolytic anaemia in two children of West European ancestry.**
Author(s): Sonnet J, Lievens M, Verpoorten C, Kriekemans J, Eeckels R.
Source: British Journal of Haematology.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=4216362&query_hl=1&itool=pubmed_docsum
- **Topical herbal medicine causing haemolysis in glucose-6-phosphate dehydrogenase deficiency.**
Author(s): Li AM, Hui J, Chik KW, Li CK, Fok TF.
Source: Acta Paediatrica (Oslo, Norway : 1992).
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12412883&query_hl=1&itool=pubmed_docsum

Additional Web Resources

A number of additional Web sites offer encyclopedic information covering CAM and related topics. The following is a representative sample:

- Alternative Medicine Foundation, Inc.: <http://www.herbmed.org/>
- AOL: <http://health.aol.com/healthyliving/althealth>
- Chinese Medicine: <http://www.newcenturynutrition.com/>
- drkoop.com[®]: <http://www.drkoop.com/naturalmedicine.html>
- Family Village: http://www.familyvillage.wisc.edu/med_altn.htm
- Google: <http://directory.google.com/Top/Health/Alternative/>
- Open Directory Project: <http://dmoz.org/Health/Alternative/>
- Yahoo.com: http://dir.yahoo.com/Health/Alternative_Medicine/

General References

A good place to find general background information on CAM is the National Library of Medicine. It has prepared within the MEDLINEplus system an information topic page dedicated to complementary and alternative medicine. To access this page, go to the MEDLINEplus site at <http://www.nlm.nih.gov/medlineplus/alternativemedicine.html>. This Web site provides a general overview of various topics and can lead to a number of general sources.

CHAPTER 3. BOOKS ON GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY

Overview

This chapter provides bibliographic book references relating to glucose-6-phosphate dehydrogenase deficiency. In addition to online booksellers such as **www.amazon.com** and **www.bn.com**, the National Library of Medicine is an excellent source for book titles on glucose-6-phosphate dehydrogenase deficiency. Your local medical library also may have these titles available for loan.

Book Summaries: Online Booksellers

Commercial Internet-based booksellers, such as Amazon.com and Barnes&Noble.com, offer summaries which have been supplied by each title's publisher. Some summaries also include customer reviews. Your local bookseller may have access to in-house and commercial databases that index all published books (e.g. Books in Print®). **IMPORTANT NOTE:** Online booksellers typically produce search results for medical and non-medical books. When searching for **glucose-6-phosphate dehydrogenase deficiency** at online booksellers' Web sites, you may discover non-medical books that use the generic term "glucose-6-phosphate dehydrogenase deficiency" (or a synonym) in their titles. The following is indicative of the results you might find when searching for **glucose-6-phosphate dehydrogenase deficiency** (sorted alphabetically by title; follow the hyperlink to view more details at Amazon.com):

- **Frequencies of Hemoglobin Variants: Thalassemia, The Glucose-6-Phosphate Dehydrogenase Deficiency, G6PD Variants, and Ovalocytosis in Human Populations** Frank B. Livingstone (1985); ISBN: 0195036344;
<http://www.amazon.com/exec/obidos/ASIN/0195036344/icongroupinterna>
- **Gale Encyclopedia of Medicine: Glucose-6-phosphate dehydrogenase deficiency** Lorraine Lica PhD (2004); ISBN: B00075UYBS;
<http://www.amazon.com/exec/obidos/ASIN/B00075UYBS/icongroupinterna>
- **Glucose-6-phosphate dehydrogenase deficiency in Micronesian peoples** Chev Kidson (1962); ISBN: B0007JQN32;
<http://www.amazon.com/exec/obidos/ASIN/B0007JQN32/icongroupinterna>

- **Glucose-6-phosphate dehydrogenase deficiency mutations in Papua New Guinea: An article from: Human Biology** Gillian Wagner, Kuldeep Bhatia, and Philip Board (2005); ISBN: B00096K5EG;
<http://www.amazon.com/exec/obidos/ASIN/B00096K5EG/icongroupinterna>
- **Hemoglobinopathies, G6PD deficiency, and hereditary elliptocytosis in Bahrain.(Brief Communications): An article from: Human Biology** Sumitra Dash (2005); ISBN: B00096ZIIY;
<http://www.amazon.com/exec/obidos/ASIN/B00096ZIIY/icongroupinterna>

APPENDICES

APPENDIX A. HELP ME UNDERSTAND GENETICS

Overview

This appendix presents basic information about genetics in clear language and provides links to online resources.⁷

The Basics: Genes and How They Work

This section gives you information on the basics of cells, DNA, genes, chromosomes, and proteins.

What Is a Cell?

Cells are the basic building blocks of all living things. The human body is composed of trillions of cells. They provide structure for the body, take in nutrients from food, convert those nutrients into energy, and carry out specialized functions. Cells also contain the body's hereditary material and can make copies of themselves.

Cells have many parts, each with a different function. Some of these parts, called organelles, are specialized structures that perform certain tasks within the cell. Human cells contain the following major parts, listed in alphabetical order:

- **Cytoplasm:** The cytoplasm is fluid inside the cell that surrounds the organelles.
- **Endoplasmic reticulum (ER):** This organelle helps process molecules created by the cell and transport them to their specific destinations either inside or outside the cell.
- **Golgi apparatus:** The golgi apparatus packages molecules processed by the endoplasmic reticulum to be transported out of the cell.
- **Lysosomes and peroxisomes:** These organelles are the recycling center of the cell. They digest foreign bacteria that invade the cell, rid the cell of toxic substances, and recycle worn-out cell components.

⁷ This appendix is an excerpt from the National Library of Medicine's handbook, *Help Me Understand Genetics*. For the full text of the *Help Me Understand Genetics* handbook, see <http://ghr.nlm.nih.gov/handbook>.

- **Mitochondria:** Mitochondria are complex organelles that convert energy from food into a form that the cell can use. They have their own genetic material, separate from the DNA in the nucleus, and can make copies of themselves.
- **Nucleus:** The nucleus serves as the cell's command center, sending directions to the cell to grow, mature, divide, or die. It also houses DNA (deoxyribonucleic acid), the cell's hereditary material. The nucleus is surrounded by a membrane called the nuclear envelope, which protects the DNA and separates the nucleus from the rest of the cell.
- **Plasma membrane:** The plasma membrane is the outer lining of the cell. It separates the cell from its environment and allows materials to enter and leave the cell.
- **Ribosomes:** Ribosomes are organelles that process the cell's genetic instructions to create proteins. These organelles can float freely in the cytoplasm or be connected to the endoplasmic reticulum.


What Is DNA?

DNA, or deoxyribonucleic acid, is the hereditary material in humans and almost all other organisms. Nearly every cell in a person's body has the same DNA. Most DNA is located in the cell nucleus (where it is called nuclear DNA), but a small amount of DNA can also be found in the mitochondria (where it is called mitochondrial DNA or mtDNA).

The information in DNA is stored as a code made up of four chemical bases: adenine (A), guanine (G), cytosine (C), and thymine (T). Human DNA consists of about 3 billion bases, and more than 99 percent of those bases are the same in all people. The order, or sequence, of these bases determines the information available for building and maintaining an organism, similar to the way in which letters of the alphabet appear in a certain order to form words and sentences.

DNA bases pair up with each other, A with T and C with G, to form units called base pairs. Each base is also attached to a sugar molecule and a phosphate molecule. Together, a base, sugar, and phosphate are called a nucleotide. Nucleotides are arranged in two long strands that form a spiral called a double helix. The structure of the double helix is somewhat like a ladder, with the base pairs forming the ladder's rungs and the sugar and phosphate molecules forming the vertical sidepieces of the ladder.

An important property of DNA is that it can replicate, or make copies of itself. Each strand of DNA in the double helix can serve as a pattern for duplicating the sequence of bases. This is critical when cells divide because each new cell needs to have an exact copy of the DNA present in the old cell.



U.S. National Library of Medicine

DNA is a double helix formed by base pairs attached to a sugar-phosphate backbone.

What Is Mitochondrial DNA?

Although most DNA is packaged in chromosomes within the nucleus, mitochondria also have a small amount of their own DNA. This genetic material is known as mitochondrial DNA or mtDNA.

Mitochondria are structures within cells that convert the energy from food into a form that cells can use. Each cell contains hundreds to thousands of mitochondria, which are located in the fluid that surrounds the nucleus (the cytoplasm).

Mitochondria produce energy through a process called oxidative phosphorylation. This process uses oxygen and simple sugars to create adenosine triphosphate (ATP), the cell's main energy source. A set of enzyme complexes, designated as complexes I-V, carry out oxidative phosphorylation within mitochondria.

In addition to energy production, mitochondria play a role in several other cellular activities. For example, mitochondria help regulate the self-destruction of cells (apoptosis). They are also necessary for the production of substances such as cholesterol and heme (a component of hemoglobin, the molecule that carries oxygen in the blood).


Mitochondrial DNA contains 37 genes, all of which are essential for normal mitochondrial function. Thirteen of these genes provide instructions for making enzymes involved in oxidative phosphorylation. The remaining genes provide instructions for making molecules called transfer RNAs (tRNAs) and ribosomal RNAs (rRNAs), which are chemical cousins of

DNA. These types of RNA help assemble protein building blocks (amino acids) into functioning proteins.

What Is a Gene?

A gene is the basic physical and functional unit of heredity. Genes, which are made up of DNA, act as instructions to make molecules called proteins. In humans, genes vary in size from a few hundred DNA bases to more than 2 million bases. The Human Genome Project has estimated that humans have between 20,000 and 25,000 genes.

Every person has two copies of each gene, one inherited from each parent. Most genes are the same in all people, but a small number of genes (less than 1 percent of the total) are slightly different between people. Alleles are forms of the same gene with small differences in their sequence of DNA bases. These small differences contribute to each person's unique physical features.




Genes are made up of DNA. Each chromosome contains many genes.

What Is a Chromosome?

In the nucleus of each cell, the DNA molecule is packaged into thread-like structures called chromosomes. Each chromosome is made up of DNA tightly coiled many times around proteins called histones that support its structure.

Chromosomes are not visible in the cell's nucleus—not even under a microscope—when the cell is not dividing. However, the DNA that makes up chromosomes becomes more tightly packed during cell division and is then visible under a microscope. Most of what researchers know about chromosomes was learned by observing chromosomes during cell division.


Each chromosome has a constriction point called the centromere, which divides the chromosome into two sections, or "arms." The short arm of the chromosome is labeled the "p arm." The long arm of the chromosome is labeled the "q arm." The location of the centromere on each chromosome gives the chromosome its characteristic shape, and can be used to help describe the location of specific genes.



DNA and histone proteins are packaged into structures called chromosomes.

How Many Chromosomes Do People Have?

In humans, each cell normally contains 23 pairs of chromosomes, for a total of 46. Twenty-two of these pairs, called autosomes, look the same in both males and females. The 23rd pair, the sex chromosomes, differ between males and females. Females have two copies of the X chromosome, while males have one X and one Y chromosome.



U.S. National Library of Medicine

The 22 autosomes are numbered by size.

The other two chromosomes, X and Y, are the sex chromosomes.

This picture of the human chromosomes lined up in pairs is called a karyotype.

How Do Geneticists Indicate the Location of a Gene?

Geneticists use maps to describe the location of a particular gene on a chromosome. One type of map uses the cytogenetic location to describe a gene's position. The cytogenetic location is based on a distinctive pattern of bands created when chromosomes are stained with certain chemicals. Another type of map uses the molecular location, a precise description of a gene's position on a chromosome. The molecular location is based on the sequence of DNA building blocks (base pairs) that make up the chromosome.

Cytogenetic Location

Geneticists use a standardized way of describing a gene's cytogenetic location. In most cases, the location describes the position of a particular band on a stained chromosome:

17q12

It can also be written as a range of bands, if less is known about the exact location:


17q12-q21

The combination of numbers and letters provide a gene's "address" on a chromosome. This address is made up of several parts:

- The chromosome on which the gene can be found. The first number or letter used to describe a gene's location represents the chromosome. Chromosomes 1 through 22 (the autosomes) are designated by their chromosome number. The sex chromosomes are designated by X or Y.

- The arm of the chromosome. Each chromosome is divided into two sections (arms) based on the location of a narrowing (constriction) called the centromere. By convention, the shorter arm is called p, and the longer arm is called q. The chromosome arm is the second part of the gene's address. For example, 5q is the long arm of chromosome 5, and Xp is the short arm of the X chromosome.
- The position of the gene on the p or q arm. The position of a gene is based on a distinctive pattern of light and dark bands that appear when the chromosome is stained in a certain way. The position is usually designated by two digits (representing a region and a band), which are sometimes followed by a decimal point and one or more additional digits (representing sub-bands within a light or dark area). The number indicating the gene position increases with distance from the centromere. For example: 14q21 represents position 21 on the long arm of chromosome 14. 14q21 is closer to the centromere than 14q22.

Sometimes, the abbreviations "cen" or "ter" are also used to describe a gene's cytogenetic location. "Cen" indicates that the gene is very close to the centromere. For example, 16pcen refers to the short arm of chromosome 16 near the centromere. "Ter" stands for terminus, which indicates that the gene is very close to the end of the p or q arm. For example, 14qter refers to the tip of the long arm of chromosome 14. ("Tel" is also sometimes used to describe a gene's location. "Tel" stands for telomeres, which are at the ends of each chromosome. The abbreviations "tel" and "ter" refer to the same location.)



The CFTR gene is located on the long arm of chromosome 7 at position 7q31.2.

Molecular Location

The Human Genome Project, an international research effort completed in 2003, determined the sequence of base pairs for each human chromosome. This sequence information allows researchers to provide a more specific address than the cytogenetic location for many genes. A gene's molecular address pinpoints the location of that gene in terms of base pairs. For example, the molecular location of the APOE gene on chromosome 19 begins with base pair 50,100,901 and ends with base pair 50,104,488. This range describes the gene's precise position on chromosome 19 and indicates the size of the gene (3,588 base pairs). Knowing a gene's molecular location also allows researchers to determine exactly how far the gene is from other genes on the same chromosome.

Different groups of researchers often present slightly different values for a gene's molecular location. Researchers interpret the sequence of the human genome using a variety of methods, which can result in small differences in a gene's molecular address. For example, the National Center for Biotechnology Information (NCBI) identifies the molecular location of the APOE gene as base pair 50,100,901 to base pair 50,104,488 on chromosome 19. The Ensembl database identifies the location of this gene as base pair 50,100,879 to base pair 50,104,489 on chromosome 19. Neither of these addresses is incorrect; they represent different interpretations of the same data. For consistency, Genetics Home Reference presents data from NCBI for the molecular location of genes.

What Are Proteins and What Do They Do?

Proteins are large, complex molecules that play many critical roles in the body. They do most of the work in cells and are required for the structure, function, and regulation of the body's tissues and organs.

Proteins are made up of hundreds or thousands of smaller units called amino acids, which are attached to one another in long chains. There are 20 different types of amino acids that can be combined to make a protein. The sequence of amino acids determines each protein's unique 3-dimensional structure and its specific function.

Examples of Protein Functions

Proteins can be described according to their large range of functions in the body, listed in alphabetical order:

Function	Description	Example
Antibody	Antibodies bind to specific foreign particles, such as viruses and bacteria, to help protect the body.	Immunoglobulin G (IgG)
Enzyme	Enzymes carry out almost all of the thousands of chemical reactions that take place in cells. They also assist with the formation of new molecules by reading the genetic information stored in DNA.	Phenylalanine hydroxylase
Messenger	Messenger proteins, such as some types of hormones, transmit signals to coordinate biological processes between different cells, tissues, and organs.	Growth hormone
Structural component	These proteins provide structure and support for cells. On a larger scale, they also allow the body to move.	Actin
Transport/storage	These proteins bind and carry atoms and small molecules within cells and throughout the body.	Ferritin

How Does a Gene Make a Protein?


Most genes contain the information needed to make functional molecules called proteins. (A few genes produce other molecules that help the cell assemble proteins.) The journey from gene to protein is complex and tightly controlled within each cell. It consists of two major steps: transcription and translation. Together, transcription and translation are known as gene expression.

During the process of transcription, the information stored in a gene's DNA is transferred to a similar molecule called RNA (ribonucleic acid) in the cell nucleus. Both RNA and DNA are made up of a chain of nucleotide bases, but they have slightly different chemical properties. The type of RNA that contains the information for making a protein is called messenger RNA (mRNA) because it carries the information, or message, from the DNA out of the nucleus into the cytoplasm.

Translation, the second step in getting from a gene to a protein, takes place in the cytoplasm. The mRNA interacts with a specialized complex called a ribosome, which "reads" the sequence of mRNA bases. Each sequence of three bases, called a codon, usually codes for

one particular amino acid. (Amino acids are the building blocks of proteins.) A type of RNA called transfer RNA (tRNA) assembles the protein, one amino acid at a time. Protein assembly continues until the ribosome encounters a “stop” codon (a sequence of three bases that does not code for an amino acid).

The flow of information from DNA to RNA to proteins is one of the fundamental principles of molecular biology. It is so important that it is sometimes called the “central dogma.”



Through the processes of transcription and translation, information from genes is used to make proteins.

Can Genes Be Turned On and Off in Cells?

Each cell expresses, or turns on, only a fraction of its genes. The rest of the genes are repressed, or turned off. The process of turning genes on and off is known as gene regulation. Gene regulation is an important part of normal development. Genes are turned on and off in different patterns during development to make a brain cell look and act different from a liver cell or a muscle cell, for example. Gene regulation also allows cells to react quickly to changes in their environments. Although we know that the regulation of genes is critical for life, this complex process is not yet fully understood.


Gene regulation can occur at any point during gene expression, but most commonly occurs at the level of transcription (when the information in a gene’s DNA is transferred to mRNA). Signals from the environment or from other cells activate proteins called transcription factors. These proteins bind to regulatory regions of a gene and increase or decrease the level of transcription. By controlling the level of transcription, this process can determine the amount of protein product that is made by a gene at any given time.

How Do Cells Divide?

There are two types of cell division: mitosis and meiosis. Most of the time when people refer to “cell division,” they mean mitosis, the process of making new body cells. Meiosis is the type of cell division that creates egg and sperm cells.

Mitosis is a fundamental process for life. During mitosis, a cell duplicates all of its contents, including its chromosomes, and splits to form two identical daughter cells. Because this process is so critical, the steps of mitosis are carefully controlled by a number of genes. When mitosis is not regulated correctly, health problems such as cancer can result.

The other type of cell division, meiosis, ensures that humans have the same number of chromosomes in each generation. It is a two-step process that reduces the chromosome number by half—from 46 to 23—to form sperm and egg cells. When the sperm and egg cells unite at conception, each contributes 23 chromosomes so the resulting embryo will have the usual 46. Meiosis also allows genetic variation through a process of DNA shuffling while the cells are dividing.



Mitosis and meiosis, the two types of cell division.

How Do Genes Control the Growth and Division of Cells?

A variety of genes are involved in the control of cell growth and division. The cell cycle is the cell’s way of replicating itself in an organized, step-by-step fashion. Tight regulation of this process ensures that a dividing cell’s DNA is copied properly, any errors in the DNA are repaired, and each daughter cell receives a full set of chromosomes. The cycle has checkpoints (also called restriction points), which allow certain genes to check for mistakes and halt the cycle for repairs if something goes wrong.

If a cell has an error in its DNA that cannot be repaired, it may undergo programmed cell death (apoptosis). Apoptosis is a common process throughout life that helps the body get rid of cells it doesn't need. Cells that undergo apoptosis break apart and are recycled by a type of white blood cell called a macrophage. Apoptosis protects the body by removing genetically damaged cells that could lead to cancer, and it plays an important role in the development of the embryo and the maintenance of adult tissues.

Cancer results from a disruption of the normal regulation of the cell cycle. When the cycle proceeds without control, cells can divide without order and accumulate genetic defects that can lead to a cancerous tumor.

Genetic Mutations and Health

This section presents basic information about gene mutations, chromosomal changes, and conditions that run in families.⁸

What Is a Gene Mutation and How Do Mutations Occur?

A gene mutation is a permanent change in the DNA sequence that makes up a gene. Mutations range in size from a single DNA building block (DNA base) to a large segment of a chromosome.

Gene mutations occur in two ways: they can be inherited from a parent or acquired during a person's lifetime. Mutations that are passed from parent to child are called hereditary mutations or germline mutations (because they are present in the egg and sperm cells, which are also called germ cells). This type of mutation is present throughout a person's life in virtually every cell in the body.

Mutations that occur only in an egg or sperm cell, or those that occur just after fertilization, are called new (de novo) mutations. De novo mutations may explain genetic disorders in which an affected child has a mutation in every cell, but has no family history of the disorder.

Acquired (or somatic) mutations occur in the DNA of individual cells at some time during a person's life. These changes can be caused by environmental factors such as ultraviolet radiation from the sun, or can occur if a mistake is made as DNA copies itself during cell division. Acquired mutations in somatic cells (cells other than sperm and egg cells) cannot be passed on to the next generation.

Mutations may also occur in a single cell within an early embryo. As all the cells divide during growth and development, the individual will have some cells with the mutation and some cells without the genetic change. This situation is called mosaicism.

Some genetic changes are very rare; others are common in the population. Genetic changes that occur in more than 1 percent of the population are called polymorphisms. They are common enough to be considered a normal variation in the DNA. Polymorphisms are

⁸ This section has been adapted from the National Library of Medicine's handbook, *Help Me Understand Genetics*, which presents basic information about genetics in clear language and provides links to online resources: <http://ghr.nlm.nih.gov/handbook>.

responsible for many of the normal differences between people such as eye color, hair color, and blood type. Although many polymorphisms have no negative effects on a person's health, some of these variations may influence the risk of developing certain disorders.

How Can Gene Mutations Affect Health and Development?

To function correctly, each cell depends on thousands of proteins to do their jobs in the right places at the right times. Sometimes, gene mutations prevent one or more of these proteins from working properly. By changing a gene's instructions for making a protein, a mutation can cause the protein to malfunction or to be missing entirely. When a mutation alters a protein that plays a critical role in the body, it can disrupt normal development or cause a medical condition. A condition caused by mutations in one or more genes is called a genetic disorder.

In some cases, gene mutations are so severe that they prevent an embryo from surviving until birth. These changes occur in genes that are essential for development, and often disrupt the development of an embryo in its earliest stages. Because these mutations have very serious effects, they are incompatible with life.

It is important to note that genes themselves do not cause disease—genetic disorders are caused by mutations that make a gene function improperly. For example, when people say that someone has “the cystic fibrosis gene,” they are usually referring to a mutated version of the CFTR gene, which causes the disease. All people, including those without cystic fibrosis, have a version of the CFTR gene.

Do All Gene Mutations Affect Health and Development?

No, only a small percentage of mutations cause genetic disorders—most have no impact on health or development. For example, some mutations alter a gene's DNA base sequence but do not change the function of the protein made by the gene.

Often, gene mutations that could cause a genetic disorder are repaired by certain enzymes before the gene is expressed (makes a protein). Each cell has a number of pathways through which enzymes recognize and repair mistakes in DNA. Because DNA can be damaged or mutated in many ways, DNA repair is an important process by which the body protects itself from disease.

A very small percentage of all mutations actually have a positive effect. These mutations lead to new versions of proteins that help an organism and its future generations better adapt to changes in their environment. For example, a beneficial mutation could result in a protein that protects the organism from a new strain of bacteria.

For More Information about DNA Repair and the Health Effects of Gene Mutations

- The University of Utah Genetic Science Learning Center provides information about genetic disorders that explains why some mutations cause disorders but others do not. (Refer to the questions in the far right column.)
See <http://learn.genetics.utah.edu/units/disorders/whataregd/>.

- Additional information about DNA repair is available from the NCBI Science Primer. In the chapter called “What Is A Cell?”, scroll down to the heading “DNA Repair Mechanisms.” See http://www.ncbi.nlm.nih.gov/About/primer/genetics_cell.html.

What Kinds of Gene Mutations Are Possible?

The DNA sequence of a gene can be altered in a number of ways. Gene mutations have varying effects on health, depending on where they occur and whether they alter the function of essential proteins. The types of mutations include:

- **Missense mutation:** This type of mutation is a change in one DNA base pair that results in the substitution of one amino acid for another in the protein made by a gene.
- **Nonsense mutation:** A nonsense mutation is also a change in one DNA base pair. Instead of substituting one amino acid for another, however, the altered DNA sequence prematurely signals the cell to stop building a protein. This type of mutation results in a shortened protein that may function improperly or not at all.
- **Insertion:** An insertion changes the number of DNA bases in a gene by adding a piece of DNA. As a result, the protein made by the gene may not function properly.
- **Deletion:** A deletion changes the number of DNA bases by removing a piece of DNA. Small deletions may remove one or a few base pairs within a gene, while larger deletions can remove an entire gene or several neighboring genes. The deleted DNA may alter the function of the resulting protein(s).
- **Duplication:** A duplication consists of a piece of DNA that is abnormally copied one or more times. This type of mutation may alter the function of the resulting protein.
- **Frameshift mutation:** This type of mutation occurs when the addition or loss of DNA bases changes a gene’s reading frame. A reading frame consists of groups of 3 bases that each code for one amino acid. A frameshift mutation shifts the grouping of these bases and changes the code for amino acids. The resulting protein is usually nonfunctional. Insertions, deletions, and duplications can all be frameshift mutations.
- **Repeat expansion:** Nucleotide repeats are short DNA sequences that are repeated a number of times in a row. For example, a trinucleotide repeat is made up of 3-base-pair sequences, and a tetranucleotide repeat is made up of 4-base-pair sequences. A repeat expansion is a mutation that increases the number of times that the short DNA sequence is repeated. This type of mutation can cause the resulting protein to function improperly.

Can Changes in Chromosomes Affect Health and Development?

Changes that affect entire chromosomes or segments of chromosomes can cause problems with growth, development, and function of the body’s systems. These changes can affect many genes along the chromosome and alter the proteins made by those genes. Conditions caused by a change in the number or structure of chromosomes are known as chromosomal disorders.

Human cells normally contain 23 pairs of chromosomes, for a total of 46 chromosomes in each cell. A change in the number of chromosomes leads to a chromosomal disorder. These

changes can occur during the formation of reproductive cells (eggs and sperm) or in early fetal development. A gain or loss of chromosomes from the normal 46 is called aneuploidy.

The most common form of aneuploidy is trisomy, or the presence of an extra chromosome in each cell. “Tri-” is Greek for “three”; people with trisomy have three copies of a particular chromosome in each cell instead of the normal two copies. Down syndrome is an example of a condition caused by trisomy – people with Down syndrome typically have three copies of chromosome 21 in each cell, for a total of 47 chromosomes per cell.

Monosomy, or the loss of one chromosome from each cell, is another kind of aneuploidy. “Mono-” is Greek for “one”; people with monosomy have one copy of a particular chromosome in each cell instead of the normal two copies. Turner syndrome is a condition caused by monosomy. Women with Turner syndrome are often missing one copy of the X chromosome in every cell, for a total of 45 chromosomes per cell.

Chromosomal disorders can also be caused by changes in chromosome structure. These changes are caused by the breakage and reunion of chromosome segments when an egg or sperm cell is formed or in early fetal development. Pieces of DNA can be rearranged within one chromosome, or transferred between two or more chromosomes. The effects of structural changes depend on their size and location. Many different structural changes are possible; some cause medical problems, while others may have no effect on a person’s health.

Many cancer cells also have changes in their chromosome number or structure. These changes most often occur in somatic cells (cells other than eggs and sperm) during a person’s lifetime.

Can Changes in Mitochondrial DNA Affect Health and Development?

Mitochondria are structures within cells that convert the energy from food into a form that cells can use. Although most DNA is packaged in chromosomes within the nucleus, mitochondria also have a small amount of their own DNA (known as mitochondrial DNA or mtDNA). In some cases, inherited changes in mitochondrial DNA can cause problems with growth, development, and function of the body’s systems. These mutations disrupt the mitochondria’s ability to generate energy efficiently for the cell.

Conditions caused by mutations in mitochondrial DNA often involve multiple organ systems. The effects of these conditions are most pronounced in organs and tissues that require a lot of energy (such as the heart, brain, and muscles). Although the health consequences of inherited mitochondrial DNA mutations vary widely, frequently observed features include muscle weakness and wasting, problems with movement, diabetes, kidney failure, heart disease, loss of intellectual functions (dementia), hearing loss, and abnormalities involving the eyes and vision.

Mitochondrial DNA is also prone to noninherited (somatic) mutations. Somatic mutations occur in the DNA of certain cells during a person’s lifetime, and typically are not passed to future generations. Because mitochondrial DNA has a limited ability to repair itself when it is damaged, these mutations tend to build up over time. A buildup of somatic mutations in mitochondrial DNA has been associated with some forms of cancer and an increased risk of certain age-related disorders such as heart disease, Alzheimer disease, and Parkinson

disease. Additionally, research suggests that the progressive accumulation of these mutations over a person's lifetime may play a role in the normal process of aging.

What Are Complex or Multifactorial Disorders?

Researchers are learning that nearly all conditions and diseases have a genetic component. Some disorders, such as sickle cell anemia and cystic fibrosis, are caused by mutations in a single gene. The causes of many other disorders, however, are much more complex. Common medical problems such as heart disease, diabetes, and obesity do not have a single genetic cause—they are likely associated with the effects of multiple genes in combination with lifestyle and environmental factors. Conditions caused by many contributing factors are called complex or multifactorial disorders.

Although complex disorders often cluster in families, they do not have a clear-cut pattern of inheritance. This makes it difficult to determine a person's risk of inheriting or passing on these disorders. Complex disorders are also difficult to study and treat because the specific factors that cause most of these disorders have not yet been identified. By 2010, however, researchers predict they will have found the major contributing genes for many common complex disorders.

What Information about a Genetic Condition Can Statistics Provide?

Statistical data can provide general information about how common a condition is, how many people have the condition, or how likely it is that a person will develop the condition. Statistics are not personalized, however—they offer estimates based on groups of people. By taking into account a person's family history, medical history, and other factors, a genetics professional can help interpret what statistics mean for a particular patient.

Common Statistical Terms

Some statistical terms are commonly used when describing genetic conditions and other disorders. These terms include:

Statistical Term	Description	Examples
<i>Incidence</i>	The incidence of a gene mutation or a genetic disorder is the number of people who are born with the mutation or disorder in a specified group per year. Incidence is often written in the form "1 in [a number]" or as a total number of live births.	About 1 in 200,000 people in the United States are born with syndrome A each year. An estimated 15,000 infants with syndrome B were born last year worldwide.

<i>Prevalence</i>	The prevalence of a gene mutation or a genetic disorder is the total number of people in a specified group at a given time who have the mutation or disorder. This term includes both newly diagnosed and pre-existing cases in people of any age. Prevalence is often written in the form "1 in [a number]" or as a total number of people who have a condition.	Approximately 1 in 100,000 people in the United States have syndrome A at the present time. About 100,000 children worldwide currently have syndrome B.
<i>Mortality</i>	Mortality is the number of deaths from a particular disorder occurring in a specified group per year. Mortality is usually expressed as a total number of deaths.	An estimated 12,000 people worldwide died from syndrome C in 2002.
<i>Lifetime risk</i>	Lifetime risk is the average risk of developing a particular disorder at some point during a lifetime. Lifetime risk is often written as a percentage or as "1 in [a number]." It is important to remember that the risk per year or per decade is much lower than the lifetime risk. In addition, other factors may increase or decrease a person's risk as compared with the average.	Approximately 1 percent of people in the United States develop disorder D during their lifetimes. The lifetime risk of developing disorder D is 1 in 100.

Naming Genetic Conditions

Genetic conditions are not named in one standard way (unlike genes, which are given an official name and symbol by a formal committee). Doctors who treat families with a particular disorder are often the first to propose a name for the condition. Expert working groups may later revise the name to improve its usefulness. Naming is important because it allows accurate and effective communication about particular conditions, which will ultimately help researchers find new approaches to treatment.

Disorder names are often derived from one or a combination of sources:

- The basic genetic or biochemical defect that causes the condition (for example, alpha-1 antitrypsin deficiency)
- One or more major signs or symptoms of the disorder (for example, sickle cell anemia)
- The parts of the body affected by the condition (for example, retinoblastoma)
- The name of a physician or researcher, often the first person to describe the disorder (for example, Marfan syndrome, which was named after Dr. Antoine Bernard-Jean Marfan)

- A geographic area (for example, familial Mediterranean fever, which occurs mainly in populations bordering the Mediterranean Sea)
- The name of a patient or family with the condition (for example, amyotrophic lateral sclerosis, which is also called Lou Gehrig disease after a famous baseball player who had the condition).

Disorders named after a specific person or place are called eponyms. There is debate as to whether the possessive form (e.g., Alzheimer's disease) or the nonpossessive form (Alzheimer disease) of eponyms is preferred. As a rule, medical geneticists use the nonpossessive form, and this form may become the standard for doctors in all fields of medicine. Genetics Home Reference uses the nonpossessive form of eponyms.

Genetics Home Reference consults with experts in the field of medical genetics to provide the current, most accurate name for each disorder. Alternate names are included as synonyms.

Naming genes

The HUGO Gene Nomenclature Committee (HGNC) designates an official name and symbol (an abbreviation of the name) for each known human gene. Some official gene names include additional information in parentheses, such as related genetic conditions, subtypes of a condition, or inheritance pattern. The HGNC is a non-profit organization funded by the U.K. Medical Research Council and the U.S. National Institutes of Health. The Committee has named more than 13,000 of the estimated 20,000 to 25,000 genes in the human genome.

During the research process, genes often acquire several alternate names and symbols. Different researchers investigating the same gene may each give the gene a different name, which can cause confusion. The HGNC assigns a unique name and symbol to each human gene, which allows effective organization of genes in large databanks, aiding the advancement of research. For specific information about how genes are named, refer to the HGNC's Guidelines for Human Gene Nomenclature.

Genetics Home Reference describes genes using the HGNC's official gene names and gene symbols. Genetics Home Reference frequently presents the symbol and name separated with a colon (for example, FGFR4: Fibroblast growth factor receptor 4).


Inheriting Genetic Conditions

This section gives you information on inheritance patterns and understanding risk.

What Does It Mean If a Disorder Seems to Run in My Family?

A particular disorder might be described as "running in a family" if more than one person in the family has the condition. Some disorders that affect multiple family members are caused by gene mutations, which can be inherited (passed down from parent to child). Other conditions that appear to run in families are not inherited. Instead, environmental factors such as dietary habits or a combination of genetic and environmental factors are responsible for these disorders.

It is not always easy to determine whether a condition in a family is inherited. A genetics professional can use a person's family history (a record of health information about a person's immediate and extended family) to help determine whether a disorder has a genetic component.



U.S. National Library of Medicine

Some disorders are seen in more than one generation of a family.

Why Is It Important to Know My Family Medical History?

A family medical history is a record of health information about a person and his or her close relatives. A complete record includes information from three generations of relatives, including children, brothers and sisters, parents, aunts and uncles, nieces and nephews, grandparents, and cousins.

Families have many factors in common, including their genes, environment, and lifestyle. Together, these factors can give clues to medical conditions that may run in a family. By noticing patterns of disorders among relatives, healthcare professionals can determine whether an individual, other family members, or future generations may be at an increased risk of developing a particular condition.

A family medical history can identify people with a higher-than-usual chance of having common disorders, such as heart disease, high blood pressure, stroke, certain cancers, and diabetes. These complex disorders are influenced by a combination of genetic factors, environmental conditions, and lifestyle choices. A family history also can provide information about the risk of rarer conditions caused by mutations in a single gene, such as cystic fibrosis and sickle cell anemia.

While a family medical history provides information about the risk of specific health concerns, having relatives with a medical condition does not mean that an individual will definitely develop that condition. On the other hand, a person with no family history of a disorder may still be at risk of developing that disorder.

Knowing one’s family medical history allows a person to take steps to reduce his or her risk. For people at an increased risk of certain cancers, healthcare professionals may recommend more frequent screening (such as mammography or colonoscopy) starting at an earlier age. Healthcare providers may also encourage regular checkups or testing for people with a medical condition that runs in their family. Additionally, lifestyle changes such as adopting a healthier diet, getting regular exercise, and quitting smoking help many people lower their chances of developing heart disease and other common illnesses.

The easiest way to get information about family medical history is to talk to relatives about their health. Have they had any medical problems, and when did they occur? A family gathering could be a good time to discuss these issues. Additionally, obtaining medical records and other documents (such as obituaries and death certificates) can help complete a family medical history. It is important to keep this information up-to-date and to share it with a healthcare professional regularly.

What Are the Different Ways in which a Genetic Condition Can Be Inherited?

Some genetic conditions are caused by mutations in a single gene. These conditions are usually inherited in one of several straightforward patterns, depending on the gene involved:

Inheritance Pattern	Description	Examples
Autosomal dominant	One mutated copy of the gene in each cell is sufficient for a person to be affected by an autosomal dominant disorder. Each affected person usually has one affected parent. Autosomal dominant disorders tend to occur in every generation of an affected family.	Huntington disease, neurofibromatosis type 1

Autosomal recessive	Two mutated copies of the gene are present in each cell when a person has an autosomal recessive disorder. An affected person usually has unaffected parents who each carry a single copy of the mutated gene (and are referred to as carriers). Autosomal recessive disorders are typically not seen in every generation of an affected family.	cystic fibrosis, sickle cell anemia
X-linked dominant	X-linked dominant disorders are caused by mutations in genes on the X chromosome. Females are more frequently affected than males, and the chance of passing on an X-linked dominant disorder differs between men and women. Families with an X-linked dominant disorder often have both affected males and affected females in each generation. A striking characteristic of X-linked inheritance is that fathers cannot pass X-linked traits to their sons (no male-to-male transmission).	fragile X syndrome
X-linked recessive	X-linked recessive disorders are also caused by mutations in genes on the X chromosome. Males are more frequently affected than females, and the chance of passing on the disorder differs between men and women. Families with an X-linked recessive disorder often have affected males, but rarely affected females, in each generation. A striking characteristic of X-linked inheritance is that fathers cannot pass X-linked traits to their sons (no male-to-male transmission).	hemophilia, Fabry disease
Codominant	In codominant inheritance, two different versions (alleles) of a gene can be expressed, and each version makes a slightly different protein. Both alleles influence the genetic trait or determine the characteristics of the genetic condition.	ABO blood group, alpha-1 antitrypsin deficiency
Mitochondrial	This type of inheritance, also known as maternal inheritance, applies to genes in mitochondrial DNA. Mitochondria, which are structures in each cell that convert molecules into energy, each contain a small amount of DNA. Because only egg cells contribute mitochondria to the developing embryo, only females can pass on mitochondrial conditions to their children. Mitochondrial disorders can appear in every generation of a family and can affect both males and females, but fathers do not pass mitochondrial traits to their children.	Leber hereditary optic neuropathy (LHON)

Many other disorders are caused by a combination of the effects of multiple genes or by interactions between genes and the environment. Such disorders are more difficult to analyze because their genetic causes are often unclear, and they do not follow the patterns of inheritance described above. Examples of conditions caused by multiple genes or gene/environment interactions include heart disease, diabetes, schizophrenia, and certain types of cancer. Disorders caused by changes in the number or structure of chromosomes do not follow the straightforward patterns of inheritance listed above. Other genetic factors can also influence how a disorder is inherited.

If a Genetic Disorder Runs in My Family, What Are the Chances That My Children Will Have the Condition?

When a genetic disorder is diagnosed in a family, family members often want to know the likelihood that they or their children will develop the condition. This can be difficult to predict in some cases because many factors influence a person's chances of developing a genetic condition. One important factor is how the condition is inherited. For example:

- **Autosomal dominant inheritance:** A person affected by an autosomal dominant disorder has a 50 percent chance of passing the mutated gene to each child. The chance that a child will not inherit the mutated gene is also 50 percent.
- **Autosomal recessive inheritance:** Two unaffected people who each carry one copy of the mutated gene for an autosomal recessive disorder (carriers) have a 25 percent chance with each pregnancy of having a child affected by the disorder. The chance with each pregnancy of having an unaffected child who is a carrier of the disorder is 50 percent, and the chance that a child will not have the disorder and will not be a carrier is 25 percent.
- **X-linked dominant inheritance:** The chance of passing on an X-linked dominant condition differs between men and women because men have one X chromosome and one Y chromosome, while women have two X chromosomes. A man passes on his Y chromosome to all of his sons and his X chromosome to all of his daughters. Therefore, the sons of a man with an X-linked dominant disorder will not be affected, but all of his daughters will inherit the condition. A woman passes on one or the other of her X chromosomes to each child. Therefore, a woman with an X-linked dominant disorder has a 50 percent chance of having an affected daughter or son with each pregnancy.
- **X-linked recessive inheritance:** Because of the difference in sex chromosomes, the probability of passing on an X-linked recessive disorder also differs between men and women. The sons of a man with an X-linked recessive disorder will not be affected, and his daughters will carry one copy of the mutated gene. With each pregnancy, a woman who carries an X-linked recessive disorder has a 50 percent chance of having sons who are affected and a 50 percent chance of having daughters who carry one copy of the mutated gene.
- **Codominant inheritance:** In codominant inheritance, each parent contributes a different version of a particular gene, and both versions influence the resulting genetic trait. The chance of developing a genetic condition with codominant inheritance, and the characteristic features of that condition, depend on which versions of the gene are passed from parents to their child.
- **Mitochondrial inheritance:** Mitochondria, which are the energy-producing centers inside cells, each contain a small amount of DNA. Disorders with mitochondrial inheritance result from mutations in mitochondrial DNA. Although mitochondrial

disorders can affect both males and females, only females can pass mutations in mitochondrial DNA to their children. A woman with a disorder caused by changes in mitochondrial DNA will pass the mutation to all of her daughters and sons, but the children of a man with such a disorder will not inherit the mutation.

It is important to note that the chance of passing on a genetic condition applies equally to each pregnancy. For example, if a couple has a child with an autosomal recessive disorder, the chance of having another child with the disorder is still 25 percent (or 1 in 4). Having one child with a disorder does not “protect” future children from inheriting the condition. Conversely, having a child without the condition does not mean that future children will definitely be affected.

Although the chances of inheriting a genetic condition appear straightforward, factors such as a person’s family history and the results of genetic testing can sometimes modify those chances. In addition, some people with a disease-causing mutation never develop any health problems or may experience only mild symptoms of the disorder. If a disease that runs in a family does not have a clear-cut inheritance pattern, predicting the likelihood that a person will develop the condition can be particularly difficult.

Estimating the chance of developing or passing on a genetic disorder can be complex. Genetics professionals can help people understand these chances and help them make informed decisions about their health.

Factors that Influence the Effects of Particular Genetic Changes

Reduced penetrance and variable expressivity are factors that influence the effects of particular genetic changes. These factors usually affect disorders that have an autosomal dominant pattern of inheritance, although they are occasionally seen in disorders with an autosomal recessive inheritance pattern.

Reduced Penetrance

Penetrance refers to the proportion of people with a particular genetic change (such as a mutation in a specific gene) who exhibit signs and symptoms of a genetic disorder. If some people with the mutation do not develop features of the disorder, the condition is said to have reduced (or incomplete) penetrance. Reduced penetrance often occurs with familial cancer syndromes. For example, many people with a mutation in the BRCA1 or BRCA2 gene will develop cancer during their lifetime, but some people will not. Doctors cannot predict which people with these mutations will develop cancer or when the tumors will develop.

Reduced penetrance probably results from a combination of genetic, environmental, and lifestyle factors, many of which are unknown. This phenomenon can make it challenging for genetics professionals to interpret a person’s family medical history and predict the risk of passing a genetic condition to future generations.

Variable Expressivity

Although some genetic disorders exhibit little variation, most have signs and symptoms that differ among affected individuals. Variable expressivity refers to the range of signs and

symptoms that can occur in different people with the same genetic condition. For example, the features of Marfan syndrome vary widely— some people have only mild symptoms (such as being tall and thin with long, slender fingers), while others also experience life-threatening complications involving the heart and blood vessels. Although the features are highly variable, most people with this disorder have a mutation in the same gene (FBN1).

As with reduced penetrance, variable expressivity is probably caused by a combination of genetic, environmental, and lifestyle factors, most of which have not been identified. If a genetic condition has highly variable signs and symptoms, it may be challenging to diagnose.

What Do Geneticists Mean by Anticipation?

The signs and symptoms of some genetic conditions tend to become more severe and appear at an earlier age as the disorder is passed from one generation to the next. This phenomenon is called anticipation. Anticipation is most often seen with certain genetic disorders of the nervous system, such as Huntington disease, myotonic dystrophy, and fragile X syndrome.

Anticipation typically occurs with disorders that are caused by an unusual type of mutation called a trinucleotide repeat expansion. A trinucleotide repeat is a sequence of three DNA building blocks (nucleotides) that is repeated a number of times in a row. DNA segments with an abnormal number of these repeats are unstable and prone to errors during cell division. The number of repeats can change as the gene is passed from parent to child. If the number of repeats increases, it is known as a trinucleotide repeat expansion. In some cases, the trinucleotide repeat may expand until the gene stops functioning normally. This expansion causes the features of some disorders to become more severe with each successive generation.

Most genetic disorders have signs and symptoms that differ among affected individuals, including affected people in the same family. Not all of these differences can be explained by anticipation. A combination of genetic, environmental, and lifestyle factors is probably responsible for the variability, although many of these factors have not been identified. Researchers study multiple generations of affected family members and consider the genetic cause of a disorder before determining that it shows anticipation.

What Is Genomic Imprinting?

Genomic imprinting is a factor that influences how some genetic conditions are inherited.

People inherit two copies of their genes—one from their mother and one from their father. Usually both copies of each gene are active, or “turned on,” in cells. In some cases, however, only one of the two copies is normally turned on. Which copy is active depends on the parent of origin: some genes are normally active only when they are inherited from a person’s father; others are active only when inherited from a person’s mother. This phenomenon is known as genomic imprinting.

In genes that undergo genomic imprinting, the parent of origin is often marked, or “stamped,” on the gene during the formation of egg and sperm cells. This stamping process, called methylation, is a chemical reaction that attaches small molecules called methyl groups to certain segments of DNA. These molecules identify which copy of a gene was inherited

from the mother and which was inherited from the father. The addition and removal of methyl groups can be used to control the activity of genes.

Only a small percentage of all human genes undergo genomic imprinting. Researchers are not yet certain why some genes are imprinted and others are not. They do know that imprinted genes tend to cluster together in the same regions of chromosomes. Two major clusters of imprinted genes have been identified in humans, one on the short (p) arm of chromosome 11 (at position 11p15) and another on the long (q) arm of chromosome 15 (in the region 15q11 to 15q13).

What Is Uniparental Disomy?

Uniparental disomy is a factor that influences how some genetic conditions are inherited.

Uniparental disomy (UPD) occurs when a person receives two copies of a chromosome, or part of a chromosome, from one parent and no copies from the other parent. UPD can occur as a random event during the formation of egg or sperm cells or may happen in early fetal development.

In many cases, UPD likely has no effect on health or development. Because most genes are not imprinted, it doesn't matter if a person inherits both copies from one parent instead of one copy from each parent. In some cases, however, it does make a difference whether a gene is inherited from a person's mother or father. A person with UPD may lack any active copies of essential genes that undergo genomic imprinting. This loss of gene function can lead to delayed development, mental retardation, or other medical problems.

Several genetic disorders can result from UPD or a disruption of normal genomic imprinting. The most well-known conditions include Prader-Willi syndrome, which is characterized by uncontrolled eating and obesity, and Angelman syndrome, which causes mental retardation and impaired speech. Both of these disorders can be caused by UPD or other errors in imprinting involving genes on the long arm of chromosome 15. Other conditions, such as Beckwith-Wiedemann syndrome (a disorder characterized by accelerated growth and an increased risk of cancerous tumors), are associated with abnormalities of imprinted genes on the short arm of chromosome 11.

Are Chromosomal Disorders Inherited?

Although it is possible to inherit some types of chromosomal abnormalities, most chromosomal disorders (such as Down syndrome and Turner syndrome) are not passed from one generation to the next.

Some chromosomal conditions are caused by changes in the number of chromosomes. These changes are not inherited, but occur as random events during the formation of reproductive cells (eggs and sperm). An error in cell division called nondisjunction results in reproductive cells with an abnormal number of chromosomes. For example, a reproductive cell may accidentally gain or lose one copy of a chromosome. If one of these atypical reproductive cells contributes to the genetic makeup of a child, the child will have an extra or missing chromosome in each of the body's cells.

Changes in chromosome structure can also cause chromosomal disorders. Some changes in chromosome structure can be inherited, while others occur as random accidents during the formation of reproductive cells or in early fetal development. Because the inheritance of these changes can be complex, people concerned about this type of chromosomal abnormality may want to talk with a genetics professional.

Some cancer cells also have changes in the number or structure of their chromosomes. Because these changes occur in somatic cells (cells other than eggs and sperm), they cannot be passed from one generation to the next.

Why Are Some Genetic Conditions More Common in Particular Ethnic Groups?

Some genetic disorders are more likely to occur among people who trace their ancestry to a particular geographic area. People in an ethnic group often share certain versions of their genes, which have been passed down from common ancestors. If one of these shared genes contains a disease-causing mutation, a particular genetic disorder may be more frequently seen in the group.

Examples of genetic conditions that are more common in particular ethnic groups are sickle cell anemia, which is more common in people of African, African-American, or Mediterranean heritage; and Tay-Sachs disease, which is more likely to occur among people of Ashkenazi (eastern and central European) Jewish or French Canadian ancestry. It is important to note, however, that these disorders can occur in any ethnic group.

Genetic Consultation

This section presents information on finding and visiting a genetic counselor or other genetics professional.

What Is a Genetic Consultation?

A genetic consultation is a health service that provides information and support to people who have, or may be at risk for, genetic disorders. During a consultation, a genetics professional meets with an individual or family to discuss genetic risks or to diagnose, confirm, or rule out a genetic condition.

Genetics professionals include medical geneticists (doctors who specialize in genetics) and genetic counselors (certified healthcare workers with experience in medical genetics and counseling). Other healthcare professionals such as nurses, psychologists, and social workers trained in genetics can also provide genetic consultations.

Consultations usually take place in a doctor's office, hospital, genetics center, or other type of medical center. These meetings are most often in-person visits with individuals or families, but they are occasionally conducted in a group or over the telephone.

Why Might Someone Have a Genetic Consultation?

Individuals or families who are concerned about an inherited condition may benefit from a genetic consultation. The reasons that a person might be referred to a genetic counselor, medical geneticist, or other genetics professional include:

- A personal or family history of a genetic condition, birth defect, chromosomal disorder, or hereditary cancer.
- Two or more pregnancy losses (miscarriages), a stillbirth, or a baby who died.
- A child with a known inherited disorder, a birth defect, mental retardation, or developmental delay.
- A woman who is pregnant or plans to become pregnant at or after age 35. (Some chromosomal disorders occur more frequently in children born to older women.)
- Abnormal test results that suggest a genetic or chromosomal condition.
- An increased risk of developing or passing on a particular genetic disorder on the basis of a person's ethnic background.
- People related by blood (for example, cousins) who plan to have children together. (A child whose parents are related may be at an increased risk of inheriting certain genetic disorders.)

A genetic consultation is also an important part of the decision-making process for genetic testing. A visit with a genetics professional may be helpful even if testing is not available for a specific condition, however.

What Happens during a Genetic Consultation?

A genetic consultation provides information, offers support, and addresses a patient's specific questions and concerns. To help determine whether a condition has a genetic component, a genetics professional asks about a person's medical history and takes a detailed family history (a record of health information about a person's immediate and extended family). The genetics professional may also perform a physical examination and recommend appropriate tests.

If a person is diagnosed with a genetic condition, the genetics professional provides information about the diagnosis, how the condition is inherited, the chance of passing the condition to future generations, and the options for testing and treatment.

During a consultation, a genetics professional will:

- Interpret and communicate complex medical information.
- Help each person make informed, independent decisions about their health care and reproductive options.
- Respect each person's individual beliefs, traditions, and feelings.

A genetics professional will NOT:

- Tell a person which decision to make.
- Advise a couple not to have children.

- Recommend that a woman continue or end a pregnancy.
- Tell someone whether to undergo testing for a genetic disorder.

How Can I Find a Genetics Professional in My Area?

To find a genetics professional in your community, you may wish to ask your doctor for a referral. If you have health insurance, you can also contact your insurance company to find a medical geneticist or genetic counselor in your area who participates in your plan.

Several resources for locating a genetics professional in your community are available online:

- GeneTests from the University of Washington provides a list of genetics clinics around the United States and international genetics clinics. You can also access the list by clicking on “Clinic Directory” at the top of the GeneTests home page. Clinics can be chosen by state or country, by service, and/or by specialty. State maps can help you locate a clinic in your area. See <http://www.genetests.org/>.
- The National Society of Genetic Counselors offers a searchable directory of genetic counselors in the United States. You can search by location, name, area of practice/specialization, and/or ZIP Code. See <http://www.nsgc.org/resource/link.cfm>.
- The National Cancer Institute provides a Cancer Genetics Services Directory, which lists professionals who provide services related to cancer genetics. You can search by type of cancer or syndrome, location, and/or provider name at the following Web site: http://cancer.gov/search/genetics_services/.

Genetic Testing

This section presents information on the benefits, costs, risks, and limitations of genetic testing.

What Is Genetic Testing?

Genetic testing is a type of medical test that identifies changes in chromosomes, genes, or proteins. Most of the time, testing is used to find changes that are associated with inherited disorders. The results of a genetic test can confirm or rule out a suspected genetic condition or help determine a person’s chance of developing or passing on a genetic disorder. Several hundred genetic tests are currently in use, and more are being developed.

Genetic testing is voluntary. Because testing has both benefits and limitations, the decision about whether to be tested is a personal and complex one. A genetic counselor can help by providing information about the pros and cons of the test and discussing the social and emotional aspects of testing.

What Are the Types of Genetic Tests?

Genetic testing can provide information about a person's genes and chromosomes. Available types of testing include:

- **Newborn screening** is used just after birth to identify genetic disorders that can be treated early in life. Millions of babies are tested each year in the United States. All states currently test infants for phenylketonuria (a genetic disorder that causes mental retardation if left untreated) and congenital hypothyroidism (a disorder of the thyroid gland). Most states also test for other genetic disorders.
- **Diagnostic testing** is used to identify or rule out a specific genetic or chromosomal condition. In many cases, genetic testing is used to confirm a diagnosis when a particular condition is suspected based on physical signs and symptoms. Diagnostic testing can be performed before birth or at any time during a person's life, but is not available for all genes or all genetic conditions. The results of a diagnostic test can influence a person's choices about health care and the management of the disorder.
- **Carrier testing** is used to identify people who carry one copy of a gene mutation that, when present in two copies, causes a genetic disorder. This type of testing is offered to individuals who have a family history of a genetic disorder and to people in certain ethnic groups with an increased risk of specific genetic conditions. If both parents are tested, the test can provide information about a couple's risk of having a child with a genetic condition.
- **Prenatal testing** is used to detect changes in a fetus's genes or chromosomes before birth. This type of testing is offered during pregnancy if there is an increased risk that the baby will have a genetic or chromosomal disorder. In some cases, prenatal testing can lessen a couple's uncertainty or help them make decisions about a pregnancy. It cannot identify all possible inherited disorders and birth defects, however.
- **Preimplantation testing**, also called preimplantation genetic diagnosis (PGD), is a specialized technique that can reduce the risk of having a child with a particular genetic or chromosomal disorder. It is used to detect genetic changes in embryos that were created using assisted reproductive techniques such as in-vitro fertilization. In-vitro fertilization involves removing egg cells from a woman's ovaries and fertilizing them with sperm cells outside the body. To perform preimplantation testing, a small number of cells are taken from these embryos and tested for certain genetic changes. Only embryos without these changes are implanted in the uterus to initiate a pregnancy.
- **Predictive and presymptomatic types of testing** are used to detect gene mutations associated with disorders that appear after birth, often later in life. These tests can be helpful to people who have a family member with a genetic disorder, but who have no features of the disorder themselves at the time of testing. Predictive testing can identify mutations that increase a person's risk of developing disorders with a genetic basis, such as certain types of cancer. Presymptomatic testing can determine whether a person will develop a genetic disorder, such as hemochromatosis (an iron overload disorder), before any signs or symptoms appear. The results of predictive and presymptomatic testing can provide information about a person's risk of developing a specific disorder and help with making decisions about medical care.
- **Forensic testing** uses DNA sequences to identify an individual for legal purposes. Unlike the tests described above, forensic testing is not used to detect gene mutations associated with disease. This type of testing can identify crime or catastrophe victims, rule out or implicate a crime suspect, or establish biological relationships between people (for example, paternity).

How Is Genetic Testing Done?

Once a person decides to proceed with genetic testing, a medical geneticist, primary care doctor, specialist, or nurse practitioner can order the test. Genetic testing is often done as part of a genetic consultation.

Genetic tests are performed on a sample of blood, hair, skin, amniotic fluid (the fluid that surrounds a fetus during pregnancy), or other tissue. For example, a procedure called a buccal smear uses a small brush or cotton swab to collect a sample of cells from the inside surface of the cheek. The sample is sent to a laboratory where technicians look for specific changes in chromosomes, DNA, or proteins, depending on the suspected disorder. The laboratory reports the test results in writing to a person's doctor or genetic counselor.

Newborn screening tests are done on a small blood sample, which is taken by pricking the baby's heel. Unlike other types of genetic testing, a parent will usually only receive the result if it is positive. If the test result is positive, additional testing is needed to determine whether the baby has a genetic disorder.

Before a person has a genetic test, it is important that he or she understands the testing procedure, the benefits and limitations of the test, and the possible consequences of the test results. The process of educating a person about the test and obtaining permission is called informed consent.

What Is Direct-to-Consumer Genetic Testing?

Traditionally, genetic tests have been available only through healthcare providers such as physicians, nurse practitioners, and genetic counselors. Healthcare providers order the appropriate test from a laboratory, collect and send the samples, and interpret the test results. Direct-to-consumer genetic testing refers to genetic tests that are marketed directly to consumers via television, print advertisements, or the Internet. This form of testing, which is also known as at-home genetic testing, provides access to a person's genetic information without necessarily involving a doctor or insurance company in the process.

If a consumer chooses to purchase a genetic test directly, the test kit is mailed to the consumer instead of being ordered through a doctor's office. The test typically involves collecting a DNA sample at home, often by swabbing the inside of the cheek, and mailing the sample back to the laboratory. In some cases, the person must visit a health clinic to have blood drawn. Consumers are notified of their results by mail or over the telephone, or the results are posted online. In some cases, a genetic counselor or other healthcare provider is available to explain the results and answer questions. The price for this type of at-home genetic testing ranges from several hundred dollars to more than a thousand dollars.

The growing market for direct-to-consumer genetic testing may promote awareness of genetic diseases, allow consumers to take a more proactive role in their health care, and offer a means for people to learn about their ancestral origins. At-home genetic tests, however, have significant risks and limitations. Consumers are vulnerable to being misled by the results of unproven or invalid tests. Without guidance from a healthcare provider, they may make important decisions about treatment or prevention based on inaccurate, incomplete, or misunderstood information about their health. Consumers may also experience an invasion of genetic privacy if testing companies use their genetic information in an unauthorized way.

Genetic testing provides only one piece of information about a person's health—other genetic and environmental factors, lifestyle choices, and family medical history also affect a person's risk of developing many disorders. These factors are discussed during a consultation with a doctor or genetic counselor, but in many cases are not addressed by at-home genetic tests. More research is needed to fully understand the benefits and limitations of direct-to-consumer genetic testing.

What Do the Results of Genetic Tests Mean?

The results of genetic tests are not always straightforward, which often makes them challenging to interpret and explain. Therefore, it is important for patients and their families to ask questions about the potential meaning of genetic test results both before and after the test is performed. When interpreting test results, healthcare professionals consider a person's medical history, family history, and the type of genetic test that was done.

A positive test result means that the laboratory found a change in a particular gene, chromosome, or protein of interest. Depending on the purpose of the test, this result may confirm a diagnosis, indicate that a person is a carrier of a particular genetic mutation, identify an increased risk of developing a disease (such as cancer) in the future, or suggest a need for further testing. Because family members have some genetic material in common, a positive test result may also have implications for certain blood relatives of the person undergoing testing. It is important to note that a positive result of a predictive or presymptomatic genetic test usually cannot establish the exact risk of developing a disorder. Also, health professionals typically cannot use a positive test result to predict the course or severity of a condition.

A negative test result means that the laboratory did not find a change in the gene, chromosome, or protein under consideration. This result can indicate that a person is not affected by a particular disorder, is not a carrier of a specific genetic mutation, or does not have an increased risk of developing a certain disease. It is possible, however, that the test missed a disease-causing genetic alteration because many tests cannot detect all genetic changes that can cause a particular disorder. Further testing may be required to confirm a negative result.

In some cases, a negative result might not give any useful information. This type of result is called uninformative, indeterminate, inconclusive, or ambiguous. Uninformative test results sometimes occur because everyone has common, natural variations in their DNA, called polymorphisms, that do not affect health. If a genetic test finds a change in DNA that has not been associated with a disorder in other people, it can be difficult to tell whether it is a natural polymorphism or a disease-causing mutation. An uninformative result cannot confirm or rule out a specific diagnosis, and it cannot indicate whether a person has an increased risk of developing a disorder. In some cases, testing other affected and unaffected family members can help clarify this type of result.

What Is the Cost of Genetic Testing, and How Long Does It Take to Get the Results?

The cost of genetic testing can range from under \$100 to more than \$2,000, depending on the nature and complexity of the test. The cost increases if more than one test is necessary or if multiple family members must be tested to obtain a meaningful result. For newborn

screening, costs vary by state. Some states cover part of the total cost, but most charge a fee of \$15 to \$60 per infant.

From the date that a sample is taken, it may take a few weeks to several months to receive the test results. Results for prenatal testing are usually available more quickly because time is an important consideration in making decisions about a pregnancy. The doctor or genetic counselor who orders a particular test can provide specific information about the cost and time frame associated with that test.

Will Health Insurance Cover the Costs of Genetic Testing?

In many cases, health insurance plans will cover the costs of genetic testing when it is recommended by a person's doctor. Health insurance providers have different policies about which tests are covered, however. A person interested in submitting the costs of testing may wish to contact his or her insurance company beforehand to ask about coverage.

Some people may choose not to use their insurance to pay for testing because the results of a genetic test can affect a person's health insurance coverage. Instead, they may opt to pay out-of-pocket for the test. People considering genetic testing may want to find out more about their state's privacy protection laws before they ask their insurance company to cover the costs.

What Are the Benefits of Genetic Testing?

Genetic testing has potential benefits whether the results are positive or negative for a gene mutation. Test results can provide a sense of relief from uncertainty and help people make informed decisions about managing their health care. For example, a negative result can eliminate the need for unnecessary checkups and screening tests in some cases. A positive result can direct a person toward available prevention, monitoring, and treatment options. Some test results can also help people make decisions about having children. Newborn screening can identify genetic disorders early in life so treatment can be started as early as possible.

What Are the Risks and Limitations of Genetic Testing?

The physical risks associated with most genetic tests are very small, particularly for those tests that require only a blood sample or buccal smear (a procedure that samples cells from the inside surface of the cheek). The procedures used for prenatal testing carry a small but real risk of losing the pregnancy (miscarriage) because they require a sample of amniotic fluid or tissue from around the fetus.

Many of the risks associated with genetic testing involve the emotional, social, or financial consequences of the test results. People may feel angry, depressed, anxious, or guilty about their results. In some cases, genetic testing creates tension within a family because the results can reveal information about other family members in addition to the person who is tested. The possibility of genetic discrimination in employment or insurance is also a concern.

Genetic testing can provide only limited information about an inherited condition. The test often can't determine if a person will show symptoms of a disorder, how severe the symptoms will be, or whether the disorder will progress over time. Another major limitation is the lack of treatment strategies for many genetic disorders once they are diagnosed.

A genetics professional can explain in detail the benefits, risks, and limitations of a particular test. It is important that any person who is considering genetic testing understand and weigh these factors before making a decision.

What Is Genetic Discrimination?

Genetic discrimination occurs when people are treated differently by their employer or insurance company because they have a gene mutation that causes or increases the risk of an inherited disorder. People who undergo genetic testing may be at risk for genetic discrimination.

The results of a genetic test are normally included in a person's medical records. When a person applies for life, disability, or health insurance, the insurance company may ask to look at these records before making a decision about coverage. An employer may also have the right to look at an employee's medical records. As a result, genetic test results could affect a person's insurance coverage or employment. People making decisions about genetic testing should be aware that when test results are placed in their medical records, the results might not be kept private.

Fear of discrimination is a common concern among people considering genetic testing. Several laws at the federal and state levels help protect people against genetic discrimination; however, genetic testing is a fast-growing field and these laws don't cover every situation.

How Does Genetic Testing in a Research Setting Differ from Clinical Genetic Testing?

The main differences between clinical genetic testing and research testing are the purpose of the test and who receives the results. The goals of research testing include finding unknown genes, learning how genes work, and advancing our understanding of genetic conditions. The results of testing done as part of a research study are usually not available to patients or their healthcare providers. Clinical testing, on the other hand, is done to find out about an inherited disorder in an individual patient or family. People receive the results of a clinical test and can use them to help them make decisions about medical care or reproductive issues.

It is important for people considering genetic testing to know whether the test is available on a clinical or research basis. Clinical and research testing both involve a process of informed consent in which patients learn about the testing procedure, the risks and benefits of the test, and the potential consequences of testing.

Gene Therapy

This section presents information on experimental techniques, safety, ethics, and availability of gene therapy.

What Is Gene Therapy?

Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery. Researchers are testing several approaches to gene therapy, including:

- Replacing a mutated gene that causes disease with a healthy copy of the gene.
- Inactivating, or “knocking out,” a mutated gene that is functioning improperly.
- Introducing a new gene into the body to help fight a disease.

Although gene therapy is a promising treatment option for a number of diseases (including inherited disorders, some types of cancer, and certain viral infections), the technique remains risky and is still under study to make sure that it will be safe and effective. Gene therapy is currently only being tested for the treatment of diseases that have no other cures.


How Does Gene Therapy Work?

Gene therapy is designed to introduce genetic material into cells to compensate for abnormal genes or to make a beneficial protein. If a mutated gene causes a necessary protein to be faulty or missing, gene therapy may be able to introduce a normal copy of the gene to restore the function of the protein.

A gene that is inserted directly into a cell usually does not function. Instead, a carrier called a vector is genetically engineered to deliver the gene. Certain viruses are often used as vectors because they can deliver the new gene by infecting the cell. The viruses are modified so they can't cause disease when used in people. Some types of virus, such as retroviruses, integrate their genetic material (including the new gene) into a chromosome in the human cell. Other viruses, such as adenoviruses, introduce their DNA into the nucleus of the cell, but the DNA is not integrated into a chromosome.

The vector can be injected or given intravenously (by IV) directly into a specific tissue in the body, where it is taken up by individual cells. Alternately, a sample of the patient's cells can be removed and exposed to the vector in a laboratory setting. The cells containing the vector are then returned to the patient. If the treatment is successful, the new gene delivered by the vector will make a functioning protein.

Researchers must overcome many technical challenges before gene therapy will be a practical approach to treating disease. For example, scientists must find better ways to deliver genes and target them to particular cells. They must also ensure that new genes are precisely controlled by the body.



A new gene is injected into an adenovirus vector, which is used to introduce the modified DNA into a human cell. If the treatment is successful, the new gene will make a functional protein.

Is Gene Therapy Safe?

Gene therapy is under study to determine whether it could be used to treat disease. Current research is evaluating the safety of gene therapy; future studies will test whether it is an effective treatment option. Several studies have already shown that this approach can have very serious health risks, such as toxicity, inflammation, and cancer. Because the techniques are relatively new, some of the risks may be unpredictable; however, medical researchers, institutions, and regulatory agencies are working to ensure that gene therapy research is as safe as possible.

Comprehensive federal laws, regulations, and guidelines help protect people who participate in research studies (called clinical trials). The U.S. Food and Drug Administration (FDA) regulates all gene therapy products in the United States and oversees research in this area. Researchers who wish to test an approach in a clinical trial must first obtain permission from the FDA. The FDA has the authority to reject or suspend clinical trials that are suspected of being unsafe for participants.

The National Institutes of Health (NIH) also plays an important role in ensuring the safety of gene therapy research. NIH provides guidelines for investigators and institutions (such as universities and hospitals) to follow when conducting clinical trials with gene therapy. These guidelines state that clinical trials at institutions receiving NIH funding for this type of research must be registered with the NIH Office of Biotechnology Activities. The protocol, or plan, for each clinical trial is then reviewed by the NIH Recombinant DNA Advisory Committee (RAC) to determine whether it raises medical, ethical, or safety issues that warrant further discussion at one of the RAC's public meetings.

An Institutional Review Board (IRB) and an Institutional Biosafety Committee (IBC) must approve each gene therapy clinical trial before it can be carried out. An IRB is a committee of scientific and medical advisors and consumers that reviews all research within an institution. An IBC is a group that reviews and approves an institution's potentially hazardous research studies. Multiple levels of evaluation and oversight ensure that safety concerns are a top priority in the planning and carrying out of gene therapy research.

What Are the Ethical Issues surrounding Gene Therapy?

Because gene therapy involves making changes to the body's set of basic instructions, it raises many unique ethical concerns. The ethical questions surrounding gene therapy include:

- How can "good" and "bad" uses of gene therapy be distinguished?
- Who decides which traits are normal and which constitute a disability or disorder?
- Will the high costs of gene therapy make it available only to the wealthy?
- Could the widespread use of gene therapy make society less accepting of people who are different?
- Should people be allowed to use gene therapy to enhance basic human traits such as height, intelligence, or athletic ability?

Current gene therapy research has focused on treating individuals by targeting the therapy to body cells such as bone marrow or blood cells. This type of gene therapy cannot be passed on to a person's children. Gene therapy could be targeted to egg and sperm cells (germ cells), however, which would allow the inserted gene to be passed on to future generations. This approach is known as germline gene therapy.

The idea of germline gene therapy is controversial. While it could spare future generations in a family from having a particular genetic disorder, it might affect the development of a fetus in unexpected ways or have long-term side effects that are not yet known. Because people who would be affected by germline gene therapy are not yet born, they can't choose whether to have the treatment. Because of these ethical concerns, the U.S. Government does not allow federal funds to be used for research on germline gene therapy in people.

Is Gene Therapy Available to Treat My Disorder?

Gene therapy is currently available only in a research setting. The U.S. Food and Drug Administration (FDA) has not yet approved any gene therapy products for sale in the United States.

Hundreds of research studies (clinical trials) are under way to test gene therapy as a treatment for genetic conditions, cancer, and HIV/AIDS. If you are interested in participating in a clinical trial, talk with your doctor or a genetics professional about how to participate.

You can also search for clinical trials online. ClinicalTrials.gov, a service of the National Institutes of Health, provides easy access to information on clinical trials. You can search for

specific trials or browse by condition or trial sponsor. You may wish to refer to a list of gene therapy trials that are accepting (or will accept) patients.

The Human Genome Project and Genomic Research

This section presents information on the goals, accomplishments, and next steps in understanding the human genome.

What Is a Genome?

A genome is an organism's complete set of DNA, including all of its genes. Each genome contains all of the information needed to build and maintain that organism. In humans, a copy of the entire genome—more than 3 billion DNA base pairs—is contained in all cells that have a nucleus.

What Was the Human Genome Project and Why Has It Been Important?

The Human Genome Project was an international research effort to determine the sequence of the human genome and identify the genes that it contains. The Project was coordinated by the National Institutes of Health and the U.S. Department of Energy. Additional contributors included universities across the United States and international partners in the United Kingdom, France, Germany, Japan, and China. The Human Genome Project formally began in 1990 and was completed in 2003, 2 years ahead of its original schedule.

The work of the Human Genome Project has allowed researchers to begin to understand the blueprint for building a person. As researchers learn more about the functions of genes and proteins, this knowledge will have a major impact in the fields of medicine, biotechnology, and the life sciences.

What Were the Goals of the Human Genome Project?

The main goals of the Human Genome Project were to provide a complete and accurate sequence of the 3 billion DNA base pairs that make up the human genome and to find all of the estimated 20,000 to 25,000 human genes. The Project also aimed to sequence the genomes of several other organisms that are important to medical research, such as the mouse and the fruit fly.

In addition to sequencing DNA, the Human Genome Project sought to develop new tools to obtain and analyze the data and to make this information widely available. Also, because advances in genetics have consequences for individuals and society, the Human Genome Project committed to exploring the consequences of genomic research through its Ethical, Legal, and Social Implications (ELSI) program.

What Did the Human Genome Project Accomplish?

In April 2003, researchers announced that the Human Genome Project had completed a high-quality sequence of essentially the entire human genome. This sequence closed the

gaps from a working draft of the genome, which was published in 2001. It also identified the locations of many human genes and provided information about their structure and organization. The Project made the sequence of the human genome and tools to analyze the data freely available via the Internet.

In addition to the human genome, the Human Genome Project sequenced the genomes of several other organisms, including brewers' yeast, the roundworm, and the fruit fly. In 2002, researchers announced that they had also completed a working draft of the mouse genome. By studying the similarities and differences between human genes and those of other organisms, researchers can discover the functions of particular genes and identify which genes are critical for life.

The Project's Ethical, Legal, and Social Implications (ELSI) program became the world's largest bioethics program and a model for other ELSI programs worldwide.

What Were Some of the Ethical, Legal, and Social Implications Addressed by the Human Genome Project?

The Ethical, Legal, and Social Implications (ELSI) program was founded in 1990 as an integral part of the Human Genome Project. The mission of the ELSI program was to identify and address issues raised by genomic research that would affect individuals, families, and society. A percentage of the Human Genome Project budget at the National Institutes of Health and the U.S. Department of Energy was devoted to ELSI research.

The ELSI program focused on the possible consequences of genomic research in four main areas:

- Privacy and fairness in the use of genetic information, including the potential for genetic discrimination in employment and insurance.
- The integration of new genetic technologies, such as genetic testing, into the practice of clinical medicine.
- Ethical issues surrounding the design and conduct of genetic research with people, including the process of informed consent.
- The education of healthcare professionals, policy makers, students, and the public about genetics and the complex issues that result from genomic research.

What Are the Next Steps in Genomic Research?

Discovering the sequence of the human genome was only the first step in understanding how the instructions coded in DNA lead to a functioning human being. The next stage of genomic research will begin to derive meaningful knowledge from the DNA sequence. Research studies that build on the work of the Human Genome Project are under way worldwide.

The objectives of continued genomic research include the following:

- Determine the function of genes and the elements that regulate genes throughout the genome.

- Find variations in the DNA sequence among people and determine their significance. These variations may one day provide information about a person's disease risk and response to certain medications.
- Discover the 3-dimensional structures of proteins and identify their functions.
- Explore how DNA and proteins interact with one another and with the environment to create complex living systems.
- Develop and apply genome-based strategies for the early detection, diagnosis, and treatment of disease.
- Sequence the genomes of other organisms, such as the rat, cow, and chimpanzee, in order to compare similar genes between species.
- Develop new technologies to study genes and DNA on a large scale and store genomic data efficiently.
- Continue to explore the ethical, legal, and social issues raised by genomic research.

What Is Pharmacogenomics?

Pharmacogenomics is the study of how genes affect a person's response to drugs. This relatively new field combines pharmacology (the science of drugs) and genomics (the study of genes and their functions) to develop effective, safe medications and doses that will be tailored to a person's genetic makeup.

Many drugs that are currently available are "one size fits all," but they don't work the same way for everyone. It can be difficult to predict who will benefit from a medication, who will not respond at all, and who will experience negative side effects (called adverse drug reactions). Adverse drug reactions are a significant cause of hospitalizations and deaths in the United States. With the knowledge gained from the Human Genome Project, researchers are learning how inherited differences in genes affect the body's response to medications. These genetic differences will be used to predict whether a medication will be effective for a particular person and to help prevent adverse drug reactions.

The field of pharmacogenomics is still in its infancy. Its use is currently quite limited, but new approaches are under study in clinical trials. In the future, pharmacogenomics will allow the development of tailored drugs to treat a wide range of health problems, including cardiovascular disease, Alzheimer disease, cancer, HIV/AIDS, and asthma.

APPENDIX B. PHYSICIAN RESOURCES

Overview

In this chapter, we focus on databases and Internet-based guidelines and information resources created or written for a professional audience.

NIH Guidelines

Commonly referred to as “clinical” or “professional” guidelines, the National Institutes of Health publish physician guidelines for the most common diseases. Publications are available at the following by relevant Institute⁹:

- National Institutes of Health (NIH); guidelines consolidated across agencies available at <http://health.nih.gov/>
- National Institute of General Medical Sciences (NIGMS); fact sheets available at <http://www.nigms.nih.gov/Publications/FactSheets.htm>
- National Library of Medicine (NLM); extensive encyclopedia (A.D.A.M., Inc.) with guidelines: <http://www.nlm.nih.gov/medlineplus/healthtopics.html>
- National Cancer Institute (NCI); guidelines available at <http://www.cancer.gov/cancertopics/pdq>
- National Eye Institute (NEI); guidelines available at <http://www.nei.nih.gov/health/>
- National Heart, Lung, and Blood Institute (NHLBI); guidelines available at <http://www.nhlbi.nih.gov/guidelines/index.htm>
- National Human Genome Research Institute (NHGRI); research available at <http://www.genome.gov/page.cfm?pageID=10000375>
- National Institute on Aging (NIA); guidelines available at <http://www.nia.nih.gov/HealthInformation/Publications/>
- National Institute on Alcohol Abuse and Alcoholism (NIAAA); guidelines available at <http://www.niaaa.nih.gov/Publications/>

⁹ These publications are typically written by one or more of the various NIH Institutes.

- National Institute of Allergy and Infectious Diseases (NIAID); guidelines available at <http://www.niaid.nih.gov/publications/>
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); fact sheets and guidelines available at <http://www.niams.nih.gov/hi/index.htm>
- National Institute of Child Health and Human Development (NICHD); guidelines available at <http://www.nichd.nih.gov/publications/pubskey.cfm>
- National Institute on Deafness and Other Communication Disorders (NIDCD); fact sheets and guidelines at <http://www.nidcd.nih.gov/health/>
- National Institute of Dental and Craniofacial Research (NIDCR); guidelines available at <http://www.nidcr.nih.gov/HealthInformation/>
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); guidelines available at <http://www.niddk.nih.gov/health/health.htm>
- National Institute on Drug Abuse (NIDA); guidelines available at <http://www.nida.nih.gov/DrugAbuse.html>
- National Institute of Environmental Health Sciences (NIEHS); environmental health information available at <http://www.niehs.nih.gov/external/facts.htm>
- National Institute of Mental Health (NIMH); guidelines available at <http://www.nimh.nih.gov/healthinformation/index.cfm>
- National Institute of Neurological Disorders and Stroke (NINDS); neurological disorder information pages available at http://www.ninds.nih.gov/health_and_medical/disorder_index.htm
- National Institute of Biomedical Imaging and Bioengineering; general information at <http://www.nibib.nih.gov/HealthEdu>
- National Center for Complementary and Alternative Medicine (NCCAM); health information available at <http://nccam.nih.gov/health/>
- National Center for Research Resources (NCRR); various information directories available at <http://www.ncrr.nih.gov/publications.asp>
- Office of Rare Diseases; various fact sheets available at http://rarediseases.info.nih.gov/html/resources/rep_pubs.html
- Centers for Disease Control and Prevention; various fact sheets on infectious diseases available at <http://www.cdc.gov/publications.htm>

NIH Databases

In addition to the various Institutes of Health that publish professional guidelines, the NIH has designed a number of databases for professionals.¹⁰ Physician-oriented resources provide a wide variety of information related to the biomedical and health sciences, both past and present. The format of these resources varies. Searchable databases, bibliographic

¹⁰ Remember, for the general public, the National Library of Medicine recommends the databases referenced in MEDLINEplus (<http://medlineplus.gov/> or <http://www.nlm.nih.gov/medlineplus/databases.html>).

citations, full-text articles (when available), archival collections, and images are all available. The following are referenced by the National Library of Medicine¹¹:

- **Bioethics:** Access to published literature on the ethical, legal, and public policy issues surrounding healthcare and biomedical research. This information is provided in conjunction with the Kennedy Institute of Ethics located at Georgetown University, Washington, D.C.: http://www.nlm.nih.gov/databases/databases_bioethics.html
- **HIV/AIDS Resources:** Describes various links and databases dedicated to HIV/AIDS research: <http://www.nlm.nih.gov/pubs/factsheets/aidsinfs.html>
- **NLM Online Exhibitions:** Describes “Exhibitions in the History of Medicine”: <http://www.nlm.nih.gov/exhibition/exhibition.html>. Additional resources for historical scholarship in medicine: <http://www.nlm.nih.gov/hmd/index.html>
- **Biotechnology Information:** Access to public databases. The National Center for Biotechnology Information conducts research in computational biology, develops software tools for analyzing genome data, and disseminates biomedical information for the better understanding of molecular processes affecting human health and disease: <http://www.ncbi.nlm.nih.gov/>
- **Population Information:** The National Library of Medicine provides access to worldwide coverage of population, family planning, and related health issues, including family planning technology and programs, fertility, and population law and policy: http://www.nlm.nih.gov/databases/databases_population.html
- **Cancer Information:** Access to cancer-oriented databases: http://www.nlm.nih.gov/databases/databases_cancer.html
- **Profiles in Science:** Offering the archival collections of prominent twentieth-century biomedical scientists to the public through modern digital technology: <http://www.profiles.nlm.nih.gov/>
- **Chemical Information:** Provides links to various chemical databases and references: <http://sis.nlm.nih.gov/Chem/ChemMain.html>
- **Clinical Alerts:** Reports the release of findings from the NIH-funded clinical trials where such release could significantly affect morbidity and mortality: http://www.nlm.nih.gov/databases/alerts/clinical_alerts.html
- **Space Life Sciences:** Provides links and information to space-based research (including NASA): http://www.nlm.nih.gov/databases/databases_space.html
- **MEDLINE:** Bibliographic database covering the fields of medicine, nursing, dentistry, veterinary medicine, the healthcare system, and the pre-clinical sciences: http://www.nlm.nih.gov/databases/databases_medline.html
- **Toxicology and Environmental Health Information (TOXNET):** Databases covering toxicology and environmental health: <http://sis.nlm.nih.gov/Tox/ToxMain.html>
- **Visible Human Interface:** Anatomically detailed, three-dimensional representations of normal male and female human bodies: http://www.nlm.nih.gov/research/visible/visible_human.html

¹¹ See <http://www.nlm.nih.gov/databases/index.html>.

The NLM Gateway¹²

The NLM (National Library of Medicine) Gateway is a Web-based system that lets users search simultaneously in multiple retrieval systems at the U.S. National Library of Medicine (NLM). It allows users of NLM services to initiate searches from one Web interface, providing one-stop searching for many of NLM's information resources or databases.¹³ To use the NLM Gateway, simply go to the search site at <http://gateway.nlm.nih.gov/gw/Cmd>. Type **glucose-6-phosphate dehydrogenase deficiency** (or synonyms) into the search box and click **Search**. The results will be presented in a tabular form, indicating the number of references in each database category.

Results Summary

Category	Items Found
Journal Articles	4042
Books / Periodicals / Audio Visual	27
Consumer Health	24
Meeting Abstracts	1
Other Collections	0
Total	4094

HSTAT¹⁴

HSTAT is a free, Web-based resource that provides access to full-text documents used in healthcare decision-making.¹⁵ These documents include clinical practice guidelines, quick-reference guides for clinicians, consumer health brochures, evidence reports and technology assessments from the Agency for Healthcare Research and Quality (AHRQ), as well as AHRQ's Put Prevention Into Practice.¹⁶ Simply search by **glucose-6-phosphate dehydrogenase deficiency** (or synonyms) at the following Web site: <http://text.nlm.nih.gov>.

Coffee Break: Tutorials for Biologists¹⁷

Coffee Break is a general healthcare site that takes a scientific view of the news and covers recent breakthroughs in biology that may one day assist physicians in developing treatments. Here you will find a collection of short reports on recent biological discoveries.

¹² Adapted from NLM: <http://gateway.nlm.nih.gov/gw/Cmd?Overview.x>.

¹³ The NLM Gateway is currently being developed by the Lister Hill National Center for Biomedical Communications (LHNCBC) at the National Library of Medicine (NLM) of the National Institutes of Health (NIH).

¹⁴ Adapted from HSTAT: <http://www.nlm.nih.gov/pubs/factsheets/hstat.html>.

¹⁵ The HSTAT URL is <http://hstat.nlm.nih.gov/>.

¹⁶ Other important documents in HSTAT include: the National Institutes of Health (NIH) Consensus Conference Reports and Technology Assessment Reports; the HIV/AIDS Treatment Information Service (ATIS) resource documents; the Substance Abuse and Mental Health Services Administration's Center for Substance Abuse Treatment (SAMHSA/CSAT) Treatment Improvement Protocols (TIP) and Center for Substance Abuse Prevention (SAMHSA/CSAP) Prevention Enhancement Protocols System (PEPS); the Public Health Service (PHS) Preventive Services Task Force's *Guide to Clinical Preventive Services*; the independent, nonfederal Task Force on Community Services' *Guide to Community Preventive Services*; and the Health Technology Advisory Committee (HTAC) of the Minnesota Health Care Commission (MHCC) health technology evaluations.

¹⁷ Adapted from <http://www.ncbi.nlm.nih.gov/Coffeefbreak/Archive/FAQ.html>.

Each report incorporates interactive tutorials that demonstrate how bioinformatics tools are used as a part of the research process. Currently, all Coffee Breaks are written by NCBI staff.¹⁸ Each report is about 400 words and is usually based on a discovery reported in one or more articles from recently published, peer-reviewed literature.¹⁹ This site has new articles every few weeks, so it can be considered an online magazine of sorts. It is intended for general background information. You can access the Coffee Break Web site at the following hyperlink: <http://www.ncbi.nlm.nih.gov/Coffeebreak/>.

Other Commercial Databases

In addition to resources maintained by official agencies, other databases exist that are commercial ventures addressing medical professionals. Here are some examples that may interest you:

- **MD Consult:** Access to electronic clinical resources, see <http://www.mdconsult.com/>.
- **Medical Matrix:** Lists over 6000 medical Web sites and links to over 1.5 million documents with clinical content, see <http://www.medmatrix.org/>.
- **Medical World Search:** Searches full text from thousands of selected medical sites on the Internet; see <http://www.mwsearch.com/>.

¹⁸ The figure that accompanies each article is frequently supplied by an expert external to NCBI, in which case the source of the figure is cited. The result is an interactive tutorial that tells a biological story.

¹⁹ After a brief introduction that sets the work described into a broader context, the report focuses on how a molecular understanding can provide explanations of observed biology and lead to therapies for diseases. Each vignette is accompanied by a figure and hypertext links that lead to a series of pages that interactively show how NCBI tools and resources are used in the research process.

APPENDIX C. PATIENT RESOURCES

Overview

Official agencies, as well as federally funded institutions supported by national grants, frequently publish a variety of guidelines written with the patient in mind. These are typically called **Fact Sheets** or **Guidelines**. They can take the form of a brochure, information kit, pamphlet, or flyer. Often they are only a few pages in length. Since new guidelines on glucose-6-phosphate dehydrogenase deficiency can appear at any moment and be published by a number of sources, the best approach to finding guidelines is to systematically scan the Internet-based services that post them.

Patient Guideline Sources

This section directs you to sources which either publish fact sheets or can help you find additional guidelines on topics related to glucose-6-phosphate dehydrogenase deficiency. Due to space limitations, these sources are listed in a concise manner. Do not hesitate to consult the following sources by either using the Internet hyperlink provided, or, in cases where the contact information is provided, contacting the publisher or author directly.

The National Institutes of Health

The NIH gateway to patients is located at <http://health.nih.gov/>. From this site, you can search across various sources and institutes, a number of which are summarized below.

Topic Pages: MEDLINEplus

The National Library of Medicine has created a vast and patient-oriented healthcare information portal called MEDLINEplus. Within this Internet-based system are **health topic pages** which list links to available materials relevant to glucose-6-phosphate dehydrogenase deficiency. Log on to <http://www.nlm.nih.gov/medlineplus/healthtopics.html> to access this system. From there you can either search using the alphabetical index or browse by broad topic areas. Recently, MEDLINEplus listed the following when searched for **glucose-6-phosphate dehydrogenase deficiency**:

Anemia

<http://www.nlm.nih.gov/medlineplus/anemia.html>

Bleeding Disorders

<http://www.nlm.nih.gov/medlineplus/bleedingdisorders.html>

Growth Disorders

<http://www.nlm.nih.gov/medlineplus/growthdisorders.html>

Hormones

<http://www.nlm.nih.gov/medlineplus/hormones.html>

Laboratory Tests

<http://www.nlm.nih.gov/medlineplus/laboratorytests.html>

Liver Diseases

<http://www.nlm.nih.gov/medlineplus/liverdiseases.html>

Metabolic Disorders

<http://www.nlm.nih.gov/medlineplus/metabolicdisorders.html>

Metabolic Syndrome

<http://www.nlm.nih.gov/medlineplus/metabolicsyndrome.html>

Newborn Screening

<http://www.nlm.nih.gov/medlineplus/newbornscreening.html>

You may also choose to use the search utility provided by MEDLINEplus at the following Web address: <http://www.nlm.nih.gov/medlineplus/>. Simply type a keyword into the search box and click **Search**. This utility is similar to the NIH search utility, with the exception that it only includes materials that are linked within the MEDLINEplus system (mostly patient-oriented information). It also has the disadvantage of generating unstructured results. We recommend, therefore, that you use this method only if you have a very targeted search.

Healthfinder™

Healthfinder™ is sponsored by the U.S. Department of Health and Human Services and offers links to hundreds of other sites that contain healthcare information. This Web site is located at <http://www.healthfinder.gov>. Again, keyword searches can be used to find guidelines. The following was recently found in this database:

- **Drug Profiles: Aspirin for Migraines**

Source: www.migraines.org

<http://www.migraines.org/treatment/proasprn.htm>

- **MedlinePlus: Metabolic Disorders**

Source: www.nlm.nih.gov

<http://www.nlm.nih.gov/medlineplus/metabolicdisorders.html>

- **MedlinePlus: Newborn Screening**

Source: www.nlm.nih.gov

<http://www.nlm.nih.gov/medlineplus/newbornscreening.html>

- **NORD - National Organization for Rare Disorders, Inc.**

Source: www.rarediseases.org

http://www.rarediseases.org/search/rdblist.html?query_start=401

The NIH Search Utility

The NIH search utility allows you to search for documents on over 100 selected Web sites that comprise the NIH-WEB-SPACE. Each of these servers is “crawled” and indexed on an ongoing basis. Your search will produce a list of various documents, all of which will relate in some way to glucose-6-phosphate dehydrogenase deficiency. The drawbacks of this approach are that the information is not organized by theme and that the references are often a mix of information for professionals and patients. Nevertheless, a large number of the listed Web sites provide useful background information. We can only recommend this route, therefore, for relatively rare or specific disorders, or when using highly targeted searches. To use the NIH search utility, visit the following Web page: <http://health.nih.gov/index.asp>. Under **Search Health Topics**, type **glucose-6-phosphate dehydrogenase deficiency** (or synonyms) into the search box, and click **Search**.

Additional Web Sources

A number of Web sites are available to the public that often link to government sites. These can also point you in the direction of essential information. The following is a representative sample:

- Family Village: <http://www.familyvillage.wisc.edu/specific.htm>
- Google: http://directory.google.com/Top/Health/Conditions_and_Diseases/
- Med Help International: <http://www.medhelp.org/HealthTopics/A.html>
- Open Directory Project: http://dmoz.org/Health/Conditions_and_Diseases/
- Yahoo.com: http://dir.yahoo.com/Health/Diseases_and_Conditions/
- WebMD®Health: http://www.webmd.com/diseases_and_conditions/default.htm

Finding Associations

There are several Internet directories that provide lists of medical associations with information on or resources relating to glucose-6-phosphate dehydrogenase deficiency. By consulting all of associations listed in this chapter, you will have nearly exhausted all sources for patient associations concerned with glucose-6-phosphate dehydrogenase deficiency.

The National Health Information Center (NHIC)

The National Health Information Center (NHIC) offers a free referral service to help people find organizations that provide information about glucose-6-phosphate dehydrogenase deficiency. For more information, see the NHIC's Web site at <http://www.health.gov/NHIC/> or contact an information specialist by calling 1-800-336-4797.

Directory of Health Organizations

The Directory of Health Organizations, provided by the National Library of Medicine Specialized Information Services, is a comprehensive source of information on associations. The Directory of Health Organizations database can be accessed via the Internet at <http://sis.nlm.nih.gov/dirline.html>. It is composed of two parts: DIRLINE and Health Hotlines.

The DIRLINE database comprises some 10,000 records of organizations, research centers, and government institutes and associations that primarily focus on health and biomedicine. Simply type in **glucose-6-phosphate dehydrogenase deficiency** (or a synonym), and you will receive information on all relevant organizations listed in the database.

Health Hotlines directs you to toll-free numbers to over 300 organizations. You can access this database directly at <http://healthhotlines.nlm.nih.gov/>. On this page, you are given the option to search by keyword or by browsing the subject list. When you have received your search results, click on the name of the organization for its description and contact information.

The National Organization for Rare Disorders, Inc.

The National Organization for Rare Disorders, Inc. has prepared a Web site that provides, at no charge, lists of associations organized by health topic. You can access this database at the following Web site: <http://www.rarediseases.org/search/orgsearch.html>. Type **glucose-6-phosphate dehydrogenase deficiency** (or a synonym) into the search box, and click **Submit Query**.

Resources for Patients and Families

The following are organizations that provide support and advocacy for patient with genetic conditions and their families²⁰:

- Genetic Alliance: <http://geneticalliance.org>
- Genetic and Rare Diseases Information Center:
http://rarediseases.info.nih.gov/html/resources/info_cntr.html
- Madisons Foundation: <http://www.madisonsfoundation.org/>
- March of Dimes: <http://www.marchofdimes.com>
- National Organization for Rare Disorders (NORD): <http://www.rarediseases.org/>

²⁰ Adapted from the National Library of Medicine: <http://ghr.nlm.nih.gov/ghr/resource/patients>.

For More Information on Genetics

The following publications offer detailed information for patients about the science of genetics:

- What Is a Genome?: http://www.ncbi.nlm.nih.gov/About/primer/genetics_genome.html
- A Science Called Genetics: <http://publications.nigms.nih.gov/genetics/science.html>
- Genetic Mapping: <http://www.genome.gov/1000715>

ONLINE GLOSSARIES

The Internet provides access to a number of free-to-use medical dictionaries. The National Library of Medicine has compiled the following list of online dictionaries:

- ADAM Medical Encyclopedia (A.D.A.M., Inc.), comprehensive medical reference:
<http://www.nlm.nih.gov/medlineplus/encyclopedia.html>
- MedicineNet.com Medical Dictionary (MedicineNet, Inc.):
<http://www.medterms.com/Script/Main/hp.asp>
- Merriam-Webster Medical Dictionary (Inteli-Health, Inc.):
<http://www.intelihealth.com/IH/>
- Multilingual Glossary of Technical and Popular Medical Terms in Eight European Languages (European Commission) - Danish, Dutch, English, French, German, Italian, Portuguese, and Spanish: <http://allserv.rug.ac.be/~rvdstich/eugloss/welcome.html>
- On-line Medical Dictionary (CancerWEB): <http://cancerweb.ncl.ac.uk/omd/>
- Rare Diseases Terms (Office of Rare Diseases):
<http://ord.aspensys.com/asp/diseases/diseases.asp>
- Technology Glossary (National Library of Medicine) - Health Care Technology:
<http://www.nlm.nih.gov/archive/20040831/nichsr/ta101/ta10108.html>

Beyond these, MEDLINEplus contains a very patient-friendly encyclopedia covering every aspect of medicine (licensed from A.D.A.M., Inc.). The ADAM Medical Encyclopedia can be accessed at <http://www.nlm.nih.gov/medlineplus/encyclopedia.html>. ADAM is also available on commercial Web sites such as drkoop.com (<http://www.drkoop.com/>) and Web MD (http://my.webmd.com/adam/asset/adam_disease_articles/a_to_z/a). The NIH suggests the following Web sites in the ADAM Medical Encyclopedia when searching for information on glucose-6-phosphate dehydrogenase deficiency:

- **Basic Guidelines for Glucose-6-Phosphate Dehydrogenase Deficiency**

Glucose-6-phosphate dehydrogenase deficiency

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/000528.htm>

- **Signs & Symptoms for Glucose-6-Phosphate Dehydrogenase Deficiency**

Anemia

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/000560.htm>

Anemic

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/000560.htm>

Dark urine

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003138.htm>

Enlarged spleen

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003276.htm>

Fatigue

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003088.htm>

Hemolytic crisis

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003270.htm>

Jaundice

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003243.htm>

Pale

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003244.htm>

Rapid heart rate

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003077.htm>

Shortness of breath

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003075.htm>

Stress

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003211.htm>

Yellow skin color

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003243.htm>

- **Diagnostics and Tests for Glucose-6-Phosphate Dehydrogenase Deficiency**

Bilirubin

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003479.htm>

Blood smear

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003665.htm>

Haptoglobin

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003634.htm>

Hemoglobin

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003645.htm>

Hemoglobinuria

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003363.htm>

Methemoglobin reduction

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003371.htm>

Methylene blue test

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003412.htm>

Red blood cell count

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003644.htm>

Reticulocyte count

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003637.htm>

Serum haptoglobin

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/003634.htm>

- **Background Topics for Glucose-6-Phosphate Dehydrogenase Deficiency**

Acute

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/002215.htm>

Chronic

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/002312.htm>

Enzyme

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/002353.htm>

Hemolysis

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/002372.htm>

Incidence

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/002387.htm>

Peripheral

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/002273.htm>

Precipitate

Web site: <http://www.nlm.nih.gov/medlineplus/ency/article/002275.htm>

Online Dictionary Directories

The following are additional online directories compiled by the National Library of Medicine, including a number of specialized medical dictionaries:

- Medical Dictionaries: Medical & Biological (World Health Organization):
<http://www.who.int/hlt/virtuallibrary/English/diction.htm#Medical>
- Patient Education: Glossaries (DMOZ Open Directory Project):
http://dmoz.org/Health/Education/Patient_Education/Glossaries/
- Web of Online Dictionaries (Bucknell University):
<http://www.yourdictionary.com/diction5.html#medicine>

GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY DICTIONARY

The definitions below are derived from official public sources, including the National Institutes of Health [NIH] and the European Union [EU].

3-dimensional: 3-D. A graphic display of depth, width, and height. Three-dimensional radiation therapy uses computers to create a 3-dimensional picture of the tumor. This allows doctors to give the highest possible dose of radiation to the tumor, while sparing the normal tissue as much as possible. [NIH]

Abdomen: That portion of the body that lies between the thorax and the pelvis. [NIH]

Acatalasia: A rare autosomal recessive disorder resulting from the absence of catalase activity. Though usually asymptomatic, a syndrome of oral ulcerations and gangrene may be present. [NIH]

Acceptor: A substance which, while normally not oxidized by oxygen or reduced by hydrogen, can be oxidized or reduced in presence of a substance which is itself undergoing oxidation or reduction. [NIH]

Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage. [NIH]

Acetylcysteine: The N-acetyl derivative of cysteine. It is used as a mucolytic agent to reduce the viscosity of mucous secretions. It has also been shown to have antiviral effects in patients with HIV due to inhibition of viral stimulation by reactive oxygen intermediates. [NIH]

Acidosis: A pathologic condition resulting from accumulation of acid or depletion of the alkaline reserve (bicarbonate content) in the blood and body tissues, and characterized by an increase in hydrogen ion concentration. [EU]

Acute renal: A condition in which the kidneys suddenly stop working. In most cases, kidneys can recover from almost complete loss of function. [NIH]

Adaptability: Ability to develop some form of tolerance to conditions extremely different from those under which a living organism evolved. [NIH]

Adaptation: 1. The adjustment of an organism to its environment, or the process by which it enhances such fitness. 2. The normal ability of the eye to adjust itself to variations in the intensity of light; the adjustment to such variations. 3. The decline in the frequency of firing of a neuron, particularly of a receptor, under conditions of constant stimulation. 4. In dentistry, (a) the proper fitting of a denture, (b) the degree of proximity and interlocking of restorative material to a tooth preparation, (c) the exact adjustment of bands to teeth. 5. In microbiology, the adjustment of bacterial physiology to a new environment. [EU]

Adenine: A purine base and a fundamental unit of adenine nucleotides. [NIH]

Adenosine: A nucleoside that is composed of adenine and d-ribose. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter. [NIH]

Adenosine Triphosphate: Adenosine 5'-(tetrahydrogen triphosphate). An adenine nucleotide containing three phosphate groups esterified to the sugar moiety. In addition to

its crucial roles in metabolism adenosine triphosphate is a neurotransmitter. [NIH]

Adenovirus: A group of viruses that cause respiratory tract and eye infections. Adenoviruses used in gene therapy are altered to carry a specific tumor-fighting gene. [NIH]

Adjustment: The dynamic process wherein the thoughts, feelings, behavior, and biophysiological mechanisms of the individual continually change to adjust to the environment. [NIH]

Adverse Effect: An unwanted side effect of treatment. [NIH]

Aerobic: In biochemistry, reactions that need oxygen to happen or happen when oxygen is present. [NIH]

Affinity: 1. Inherent likeness or relationship. 2. A special attraction for a specific element, organ, or structure. 3. Chemical affinity; the force that binds atoms in molecules; the tendency of substances to combine by chemical reaction. 4. The strength of noncovalent chemical binding between two substances as measured by the dissociation constant of the complex. 5. In immunology, a thermodynamic expression of the strength of interaction between a single antigen-binding site and a single antigenic determinant (and thus of the stereochemical compatibility between them), most accurately applied to interactions among simple, uniform antigenic determinants such as haptens. Expressed as the association constant (K litres mole⁻¹), which, owing to the heterogeneity of affinities in a population of antibody molecules of a given specificity, actually represents an average value (mean intrinsic association constant). 6. The reciprocal of the dissociation constant. [EU]

Algorithms: A procedure consisting of a sequence of algebraic formulas and/or logical steps to calculate or determine a given task. [NIH]

Alkaline: Having the reactions of an alkali. [EU]

Alkaloid: A member of a large group of chemicals that are made by plants and have nitrogen in them. Some alkaloids have been shown to work against cancer. [NIH]

Alleles: Mutually exclusive forms of the same gene, occupying the same locus on homologous chromosomes, and governing the same biochemical and developmental process. [NIH]

Alpha-1: A protein with the property of inactivating proteolytic enzymes such as leucocyte collagenase and elastase. [NIH]

Alpha-Thalassemia: A disorder characterized by reduced synthesis of the alpha chains of hemoglobin. The severity of this condition can vary from mild anemia to death, depending on the number of genes deleted. [NIH]

Alternative medicine: Practices not generally recognized by the medical community as standard or conventional medical approaches and used instead of standard treatments. Alternative medicine includes the taking of dietary supplements, megadose vitamins, and herbal preparations; the drinking of special teas; and practices such as massage therapy, magnet therapy, spiritual healing, and meditation. [NIH]

Amino Acids: Organic compounds that generally contain an amino (-NH₂) and a carboxyl (-COOH) group. Twenty alpha-amino acids are the subunits which are polymerized to form proteins. [NIH]

Amino Acids: Organic compounds that generally contain an amino (-NH₂) and a carboxyl (-COOH) group. Twenty alpha-amino acids are the subunits which are polymerized to form proteins. [NIH]

Amnion: The extraembryonic membrane which contains the embryo and amniotic fluid. [NIH]

Amniotic Fluid: Amniotic cavity fluid which is produced by the amnion and fetal lungs and

kidneys. [NIH]

Ampulla: A sac-like enlargement of a canal or duct. [NIH]

Anaemia: A reduction below normal in the number of erythrocytes per cu. mm., in the quantity of haemoglobin, or in the volume of packed red cells per 100 ml. of blood which occurs when the equilibrium between blood loss (through bleeding or destruction) and blood production is disturbed. [EU]

Analgesic: An agent that alleviates pain without causing loss of consciousness. [EU]

Analog: In chemistry, a substance that is similar, but not identical, to another. [NIH]

Analogous: Resembling or similar in some respects, as in function or appearance, but not in origin or development;. [EU]

Anaphylatoxins: The family of peptides C3a, C4a, C5a, and C5a des-arginine produced in the serum during complement activation. They produce smooth muscle contraction, mast cell histamine release, affect platelet aggregation, and act as mediators of the local inflammatory process. The order of anaphylatoxin activity from strongest to weakest is C5a, C3a, C4a, and C5a des-arginine. The latter is the so-called "classical" anaphylatoxin but shows no spasmogenic activity though it contains some chemotactic ability. [NIH]

Anatomical: Pertaining to anatomy, or to the structure of the organism. [EU]

Anemia: A reduction in the number of circulating erythrocytes or in the quantity of hemoglobin. [NIH]

Aneuploidy: The chromosomal constitution of cells which deviate from the normal by the addition or subtraction of chromosomes or chromosome pairs. In a normally diploid cell the loss of a chromosome pair is termed nullisomy (symbol: 2N-2), the loss of a single chromosome is monosomy (symbol: 2N-1), the addition of a chromosome pair is tetrasomy (symbol: 2N+2), the addition of a single chromosome is trisomy (symbol: 2N+1). [NIH]

Animal model: An animal with a disease either the same as or like a disease in humans. Animal models are used to study the development and progression of diseases and to test new treatments before they are given to humans. Animals with transplanted human cancers or other tissues are called xenograft models. [NIH]

Anions: Negatively charged atoms, radicals or groups of atoms which travel to the anode or positive pole during electrolysis. [NIH]

Antibacterial: A substance that destroys bacteria or suppresses their growth or reproduction. [EU]

Antibiotics: Substances produced by microorganisms that can inhibit or suppress the growth of other microorganisms. [NIH]

Antibodies: Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the antigen that induced their synthesis in cells of the lymphoid series (especially plasma cells), or with an antigen closely related to it. [NIH]

Antibody: A type of protein made by certain white blood cells in response to a foreign substance (antigen). Each antibody can bind to only a specific antigen. The purpose of this binding is to help destroy the antigen. Antibodies can work in several ways, depending on the nature of the antigen. Some antibodies destroy antigens directly. Others make it easier for white blood cells to destroy the antigen. [NIH]

Anticoagulant: A drug that helps prevent blood clots from forming. Also called a blood thinner. [NIH]

Antidote: A remedy for counteracting a poison. [EU]

Antigen: Any substance which is capable, under appropriate conditions, of inducing a

specific immune response and of reacting with the products of that response, that is, with specific antibody or specifically sensitized T-lymphocytes, or both. Antigens may be soluble substances, such as toxins and foreign proteins, or particulate, such as bacteria and tissue cells; however, only the portion of the protein or polysaccharide molecule known as the antigenic determinant (q.v.) combines with antibody or a specific receptor on a lymphocyte. Abbreviated Ag. [EU]

Antigen-Antibody Complex: The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes immune complex diseases. [NIH]

Anti-infective: An agent that so acts. [EU]

Anti-inflammatory: Having to do with reducing inflammation. [NIH]

Anti-Inflammatory Agents: Substances that reduce or suppress inflammation. [NIH]

Antimetabolite: A chemical that is very similar to one required in a normal biochemical reaction in cells. Antimetabolites can stop or slow down the reaction. [NIH]

Antioxidant: A substance that prevents damage caused by free radicals. Free radicals are highly reactive chemicals that often contain oxygen. They are produced when molecules are split to give products that have unpaired electrons. This process is called oxidation. [NIH]

Antipyretic: An agent that relieves or reduces fever. Called also antifebrile, antithermic and febrifuge. [EU]

Antitussive: An agent that relieves or prevents cough. [EU]

Antiviral: Destroying viruses or suppressing their replication. [EU]

Anuria: Inability to form or excrete urine. [NIH]

Anus: The opening of the rectum to the outside of the body. [NIH]

Aorta: The main trunk of the systemic arteries. [NIH]

Apolipoproteins: The protein components of lipoproteins which remain after the lipids to which the proteins are bound have been removed. They play an important role in lipid transport and metabolism. [NIH]

Apoptosis: One of the two mechanisms by which cell death occurs (the other being the pathological process of necrosis). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA (DNA fragmentation) at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. [NIH]

Aqueous: Having to do with water. [NIH]

Arginine: An essential amino acid that is physiologically active in the L-form. [NIH]

Arterial: Pertaining to an artery or to the arteries. [EU]

Arteries: The vessels carrying blood away from the heart. [NIH]

Arterioles: The smallest divisions of the arteries located between the muscular arteries and the capillaries. [NIH]

Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is

considered an antioxidant. [NIH]

Aspartate: A synthetic amino acid. [NIH]

Aspirin: A drug that reduces pain, fever, inflammation, and blood clotting. Aspirin belongs to the family of drugs called nonsteroidal anti-inflammatory agents. It is also being studied in cancer prevention. [NIH]

Assay: Determination of the amount of a particular constituent of a mixture, or of the biological or pharmacological potency of a drug. [EU]

Asymptomatic: Having no signs or symptoms of disease. [NIH]

Atrium: A chamber; used in anatomical nomenclature to designate a chamber affording entrance to another structure or organ. Usually used alone to designate an atrium of the heart. [EU]

Atypical: Irregular; not conformable to the type; in microbiology, applied specifically to strains of unusual type. [EU]

Babesiosis: A group of tick-borne diseases of mammals including zoonoses in humans. They are caused by protozoans of the genus *babesia*, which parasitize erythrocytes, producing hemolysis. In the U.S., the organism's natural host is mice and transmission is by the deer tick *ixodes scapularis*. [NIH]

Bacteria: Unicellular prokaryotic microorganisms which generally possess rigid cell walls, multiply by cell division, and exhibit three principal forms: round or coccid, rodlike or bacillary, and spiral or spirochetal. [NIH]

Bacterial Physiology: Physiological processes and activities of bacteria. [NIH]

Bacterium: Microscopic organism which may have a spherical, rod-like, or spiral unicellular or non-cellular body. Bacteria usually reproduce through asexual processes. [NIH]

Base: In chemistry, the nonacid part of a salt; a substance that combines with acids to form salts; a substance that dissociates to give hydroxide ions in aqueous solutions; a substance whose molecule or ion can combine with a proton (hydrogen ion); a substance capable of donating a pair of electrons (to an acid) for the formation of a coordinate covalent bond. [EU]

Base Sequence: The sequence of purines and pyrimidines in nucleic acids and polynucleotides. It is also called nucleotide or nucleoside sequence. [NIH]

Benzo(a)pyrene: A potent mutagen and carcinogen. It is a public health concern because of its possible effects on industrial workers, as an environmental pollutant, and as a component of tobacco smoke. [NIH]

Beta-Thalassemia: A disorder characterized by reduced synthesis of the beta chains of hemoglobin. There is retardation of hemoglobin A synthesis in the heterozygous form (thalassemia minor), which is asymptomatic, while in the homozygous form (thalassemia major, Cooley's anemia, Mediterranean anemia, erythroblastic anemia), which can result in severe complications and even death, hemoglobin A synthesis is absent. [NIH]

Bewilderment: Impairment or loss of will power. [NIH]

Bile: An emulsifying agent produced in the liver and secreted into the duodenum. Its composition includes bile acids and salts, cholesterol, and electrolytes. It aids digestion of fats in the duodenum. [NIH]

Bile Pigments: Pigments that give a characteristic color to bile including: bilirubin, biliverdine, and bilicyanin. [NIH]

Bilirubin: A bile pigment that is a degradation product of heme. [NIH]

Biochemical: Relating to biochemistry; characterized by, produced by, or involving chemical reactions in living organisms. [EU]

Biological response modifier: BRM. A substance that stimulates the body's response to infection and disease. [NIH]

Biotechnology: Body of knowledge related to the use of organisms, cells or cell-derived constituents for the purpose of developing products which are technically, scientifically and clinically useful. Alteration of biologic function at the molecular level (i.e., genetic engineering) is a central focus; laboratory methods used include transfection and cloning technologies, sequence and structure analysis algorithms, computer databases, and gene and protein structure function analysis and prediction. [NIH]

Blackwater Fever: A complication of malaria, falciparum characterized by the passage of dark red to black urine. [NIH]

Bladder: The organ that stores urine. [NIH]

Blastocyst: The mammalian embryo in the post-morula stage in which a fluid-filled cavity, enclosed primarily by trophoblast, contains an inner cell mass which becomes the embryonic disc. [NIH]

Blood Cell Count: A count of the number of leukocytes and erythrocytes per unit volume in a sample of venous blood. A complete blood count (CBC) also includes measurement of the hemoglobin, hematocrit, and erythrocyte indices. [NIH]

Blood Coagulation: The process of the interaction of blood coagulation factors that results in an insoluble fibrin clot. [NIH]

Blood Glucose: Glucose in blood. [NIH]

Blood Groups: The classification systems (or schemes) of the different antigens located on erythrocytes. The antigens are the phenotypic expression of the genetic differences characteristic of specific blood groups. [NIH]

Blood pressure: The pressure of blood against the walls of a blood vessel or heart chamber. Unless there is reference to another location, such as the pulmonary artery or one of the heart chambers, it refers to the pressure in the systemic arteries, as measured, for example, in the forearm. [NIH]

Blood vessel: A tube in the body through which blood circulates. Blood vessels include a network of arteries, arterioles, capillaries, venules, and veins. [NIH]

Body Burden: The total amount of a chemical, metal or radioactive substance present at any time after absorption in the body of man or animal. [NIH]

Bone Marrow: The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. [NIH]

Buccal: Pertaining to or directed toward the cheek. In dental anatomy, used to refer to the buccal surface of a tooth. [EU]

Calcium: A basic element found in nearly all organized tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. [NIH]

Carbohydrate: An aldehyde or ketone derivative of a polyhydric alcohol, particularly of the pentahydric and hexahydric alcohols. They are so named because the hydrogen and oxygen

are usually in the proportion to form water, $(\text{CH}_2\text{O})_n$. The most important carbohydrates are the starches, sugars, celluloses, and gums. They are classified into mono-, di-, tri-, poly- and heterosaccharides. [EU]

Carbon Dioxide: A colorless, odorless gas that can be formed by the body and is necessary for the respiration cycle of plants and animals. [NIH]

Carcinogen: Any substance that causes cancer. [NIH]

Carcinogenic: Producing carcinoma. [EU]

Carcinoma: Cancer that begins in the skin or in tissues that line or cover internal organs. [NIH]

Cardiopulmonary: Having to do with the heart and lungs. [NIH]

Cardiopulmonary Bypass: Diversion of the flow of blood from the entrance of the right atrium directly to the aorta (or femoral artery) via an oxygenator thus bypassing both the heart and lungs. [NIH]

Cardiovascular: Having to do with the heart and blood vessels. [NIH]

Cardiovascular disease: Any abnormal condition characterized by dysfunction of the heart and blood vessels. CVD includes atherosclerosis (especially coronary heart disease, which can lead to heart attacks), cerebrovascular disease (e.g., stroke), and hypertension (high blood pressure). [NIH]

Case report: A detailed report of the diagnosis, treatment, and follow-up of an individual patient. Case reports also contain some demographic information about the patient (for example, age, gender, ethnic origin). [NIH]

Catalase: An oxidoreductase that catalyzes the conversion of hydrogen peroxide to water and oxygen. It is present in many animal cells. A deficiency of this enzyme results in acatalasia. EC 1.11.1.6. [NIH]

Cataract: An opacity, partial or complete, of one or both eyes, on or in the lens or capsule, especially an opacity impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). [EU]

Causal: Pertaining to a cause; directed against a cause. [EU]

Cause of Death: Factors which produce cessation of all vital bodily functions. They can be analyzed from an epidemiologic viewpoint. [NIH]

Cell: The individual unit that makes up all of the tissues of the body. All living things are made up of one or more cells. [NIH]

Cell Cycle: The complex series of phenomena, occurring between the end of one cell division and the end of the next, by which cellular material is divided between daughter cells. [NIH]

Cell Death: The termination of the cell's ability to carry out vital functions such as metabolism, growth, reproduction, responsiveness, and adaptability. [NIH]

Cell Division: The fission of a cell. [NIH]

Cell membrane: Cell membrane = plasma membrane. The structure enveloping a cell, enclosing the cytoplasm, and forming a selective permeability barrier; it consists of lipids, proteins, and some carbohydrates, the lipids thought to form a bilayer in which integral proteins are embedded to varying degrees. [EU]

Cell Respiration: The metabolic process of all living cells (animal and plant) in which oxygen is used to provide a source of energy for the cell. [NIH]

Cell Survival: The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. [NIH]

Centromere: The clear constricted portion of the chromosome at which the chromatids are joined and by which the chromosome is attached to the spindle during cell division. [NIH]

Cerebral: Of or pertaining of the cerebrum or the brain. [EU]

Cerebrospinal: Pertaining to the brain and spinal cord. [EU]

Cerebrospinal fluid: CSF. The fluid flowing around the brain and spinal cord. Cerebrospinal fluid is produced in the ventricles in the brain. [NIH]

Cerebrovascular: Pertaining to the blood vessels of the cerebrum, or brain. [EU]

Cerebrum: The largest part of the brain. It is divided into two hemispheres, or halves, called the cerebral hemispheres. The cerebrum controls muscle functions of the body and also controls speech, emotions, reading, writing, and learning. [NIH]

Chelation: Combination with a metal in complexes in which the metal is part of a ring. [EU]

Chemotactic Factors: Chemical substances that attract or repel cells or organisms. The concept denotes especially those factors released as a result of tissue injury, invasion, or immunologic activity, that attract leukocytes, macrophages, or other cells to the site of infection or insult. [NIH]

Chemotherapeutic agent: A drug used to treat cancer. [NIH]

Chin: The anatomical frontal portion of the mandible, also known as the mentum, that contains the line of fusion of the two separate halves of the mandible (symphysis menti). This line of fusion divides inferiorly to enclose a triangular area called the mental protuberance. On each side, inferior to the second premolar tooth, is the mental foramen for the passage of blood vessels and a nerve. [NIH]

Cholelithiasis: Presence or formation of gallstones. [NIH]

Cholesterol: The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. [NIH]

Cholesterol Esters: Fatty acid esters of cholesterol which constitute about two-thirds of the cholesterol in the plasma. The accumulation of cholesterol esters in the arterial intima is a characteristic feature of atherosclerosis. [NIH]

Chromatin: The material of chromosomes. It is a complex of DNA, histones, and nonhistone proteins (chromosomal proteins, non-histone) found within the nucleus of a cell. [NIH]

Chromosomal: Pertaining to chromosomes. [EU]

Chromosome: Part of a cell that contains genetic information. Except for sperm and eggs, all human cells contain 46 chromosomes. [NIH]

Chromosome Fragility: Susceptibility of chromosomes to breakage and translocation or other aberrations. Chromosome fragile sites are regions that show up in karyotypes as a gap (uncondensed stretch) on the chromatid arm. They are associated with chromosome break sites and other aberrations. A fragile site on the X chromosome is associated with fragile X syndrome. Fragile sites are designated by the letters "FRA" followed by the designation for the specific chromosome and a letter which refers to the different fragile sites on a chromosome (e.g. FRAXA). [NIH]

Chronic: A disease or condition that persists or progresses over a long period of time. [NIH]

Chylomicrons: A class of lipoproteins that carry dietary cholesterol and triglycerides from the small intestines to the tissues. [NIH]

Cinchona: A genus of rubiaceous South American trees that yields the toxic cinchona alkaloids from their bark; quinine, quinidine, chinconine, cinchonidine and others are used to treat malaria and cardiac arrhythmias. [NIH]

Cirrhosis: A type of chronic, progressive liver disease. [NIH]

CIS: Cancer Information Service. The CIS is the National Cancer Institute's link to the public, interpreting and explaining research findings in a clear and understandable manner, and providing personalized responses to specific questions about cancer. Access the CIS by calling 1-800-4-CANCER, or by using the Web site at <http://cis.nci.nih.gov>. [NIH]

Clinical Medicine: The study and practice of medicine by direct examination of the patient. [NIH]

Clinical trial: A research study that tests how well new medical treatments or other interventions work in people. Each study is designed to test new methods of screening, prevention, diagnosis, or treatment of a disease. [NIH]

Cloning: The production of a number of genetically identical individuals; in genetic engineering, a process for the efficient replication of a great number of identical DNA molecules. [NIH]

Codeine: An opioid analgesic related to morphine but with less potent analgesic properties and mild sedative effects. It also acts centrally to suppress cough. [NIH]

Codon: A set of three nucleotides in a protein coding sequence that specifies individual amino acids or a termination signal (codon, terminator). Most codons are universal, but some organisms do not produce the transfer RNAs (RNA, transfer) complementary to all codons. These codons are referred to as unassigned codons (codons, nonsense). [NIH]

Coenzyme: An organic nonprotein molecule, frequently a phosphorylated derivative of a water-soluble vitamin, that binds with the protein molecule (apoenzyme) to form the active enzyme (holoenzyme). [EU]

Cofactor: A substance, microorganism or environmental factor that activates or enhances the action of another entity such as a disease-causing agent. [NIH]

Collagen: A polypeptide substance comprising about one third of the total protein in mammalian organisms. It is the main constituent of skin, connective tissue, and the organic substance of bones and teeth. Different forms of collagen are produced in the body but all consist of three alpha-polypeptide chains arranged in a triple helix. Collagen is differentiated from other fibrous proteins, such as elastin, by the content of proline, hydroxyproline, and hydroxylysine; by the absence of tryptophan; and particularly by the high content of polar groups which are responsible for its swelling properties. [NIH]

Colon: The long, coiled, tubelike organ that removes water from digested food. The remaining material, solid waste called stool, moves through the colon to the rectum and leaves the body through the anus. [NIH]

Colonoscopy: Endoscopic examination, therapy or surgery of the luminal surface of the colon. [NIH]

Color blindness: A form of defective color vision requiring only two primary colors, mixed in various proportions, to match all other colors. [NIH]

Complement: A term originally used to refer to the heat-labile factor in serum that causes immune cytolysis, the lysis of antibody-coated cells, and now referring to the entire functionally related system comprising at least 20 distinct serum proteins that is the effector not only of immune cytolysis but also of other biologic functions. Complement activation occurs by two different sequences, the classic and alternative pathways. The proteins of the classic pathway are termed 'components of complement' and are designated by the symbols

C1 through C9. C1 is a calcium-dependent complex of three distinct proteins C1q, C1r and C1s. The proteins of the alternative pathway (collectively referred to as the properdin system) and complement regulatory proteins are known by semisystematic or trivial names. Fragments resulting from proteolytic cleavage of complement proteins are designated with lower-case letter suffixes, e.g., C3a. Inactivated fragments may be designated with the suffix 'i', e.g. C3bi. Activated components or complexes with biological activity are designated by a bar over the symbol e.g. C1 or C4b,2a. The classic pathway is activated by the binding of C1 to classic pathway activators, primarily antigen-antibody complexes containing IgM, IgG1, IgG3; C1q binds to a single IgM molecule or two adjacent IgG molecules. The alternative pathway can be activated by IgA immune complexes and also by nonimmunologic materials including bacterial endotoxins, microbial polysaccharides, and cell walls. Activation of the classic pathway triggers an enzymatic cascade involving C1, C4, C2 and C3; activation of the alternative pathway triggers a cascade involving C3 and factors B, D and P. Both result in the cleavage of C5 and the formation of the membrane attack complex. Complement activation also results in the formation of many biologically active complement fragments that act as anaphylatoxins, opsonins, or chemotactic factors. [EU]

Complementary and alternative medicine: CAM. Forms of treatment that are used in addition to (complementary) or instead of (alternative) standard treatments. These practices are not considered standard medical approaches. CAM includes dietary supplements, megadose vitamins, herbal preparations, special teas, massage therapy, magnet therapy, spiritual healing, and meditation. [NIH]

Complementary medicine: Practices not generally recognized by the medical community as standard or conventional medical approaches and used to enhance or complement the standard treatments. Complementary medicine includes the taking of dietary supplements, megadose vitamins, and herbal preparations; the drinking of special teas; and practices such as massage therapy, magnet therapy, spiritual healing, and meditation. [NIH]

Computational Biology: A field of biology concerned with the development of techniques for the collection and manipulation of biological data, and the use of such data to make biological discoveries or predictions. This field encompasses all computational methods and theories applicable to molecular biology and areas of computer-based techniques for solving biological problems including manipulation of models and datasets. [NIH]

Concentric: Having a common center of curvature or symmetry. [NIH]

Conception: The onset of pregnancy, marked by implantation of the blastocyst; the formation of a viable zygote. [EU]

Confusion: A mental state characterized by bewilderment, emotional disturbance, lack of clear thinking, and perceptual disorientation. [NIH]

Congenita: Displacement, subluxation, or malposition of the crystalline lens. [NIH]

Conjugated: Acting or operating as if joined; simultaneous. [EU]

Conjugation: 1. The act of joining together or the state of being conjugated. 2. A sexual process seen in bacteria, ciliate protozoa, and certain fungi in which nuclear material is exchanged during the temporary fusion of two cells (conjugants). In bacterial genetics a form of sexual reproduction in which a donor bacterium (male) contributes some, or all, of its DNA (in the form of a replicated set) to a recipient (female) which then incorporates differing genetic information into its own chromosome by recombination and passes the recombined set on to its progeny by replication. In ciliate protozoa, two conjugants of separate mating types exchange micronuclear material and then separate, each now being a fertilized cell. In certain fungi, the process involves fusion of two gametes, resulting in union of their nuclei and formation of a zygote. 3. In chemistry, the joining together of two compounds to produce another compound, such as the combination of a toxic product with

some substance in the body to form a detoxified product, which is then eliminated. [EU]

Connective Tissue: Tissue that supports and binds other tissues. It consists of connective tissue cells embedded in a large amount of extracellular matrix. [NIH]

Connective Tissue: Tissue that supports and binds other tissues. It consists of connective tissue cells embedded in a large amount of extracellular matrix. [NIH]

Consciousness: Sense of awareness of self and of the environment. [NIH]

Constriction: The act of constricting. [NIH]

Consultation: A deliberation between two or more physicians concerning the diagnosis and the proper method of treatment in a case. [NIH]

Contamination: The soiling or pollution by inferior material, as by the introduction of organisms into a wound, or sewage into a stream. [EU]

Contraindications: Any factor or sign that it is unwise to pursue a certain kind of action or treatment, e. g. giving a general anesthetic to a person with pneumonia. [NIH]

Coronary: Encircling in the manner of a crown; a term applied to vessels; nerves, ligaments, etc. The term usually denotes the arteries that supply the heart muscle and, by extension, a pathologic involvement of them. [EU]

Coronary heart disease: A type of heart disease caused by narrowing of the coronary arteries that feed the heart, which needs a constant supply of oxygen and nutrients carried by the blood in the coronary arteries. When the coronary arteries become narrowed or clogged by fat and cholesterol deposits and cannot supply enough blood to the heart, CHD results. [NIH]

Corpuscle: A small mass or body; a sensory nerve end bulb; a cell, especially that of the blood or the lymph. [NIH]

Cyanide: An extremely toxic class of compounds that can be lethal on inhaling or ingesting in minute quantities. [NIH]

Cysteine: A thiol-containing non-essential amino acid that is oxidized to form cystine. [NIH]

Cytochrome: Any electron transfer hemoprotein having a mode of action in which the transfer of a single electron is effected by a reversible valence change of the central iron atom of the heme prosthetic group between the +2 and +3 oxidation states; classified as cytochromes a in which the heme contains a formyl side chain, cytochromes b, which contain protoheme or a closely similar heme that is not covalently bound to the protein, cytochromes c in which protoheme or other heme is covalently bound to the protein, and cytochromes d in which the iron-tetrapyrrole has fewer conjugated double bonds than the hemes have. Well-known cytochromes have been numbered consecutively within groups and are designated by subscripts (beginning with no subscript), e.g. cytochromes c, c1, C2, . . . New cytochromes are named according to the wavelength in nanometres of the absorption maximum of the a-band of the iron (II) form in pyridine, e.g., c-555. [EU]

Cytomegalovirus: A genus of the family Herpesviridae, subfamily Betaherpesvirinae, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS. [NIH]

Cytoplasm: The protoplasm of a cell exclusive of that of the nucleus; it consists of a continuous aqueous solution (cytosol) and the organelles and inclusions suspended in it (phaneroplasm), and is the site of most of the chemical activities of the cell. [EU]

Cytosine: A pyrimidine base that is a fundamental unit of nucleic acids. [NIH]

Cytotoxicity: Quality of being capable of producing a specific toxic action upon cells of

special organs. [NIH]

De novo: In cancer, the first occurrence of cancer in the body. [NIH]

Death Certificates: Official records of individual deaths including the cause of death certified by a physician, and any other required identifying information. [NIH]

Degenerative: Undergoing degeneration : tending to degenerate; having the character of or involving degeneration; causing or tending to cause degeneration. [EU]

Deletion: A genetic rearrangement through loss of segments of DNA (chromosomes), bringing sequences, which are normally separated, into close proximity. [NIH]

Dementia: An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness. [NIH]

Demethylation: Process that releases substantial amounts of carbon dioxide in the liver. [NIH]

Deoxyribonucleic: A polymer of subunits called deoxyribonucleotides which is the primary genetic material of a cell, the material equivalent to genetic information. [NIH]

Deoxyribonucleic acid: A polymer of subunits called deoxyribonucleotides which is the primary genetic material of a cell, the material equivalent to genetic information. [NIH]

Deoxyribonucleotides: A purine or pyrimidine base bonded to a deoxyribose containing a bond to a phosphate group. [NIH]

Deuterium: Deuterium. The stable isotope of hydrogen. It has one neutron and one proton in the nucleus. [NIH]

Dextromethorphan: The d-isomer of the codeine analog of levorphanol. Dextromethorphan shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is a NMDA receptor antagonist (receptors, N-methyl-D-aspartate) and acts as a non-competitive channel blocker. It is used widely as an antitussive agent, and is also used to study the involvement of glutamate receptors in neurotoxicity. [NIH]

Diabetes Mellitus: A heterogeneous group of disorders that share glucose intolerance in common. [NIH]

Digestion: The process of breakdown of food for metabolism and use by the body. [NIH]

Dihydrotestosterone: Anabolic agent. [NIH]

Diploid: Having two sets of chromosomes. [NIH]

Direct: 1. Straight; in a straight line. 2. Performed immediately and without the intervention of subsidiary means. [EU]

Discrimination: The act of qualitative and/or quantitative differentiation between two or more stimuli. [NIH]

Disorientation: The loss of proper bearings, or a state of mental confusion as to time, place, or identity. [EU]

Duodenum: The first part of the small intestine. [NIH]

Dysmenorrhea: Painful menstruation. [NIH]

Effector: It is often an enzyme that converts an inactive precursor molecule into an active second messenger. [NIH]

Electrolytes: Substances that break up into ions (electrically charged particles) when they are dissolved in body fluids or water. Some examples are sodium, potassium, chloride, and

calcium. Electrolytes are primarily responsible for the movement of nutrients into cells, and the movement of wastes out of cells. [NIH]

Electrons: Stable elementary particles having the smallest known negative charge, present in all elements; also called negatrons. Positively charged electrons are called positrons. The numbers, energies and arrangement of electrons around atomic nuclei determine the chemical identities of elements. Beams of electrons are called cathode rays or beta rays, the latter being a high-energy biproduct of nuclear decay. [NIH]

Embryo: The prenatal stage of mammalian development characterized by rapid morphological changes and the differentiation of basic structures. [NIH]

Endemic: Present or usually prevalent in a population or geographical area at all times; said of a disease or agent. Called also endemial. [EU]

Endoscope: A thin, lighted tube used to look at tissues inside the body. [NIH]

Endoscopic: A technique where a lateral-view endoscope is passed orally to the duodenum for visualization of the ampulla of Vater. [NIH]

Endotoxins: Toxins closely associated with the living cytoplasm or cell wall of certain microorganisms, which do not readily diffuse into the culture medium, but are released upon lysis of the cells. [NIH]

Environmental Health: The science of controlling or modifying those conditions, influences, or forces surrounding man which relate to promoting, establishing, and maintaining health. [NIH]

Enzymatic: Phase where enzyme cuts the precursor protein. [NIH]

Enzyme: A protein that speeds up chemical reactions in the body. [NIH]

Epidemiological: Relating to, or involving epidemiology. [EU]

Erythrocyte Indices: Quantification of size and cell hemoglobin content or concentration of the erythrocyte, usually derived from erythrocyte count, blood hemoglobin concentration, and hematocrit. Includes the mean cell volume (MCV), mean cell hemoglobin (MCH), and mean cell hemoglobin concentration (MCHC). Use also for cell diameter and thickness. [NIH]

Erythrocyte Membrane: The semipermeable outer portion of the red corpuscle. It is known as a 'ghost' after hemolysis. [NIH]

Erythrocytes: Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing hemoglobin whose function is to transport oxygen. [NIH]

Ethnic Groups: A group of people with a common cultural heritage that sets them apart from others in a variety of social relationships. [NIH]

Eukaryotic Cells: Cells of the higher organisms, containing a true nucleus bounded by a nuclear membrane. [NIH]

Excrete: To get rid of waste from the body. [NIH]

Exhaustion: The feeling of weariness of mind and body. [NIH]

Extracellular: Outside a cell or cells. [EU]

Extracellular Matrix: A meshwork-like substance found within the extracellular space and in association with the basement membrane of the cell surface. It promotes cellular proliferation and provides a supporting structure to which cells or cell lysates in culture dishes adhere. [NIH]

Eye Color: Color of the iris. [NIH]

Eye Infections: Infection, moderate to severe, caused by bacteria, fungi, or viruses, which occurs either on the external surface of the eye or intraocularly with probable inflammation,

visual impairment, or blindness. [NIH]

Family Planning: Programs or services designed to assist the family in controlling reproduction by either improving or diminishing fertility. [NIH]

Fat: Total lipids including phospholipids. [NIH]

Fathers: Male parents, human or animal. [NIH]

Fatigue: The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli. [NIH]

Favism: Hemolytic anemia due to the ingestion of fava beans or after inhalation of pollen from the *Vicia fava* plant by persons with glucose-6-phosphate dehydrogenase deficient erythrocytes. [NIH]

Febrile: Pertaining to or characterized by fever. [EU]

Femoral: Pertaining to the femur, or to the thigh. [EU]

Femoral Artery: The main artery of the thigh, a continuation of the external iliac artery. [NIH]

Fetus: The developing offspring from 7 to 8 weeks after conception until birth. [NIH]

Fibroblasts: Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules. [NIH]

Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury. [NIH]

Fluorescence: The property of emitting radiation while being irradiated. The radiation emitted is usually of longer wavelength than that incident or absorbed, e.g., a substance can be irradiated with invisible radiation and emit visible light. X-ray fluorescence is used in diagnosis. [NIH]

Follicles: Shafts through which hair grows. [NIH]

Forearm: The part between the elbow and the wrist. [NIH]

Frameshift: A type of mutation which causes out-of-phase transcription of the base sequence; such mutations arise from the addition or deletion of nucleotide(s) in numbers other than 3 or multiples of 3. [NIH]

Frameshift Mutation: A type of mutation in which a number of nucleotides not divisible by three is deleted from or inserted into a coding sequence, thereby causing an alteration in the reading frame of the entire sequence downstream of the mutation. These mutations may be induced by certain types of mutagens or may occur spontaneously. [NIH]

Gallate: Antioxidant present in tea. [NIH]

Ganglia: Clusters of multipolar neurons surrounded by a capsule of loosely organized connective tissue located outside the central nervous system. [NIH]

Gas: Air that comes from normal breakdown of food. The gases are passed out of the body through the rectum (flatus) or the mouth (burp). [NIH]

Gastrin: A hormone released after eating. Gastrin causes the stomach to produce more acid. [NIH]

Gene: The functional and physical unit of heredity passed from parent to offspring. Genes are pieces of DNA, and most genes contain the information for making a specific protein. [NIH]

Gene Expression: The phenotypic manifestation of a gene or genes by the processes of gene action. [NIH]

Gene Products, rev: Trans-acting nuclear proteins whose functional expression are required

for HIV viral replication. Specifically, the rev gene products are required for processing and translation of the HIV gag and env mRNAs, and thus rev regulates the expression of the viral structural proteins. rev can also regulate viral regulatory proteins. A cis-acting antirepression sequence (CAR) in env, also known as the rev-responsive element (RRE), is responsive to the rev gene product. rev is short for regulator of virion. [NIH]

Gene Therapy: The introduction of new genes into cells for the purpose of treating disease by restoring or adding gene expression. Techniques include insertion of retroviral vectors, transfection, homologous recombination, and injection of new genes into the nuclei of single cell embryos. The entire gene therapy process may consist of multiple steps. The new genes may be introduced into proliferating cells in vivo (e.g., bone marrow) or in vitro (e.g., fibroblast cultures) and the modified cells transferred to the site where the gene expression is required. Gene therapy may be particularly useful for treating enzyme deficiency diseases, hemoglobinopathies, and leukemias and may also prove useful in restoring drug sensitivity, particularly for leukemia. [NIH]

Genes, env: DNA sequences that form the coding region for the viral envelope (env) proteins in retroviruses. The env genes contain a cis-acting RNA target sequence for the rev protein (= gene products, rev), termed the rev-responsive element (RRE). [NIH]

Genetic testing: Analyzing DNA to look for a genetic alteration that may indicate an increased risk for developing a specific disease or disorder. [NIH]

Genetics: The biological science that deals with the phenomena and mechanisms of heredity. [NIH]

Genomics: The systematic study of the complete DNA sequences (genome) of organisms. [NIH]

Germ Cells: The reproductive cells in multicellular organisms. [NIH]

Germline mutation: A gene change in the body's reproductive cells (egg or sperm) that becomes incorporated into the DNA of every cell in the body of offspring; germline mutations are passed on from parents to offspring. Also called hereditary mutation. [NIH]

Gland: An organ that produces and releases one or more substances for use in the body. Some glands produce fluids that affect tissues or organs. Others produce hormones or participate in blood production. [NIH]

Glomerular: Pertaining to or of the nature of a glomerulus, especially a renal glomerulus. [EU]

Glucose: D-Glucose. A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. [NIH]

Glucose Intolerance: A pathological state in which the fasting plasma glucose level is less than 140 mg per deciliter and the 30-, 60-, or 90-minute plasma glucose concentration following a glucose tolerance test exceeds 200 mg per deciliter. This condition is seen frequently in diabetes mellitus but also occurs with other diseases. [NIH]

Glutamate: Excitatory neurotransmitter of the brain. [NIH]

Glutathione Peroxidase: An enzyme catalyzing the oxidation of 2 moles of glutathione in the presence of hydrogen peroxide to yield oxidized glutathione and water. EC 1.11.1.9. [NIH]

Glycosylation: The chemical or biochemical addition of carbohydrate or glycosyl groups to other chemicals, especially peptides or proteins. Glycosyl transferases are used in this biochemical reaction. [NIH]

Governing Board: The group in which legal authority is vested for the control of health-

related institutions and organizations. [NIH]

Gram-negative: Losing the stain or decolorized by alcohol in Gram's method of staining, a primary characteristic of bacteria having a cell wall composed of a thin layer of peptidoglycan covered by an outer membrane of lipoprotein and lipopolysaccharide. [EU]

Gram-positive: Retaining the stain or resisting decolorization by alcohol in Gram's method of staining, a primary characteristic of bacteria whose cell wall is composed of a thick layer of peptidoglycan with attached teichoic acids. [EU]

Granule: A small pill made from sucrose. [EU]

Granulocytes: Leukocytes with abundant granules in the cytoplasm. They are divided into three groups: neutrophils, eosinophils, and basophils. [NIH]

Guanine: One of the four DNA bases. [NIH]

Haematological: Relating to haematology, that is that branch of medical science which treats of the morphology of the blood and blood-forming tissues. [EU]

Haematology: The science of the blood, its nature, functions, and diseases. [NIH]

Haemolysis: Disruption of the integrity of the red cell membrane causing release of haemoglobin. Haemolysis may be caused by bacterial haemolysins, by antibodies that cause complement-dependent lysis, by placing red cells in a hypotonic solution, or by defects in the red cell membrane. [EU]

Hair Color: Color of hair or fur. [NIH]

Hair follicles: Shafts or openings on the surface of the skin through which hair grows. [NIH]

Half-Life: The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. [NIH]

Haploid: An organism with one basic chromosome set, symbolized by n ; the normal condition of gametes in diploids. [NIH]

Haplotypes: The genetic constitution of individuals with respect to one member of a pair of allelic genes, or sets of genes that are closely linked and tend to be inherited together such as those of the major histocompatibility complex. [NIH]

Heart attack: A seizure of weak or abnormal functioning of the heart. [NIH]

Hematocrit: Measurement of the volume of packed red cells in a blood specimen by centrifugation. The procedure is performed using a tube with graduated markings or with automated blood cell counters. It is used as an indicator of erythrocyte status in disease. For example, anemia shows a low hematocrit, polycythemia, high values. [NIH]

Hemochromatosis: A disease that occurs when the body absorbs too much iron. The body stores the excess iron in the liver, pancreas, and other organs. May cause cirrhosis of the liver. Also called iron overload disease. [NIH]

Hemodialysis: The use of a machine to clean wastes from the blood after the kidneys have failed. The blood travels through tubes to a dialyzer, which removes wastes and extra fluid. The cleaned blood then flows through another set of tubes back into the body. [NIH]

Hemoglobin: One of the fractions of glycosylated hemoglobin A1c. Glycosylated hemoglobin is formed when linkages of glucose and related monosaccharides bind to hemoglobin A and its concentration represents the average blood glucose level over the previous several weeks. HbA1c levels are used as a measure of long-term control of plasma glucose (normal, 4 to 6 percent). In controlled diabetes mellitus, the concentration of glycosylated hemoglobin A is within the normal range, but in uncontrolled cases the level may be 3 to 4 times the normal concentration. Generally, complications are substantially lower among patients with Hb levels of 7 percent or less than in patients with HbA1c levels

of 9 percent or more. [NIH]

Hemoglobin A: Normal adult human hemoglobin. The globin moiety consists of two alpha and two beta chains. [NIH]

Hemoglobinopathies: A group of inherited disorders characterized by structural alterations within the hemoglobin molecule. [NIH]

Hemolysis: The destruction of erythrocytes by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity. [NIH]

Hemolytic: A disease that affects the blood and blood vessels. It destroys red blood cells, cells that cause the blood to clot, and the lining of blood vessels. HUS is often caused by the *Escherichia coli* bacterium in contaminated food. People with HUS may develop acute renal failure. [NIH]

Hemophilia: Refers to a group of hereditary disorders in which affected individuals fail to make enough of certain proteins needed to form blood clots. [NIH]

Hemorrhage: Bleeding or escape of blood from a vessel. [NIH]

Hepatitis: Inflammation of the liver and liver disease involving degenerative or necrotic alterations of hepatocytes. [NIH]

Hepatitis A: Hepatitis caused by hepatovirus. It can be transmitted through fecal contamination of food or water. [NIH]

Hepatocytes: The main structural component of the liver. They are specialized epithelial cells that are organized into interconnected plates called lobules. [NIH]

Hepatovirus: A genus of Picornaviridae causing infectious hepatitis naturally in humans and experimentally in other primates. It is transmitted through fecal contamination of food or water. [NIH]

Hereditary: Of, relating to, or denoting factors that can be transmitted genetically from one generation to another. [NIH]

Hereditary mutation: A gene change in the body's reproductive cells (egg or sperm) that becomes incorporated into the DNA of every cell in the body of offspring; hereditary mutations are passed on from parents to offspring. Also called germline mutation. [NIH]

Heredity: 1. The genetic transmission of a particular quality or trait from parent to offspring. 2. The genetic constitution of an individual. [EU]

Heterogeneity: The property of one or more samples or populations which implies that they are not identical in respect of some or all of their parameters, e. g. heterogeneity of variance. [NIH]

Heterozygote: An individual having different alleles at one or more loci in homologous chromosome segments. [NIH]

Histones: Small chromosomal proteins (approx 12-20 kD) possessing an open, unfolded structure and attached to the DNA in cell nuclei by ionic linkages. Classification into the various types (designated histone I, histone II, etc.) is based on the relative amounts of arginine and lysine in each. [NIH]

Homologous: Corresponding in structure, position, origin, etc., as (a) the feathers of a bird and the scales of a fish, (b) antigen and its specific antibody, (c) allelic chromosomes. [EU]

Hormone: A substance in the body that regulates certain organs. Hormones such as gastrin help in breaking down food. Some hormones come from cells in the stomach and small intestine. [NIH]

Hydrogen: The first chemical element in the periodic table. It has the atomic symbol H, atomic number 1, and atomic weight 1. It exists, under normal conditions, as a colorless,

odorless, tasteless, diatomic gas. Hydrogen ions are protons. Besides the common H1 isotope, hydrogen exists as the stable isotope deuterium and the unstable, radioactive isotope tritium. [NIH]

Hydrogen Peroxide: A strong oxidizing agent used in aqueous solution as a ripening agent, bleach, and topical anti-infective. It is relatively unstable and solutions deteriorate over time unless stabilized by the addition of acetanilide or similar organic materials. [NIH]

Hydrophobic: Not readily absorbing water, or being adversely affected by water, as a hydrophobic colloid. [EU]

Hyperbilirubinemia: Pathologic process consisting of an abnormal increase in the amount of bilirubin in the circulating blood, which may result in jaundice. [NIH]

Hypertension: Persistently high arterial blood pressure. Currently accepted threshold levels are 140 mm Hg systolic and 90 mm Hg diastolic pressure. [NIH]

Hyperthermia: A type of treatment in which body tissue is exposed to high temperatures to damage and kill cancer cells or to make cancer cells more sensitive to the effects of radiation and certain anticancer drugs. [NIH]

Hysteroscopy: Endoscopic examination, therapy or surgery of the interior of the uterus. [NIH]

Immune response: The activity of the immune system against foreign substances (antigens). [NIH]

Immune system: The organs, cells, and molecules responsible for the recognition and disposal of foreign ("non-self") material which enters the body. [NIH]

Impairment: In the context of health experience, an impairment is any loss or abnormality of psychological, physiological, or anatomical structure or function. [NIH]

Implantation: The insertion or grafting into the body of biological, living, inert, or radioactive material. [EU]

In situ: In the natural or normal place; confined to the site of origin without invasion of neighbouring tissues. [EU]

In vitro: In the laboratory (outside the body). The opposite of in vivo (in the body). [NIH]

In vivo: In the body. The opposite of in vitro (outside the body or in the laboratory). [NIH]

Incubation: The development of an infectious disease from the entrance of the pathogen to the appearance of clinical symptoms. [EU]

Infancy: The period of complete dependency prior to the acquisition of competence in walking, talking, and self-feeding. [NIH]

Infection: 1. Invasion and multiplication of microorganisms in body tissues, which may be clinically unapparent or result in local cellular injury due to competitive metabolism, toxins, intracellular replication, or antigen-antibody response. The infection may remain localized, subclinical, and temporary if the body's defensive mechanisms are effective. A local infection may persist and spread by extension to become an acute, subacute, or chronic clinical infection or disease state. A local infection may also become systemic when the microorganisms gain access to the lymphatic or vascular system. 2. An infectious disease. [EU]

Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. [NIH]

Informed Consent: Voluntary authorization, given to the physician by the patient, with full comprehension of the risks involved, for diagnostic or investigative procedures and medical

and surgical treatment. [NIH]

Infusion: A method of putting fluids, including drugs, into the bloodstream. Also called intravenous infusion. [NIH]

Ingestion: Taking into the body by mouth [NIH]

Inhalation: The drawing of air or other substances into the lungs. [EU]

Initiation: Mutation induced by a chemical reactive substance causing cell changes; being a step in a carcinogenic process. [NIH]

Interferon: A biological response modifier (a substance that can improve the body's natural response to disease). Interferons interfere with the division of cancer cells and can slow tumor growth. There are several types of interferons, including interferon-alpha, -beta, and -gamma. These substances are normally produced by the body. They are also made in the laboratory for use in treating cancer and other diseases. [NIH]

Interferon-alpha: One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells when exposed to live or inactivated virus, double-stranded RNA, or bacterial products. It is the major interferon produced by virus-induced leukocyte cultures and, in addition to its pronounced antiviral activity, it causes activation of NK cells. [NIH]

Interstitial: Pertaining to or situated between parts or in the interspaces of a tissue. [EU]

Intracellular: Inside a cell. [NIH]

Intravascular: Within a vessel or vessels. [EU]

Ions: An atom or group of atoms that have a positive or negative electric charge due to a gain (negative charge) or loss (positive charge) of one or more electrons. Atoms with a positive charge are known as cations; those with a negative charge are anions. [NIH]

Iris: The most anterior portion of the uveal layer, separating the anterior chamber from the posterior. It consists of two layers - the stroma and the pigmented epithelium. Color of the iris depends on the amount of melanin in the stroma on reflection from the pigmented epithelium. [NIH]

Isozymes: The multiple forms of a single enzyme. [NIH]

Jaundice: A clinical manifestation of hyperbilirubinemia, consisting of deposition of bile pigments in the skin, resulting in a yellowish staining of the skin and mucous membranes. [NIH]

Karyotype: The characteristic chromosome complement of an individual, race, or species as defined by their number, size, shape, etc. [NIH]

Ketoacidosis: Acidosis accompanied by the accumulation of ketone bodies (ketosis) in the body tissues and fluids, as in diabetic acidosis. [EU]

Ketone Bodies: Chemicals that the body makes when there is not enough insulin in the blood and it must break down fat for its energy. Ketone bodies can poison and even kill body cells. When the body does not have the help of insulin, the ketones build up in the blood and then "spill" over into the urine so that the body can get rid of them. The body can also rid itself of one type of ketone, called acetone, through the lungs. This gives the breath a fruity odor. Ketones that build up in the body for a long time lead to serious illness and coma. [NIH]

Ketosis: A condition of having ketone bodies build up in body tissues and fluids. The signs of ketosis are nausea, vomiting, and stomach pain. Ketosis can lead to ketoacidosis. [NIH]

Kidney Failure: The inability of a kidney to excrete metabolites at normal plasma levels under conditions of normal loading, or the inability to retain electrolytes under conditions of normal intake. In the acute form (kidney failure, acute), it is marked by uremia and usually

by oliguria or anuria, with hyperkalemia and pulmonary edema. The chronic form (kidney failure, chronic) is irreversible and requires hemodialysis. [NIH]

Kidney Failure, Acute: A clinical syndrome characterized by a sudden decrease in glomerular filtration rate, often to values of less than 1 to 2 ml per minute. It is usually associated with oliguria (urine volumes of less than 400 ml per day) and is always associated with biochemical consequences of the reduction in glomerular filtration rate such as a rise in blood urea nitrogen (BUN) and serum creatinine concentrations. [NIH]

Kidney Failure, Chronic: An irreversible and usually progressive reduction in renal function in which both kidneys have been damaged by a variety of diseases to the extent that they are unable to adequately remove the metabolic products from the blood and regulate the body's electrolyte composition and acid-base balance. Chronic kidney failure requires hemodialysis or surgery, usually kidney transplantation. [NIH]

Labile: 1. Gliding; moving from point to point over the surface; unstable; fluctuating. 2. Chemically unstable. [EU]

Lens: The transparent, double convex (outward curve on both sides) structure suspended between the aqueous and vitreous; helps to focus light on the retina. [NIH]

Lethal: Deadly, fatal. [EU]

Leucocyte: All the white cells of the blood and their precursors (myeloid cell series, lymphoid cell series) but commonly used to indicate granulocytes exclusive of lymphocytes. [NIH]

Leukemia: Cancer of blood-forming tissue. [NIH]

Levorphanol: A narcotic analgesic that may be habit-forming. It is nearly as effective orally as by injection. [NIH]

Linkages: The tendency of two or more genes in the same chromosome to remain together from one generation to the next more frequently than expected according to the law of independent assortment. [NIH]

Lipid: Fat. [NIH]

Lipid Peroxidation: Peroxidase catalyzed oxidation of lipids using hydrogen peroxide as an electron acceptor. [NIH]

Lipoprotein: Any of the lipid-protein complexes in which lipids are transported in the blood; lipoprotein particles consist of a spherical hydrophobic core of triglycerides or cholesterol esters surrounded by an amphipathic monolayer of phospholipids, cholesterol, and apolipoproteins; the four principal classes are high-density, low-density, and very-low-density lipoproteins and chylomicrons. [EU]

Liver: A large, glandular organ located in the upper abdomen. The liver cleanses the blood and aids in digestion by secreting bile. [NIH]

Localized: Cancer which has not metastasized yet. [NIH]

Locomotion: Movement or the ability to move from one place or another. It can refer to humans, vertebrate or invertebrate animals, and microorganisms. [NIH]

Low-density lipoprotein: Lipoprotein that contains most of the cholesterol in the blood. LDL carries cholesterol to the tissues of the body, including the arteries. A high level of LDL increases the risk of heart disease. LDL typically contains 60 to 70 percent of the total serum cholesterol and both are directly correlated with CHD risk. [NIH]

Lymphatic: The tissues and organs, including the bone marrow, spleen, thymus, and lymph nodes, that produce and store cells that fight infection and disease. [NIH]

Lymphatic system: The tissues and organs that produce, store, and carry white blood cells

that fight infection and other diseases. This system includes the bone marrow, spleen, thymus, lymph nodes and a network of thin tubes that carry lymph and white blood cells. These tubes branch, like blood vessels, into all the tissues of the body. [NIH]

Lymphocytes: White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each); those with characteristics of neither major class are called null cells. [NIH]

Lysine: An essential amino acid. It is often added to animal feed. [NIH]

Macrophage: A type of white blood cell that surrounds and kills microorganisms, removes dead cells, and stimulates the action of other immune system cells. [NIH]

Mafenide: A sulfonamide that inhibits the enzyme carbonic anhydrase and is used as topical anti-infective, especially in burn therapy. [NIH]

Major Histocompatibility Complex: The genetic region which contains the loci of genes which determine the structure of the serologically defined (SD) and lymphocyte-defined (LD) transplantation antigens, genes which control the structure of the immune response-associated (Ia) antigens, the immune response (Ir) genes which control the ability of an animal to respond immunologically to antigenic stimuli, and genes which determine the structure and/or level of the first four components of complement. [NIH]

Malaria: A protozoan disease caused in humans by four species of the genus *Plasmodium* (*P. falciparum* (malaria, falciparum), *P. vivax* (malaria, vivax), *P. ovale*, and *P. malariae*) and transmitted by the bite of an infected female mosquito of the genus *Anopheles*. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high fever, sweating, shaking chills, and anemia. Malaria in animals is caused by other species of plasmodia. [NIH]

Malaria, Falciparum: Malaria caused by *Plasmodium falciparum*. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations. [NIH]

Malaria, Vivax: Malaria caused by *Plasmodium vivax*. This form of malaria is less severe than malaria, falciparum, but there is a higher probability for relapses to occur. Febrile paroxysms often occur every other day. [NIH]

Mammography: Radiographic examination of the breast. [NIH]

Mania: Excitement of psychotic proportions manifested by mental and physical hyperactivity, disorganization of behaviour, and elevation of mood. [EU]

Manic: Affected with mania. [EU]

Manic-depressive psychosis: One of a group of psychotic reactions, fundamentally marked by severe mood swings and a tendency to remission and recurrence. [NIH]

Medical Records: Recording of pertinent information concerning patient's illness or illnesses. [NIH]

MEDLINE: An online database of MEDLARS, the computerized bibliographic Medical Literature Analysis and Retrieval System of the National Library of Medicine. [NIH]

Medullary: Pertaining to the marrow or to any medulla; resembling marrow. [EU]

Meiosis: A special method of cell division, occurring in maturation of the germ cells, by means of which each daughter nucleus receives half the number of chromosomes

characteristic of the somatic cells of the species. [NIH]

Melanocytes: Epidermal dendritic pigment cells which control long-term morphological color changes by alteration in their number or in the amount of pigment they produce and store in the pigment containing organelles called melanosomes. Melanophores are larger cells which do not exist in mammals. [NIH]

Melanoma: A form of skin cancer that arises in melanocytes, the cells that produce pigment. Melanoma usually begins in a mole. [NIH]

Membrane: A very thin layer of tissue that covers a surface. [NIH]

Memory: Complex mental function having four distinct phases: (1) memorizing or learning, (2) retention, (3) recall, and (4) recognition. Clinically, it is usually subdivided into immediate, recent, and remote memory. [NIH]

Mental: Pertaining to the mind; psychic. 2. (L. mentum chin) pertaining to the chin. [EU]

Mental Retardation: Refers to sub-average general intellectual functioning which originated during the developmental period and is associated with impairment in adaptive behavior. [NIH]

Methylene Blue: A compound consisting of dark green crystals or crystalline powder, having a bronze-like luster. Solutions in water or alcohol have a deep blue color. Methylene blue is used as a bacteriologic stain and as an indicator. It inhibits Guanylate cyclase, and has been used to treat cyanide poisoning and to lower levels of methemoglobin. [NIH]

Microbe: An organism which cannot be observed with the naked eye; e. g. unicellular animals, lower algae, lower fungi, bacteria. [NIH]

Microbiology: The study of microorganisms such as fungi, bacteria, algae, archaea, and viruses. [NIH]

Microorganism: An organism that can be seen only through a microscope. Microorganisms include bacteria, protozoa, algae, and fungi. Although viruses are not considered living organisms, they are sometimes classified as microorganisms. [NIH]

Microspectrophotometry: Analytical technique for studying substances present at enzyme concentrations in single cells, in situ, by measuring light absorption. Light from a tungsten strip lamp or xenon arc dispersed by a grating monochromator illuminates the optical system of a microscope. The absorbance of light is measured (in nanometers) by comparing the difference between the image of the sample and a reference image. [NIH]

Miscarriage: Spontaneous expulsion of the products of pregnancy before the middle of the second trimester. [NIH]

Mitochondria: Parts of a cell where aerobic production (also known as cell respiration) takes place. [NIH]

Mitosis: A method of indirect cell division by means of which the two daughter nuclei normally receive identical complements of the number of chromosomes of the somatic cells of the species. [NIH]

Molecular: Of, pertaining to, or composed of molecules : a very small mass of matter. [EU]

Molecule: A chemical made up of two or more atoms. The atoms in a molecule can be the same (an oxygen molecule has two oxygen atoms) or different (a water molecule has two hydrogen atoms and one oxygen atom). Biological molecules, such as proteins and DNA, can be made up of many thousands of atoms. [NIH]

Monitor: An apparatus which automatically records such physiological signs as respiration, pulse, and blood pressure in an anesthetized patient or one undergoing surgical or other procedures. [NIH]

Monophosphate: So called second messenger for neurotransmitters and hormones. [NIH]

Monosomy: The condition in which one chromosome of a pair is missing. In a normally diploid cell it is represented symbolically as $2N-1$. [NIH]

Morphological: Relating to the configuration or the structure of live organs. [NIH]

Morphology: The science of the form and structure of organisms (plants, animals, and other forms of life). [NIH]

Mosaicism: The occurrence in an individual of two or more cell populations of different chromosomal constitutions, derived from a single zygote, as opposed to chimerism in which the different cell populations are derived from more than one zygote. [NIH]

Mucins: A secretion containing mucopolysaccharides and protein that is the chief constituent of mucus. [NIH]

Mucolytic: Destroying or dissolving mucin; an agent that so acts : a mucopolysaccharide or glycoprotein, the chief constituent of mucus. [EU]

Mutagen: Any agent, such as X-rays, gamma rays, mustard gas, TCDD, that can cause abnormal mutation in living cells; having the power to cause mutations. [NIH]

Mutagenic: Inducing genetic mutation. [EU]

Myotonia: Prolonged failure of muscle relaxation after contraction. This may occur after voluntary contractions, muscle percussion, or electrical stimulation of the muscle. Myotonia is a characteristic feature of myotonic disorders. [NIH]

Myotonic Dystrophy: A condition presenting muscle weakness and wasting which may be progressive. [NIH]

Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses. [NIH]

NCI: National Cancer Institute. NCI, part of the National Institutes of Health of the United States Department of Health and Human Services, is the federal government's principal agency for cancer research. NCI conducts, coordinates, and funds cancer research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer. Access the NCI Web site at <http://cancer.gov>. [NIH]

Necrosis: A pathological process caused by the progressive degradative action of enzymes that is generally associated with severe cellular trauma. It is characterized by mitochondrial swelling, nuclear flocculation, uncontrolled cell lysis, and ultimately cell death. [NIH]

Neonatal: Pertaining to the first four weeks after birth. [EU]

Neonatal period: The first 4 weeks after birth. [NIH]

Neonatal Screening: The identification of selected parameters in newborn infants by various tests, examinations, or other procedures. Screening may be performed by clinical or laboratory measures. A screening test is designed to sort out healthy neonates from those not well, but the screening test is not intended as a diagnostic device, rather instead as epidemiologic. [NIH]

Nervous System: The entire nerve apparatus composed of the brain, spinal cord, nerves and ganglia. [NIH]

Neuropathy: A problem in any part of the nervous system except the brain and spinal cord. Neuropathies can be caused by infection, toxic substances, or disease. [NIH]

Neurotoxicity: The tendency of some treatments to cause damage to the nervous system. [NIH]

Neurotransmitter: Any of a group of substances that are released on excitation from the axon terminal of a presynaptic neuron of the central or peripheral nervous system and travel across the synaptic cleft to either excite or inhibit the target cell. Among the many substances that have the properties of a neurotransmitter are acetylcholine, norepinephrine, epinephrine, dopamine, glycine, γ -aminobutyrate, glutamic acid, substance P, enkephalins, endorphins, and serotonin. [EU]

Neutrophil: A type of white blood cell. [NIH]

Nuclear: A test of the structure, blood flow, and function of the kidneys. The doctor injects a mildly radioactive solution into an arm vein and uses x-rays to monitor its progress through the kidneys. [NIH]

Nuclear Envelope: The membrane system of the cell nucleus that surrounds the nucleoplasm. It consists of two concentric membranes separated by the perinuclear space. The structures of the envelope where it opens to the cytoplasm are called the nuclear pores (nuclear pore). [NIH]

Nuclear Pore: An opening through the nuclear envelope formed by the nuclear pore complex which transports nuclear proteins or RNA into or out of the cell nucleus and which, under some conditions, acts as an ion channel. [NIH]

Nuclei: A body of specialized protoplasm found in nearly all cells and containing the chromosomes. [NIH]

Nucleic acid: Either of two types of macromolecule (DNA or RNA) formed by polymerization of nucleotides. Nucleic acids are found in all living cells and contain the information (genetic code) for the transfer of genetic information from one generation to the next. [NIH]

Nucleus: A body of specialized protoplasm found in nearly all cells and containing the chromosomes. [NIH]

Nurse Practitioners: Nurses who are specially trained to assume an expanded role in providing medical care under the supervision of a physician. [NIH]

Ocular: 1. Of, pertaining to, or affecting the eye. 2. Eyepiece. [EU]

Oliguria: Clinical manifestation of the urinary system consisting of a decrease in the amount of urine secreted. [NIH]

Opacity: Degree of density (area most dense taken for reading). [NIH]

Organelles: Specific particles of membrane-bound organized living substances present in eukaryotic cells, such as the mitochondria; the golgi apparatus; endoplasmic reticulum; lysosomes; plastids; and vacuoles. [NIH]

Osteoarthritis: A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans. [NIH]

Outpatient: A patient who is not an inmate of a hospital but receives diagnosis or treatment in a clinic or dispensary connected with the hospital. [NIH]

Ovaries: The pair of female reproductive glands in which the ova, or eggs, are formed. The ovaries are located in the pelvis, one on each side of the uterus. [NIH]

Ovary: Either of the paired glands in the female that produce the female germ cells and secrete some of the female sex hormones. [NIH]

Overdose: An accidental or deliberate dose of a medication or street drug that is in excess of what is normally used. [NIH]

Oxidation: The act of oxidizing or state of being oxidized. Chemically it consists in the increase of positive charges on an atom or the loss of negative charges. Most biological oxidations are accomplished by the removal of a pair of hydrogen atoms (dehydrogenation) from a molecule. Such oxidations must be accompanied by reduction of an acceptor molecule. Univalent o. indicates loss of one electron; divalent o., the loss of two electrons. [EU]

Oxidative Phosphorylation: Electron transfer through the cytochrome system liberating free energy which is transformed into high-energy phosphate bonds. [NIH]

Oxidative Stress: A disturbance in the prooxidant-antioxidant balance in favor of the former, leading to potential damage. Indicators of oxidative stress include damaged DNA bases, protein oxidation products, and lipid peroxidation products (Sies, *Oxidative Stress*, 1991, p xv-xvi). [NIH]

Oxygenation: The process of supplying, treating, or mixing with oxygen. No:1245 - oxygenation the process of supplying, treating, or mixing with oxygen. [EU]

Oxygenator: An apparatus by which oxygen is introduced into the blood during circulation outside the body, as during open heart surgery. [NIH]

Pancreas: A mixed exocrine and endocrine gland situated transversely across the posterior abdominal wall in the epigastric and hypochondriac regions. The endocrine portion is comprised of the Islets of Langerhans, while the exocrine portion is a compound acinar gland that secretes digestive enzymes. [NIH]

Parasite: An animal or a plant that lives on or in an organism of another species and gets at least some of its nutrition from that other organism. [NIH]

Parasitic: Having to do with or being a parasite. A parasite is an animal or a plant that lives on or in an organism of another species and gets at least some of its nutrients from it. [NIH]

Paternity: Establishing the father relationship of a man and a child. [NIH]

Pathogen: Any disease-producing microorganism. [EU]

Pathologic: 1. Indicative of or caused by a morbid condition. 2. Pertaining to pathology (= branch of medicine that treats the essential nature of the disease, especially the structural and functional changes in tissues and organs of the body caused by the disease). [EU]

Pathologic Processes: The abnormal mechanisms and forms involved in the dysfunctions of tissues and organs. [NIH]

PDQ: Physician Data Query. PDQ is an online database developed and maintained by the National Cancer Institute. Designed to make the most current, credible, and accurate cancer information available to health professionals and the public, PDQ contains peer-reviewed summaries on cancer treatment, screening, prevention, genetics, and supportive care; a registry of cancer clinical trials from around the world; and directories of physicians, professionals who provide genetics services, and organizations that provide cancer care. Most of this information is available on the CancerNet Web site, and more specific information about PDQ can be found at <http://cancernet.nci.nih.gov/pdq.html>. [NIH]

Pefloxacin: An orally administered broad spectrum quinolone antibacterial agent active against most gram-negative and gram-positive bacteria. It is effective against urinary tract infections as well as against many other systemic infections. The drug is well tolerated in adults, but should not be given to children and pregnant women. [NIH]

Pelvis: The lower part of the abdomen, located between the hip bones. [NIH]

Peptide: Any compound consisting of two or more amino acids, the building blocks of proteins. Peptides are combined to make proteins. [NIH]

Peripheral blood: Blood circulating throughout the body. [NIH]

Peroxide: Chemical compound which contains an atom group with two oxygen atoms tied to each other. [NIH]

Phagocytosis: The engulfing of microorganisms, other cells, and foreign particles by phagocytic cells. [NIH]

Pharmacologic: Pertaining to pharmacology or to the properties and reactions of drugs. [EU]

Phosphogluconate Dehydrogenase: An enzyme of the oxidoreductase class that catalyzes the reaction 6-phospho-D-gluconate and NADP⁺ to yield D-ribulose 5-phosphate, carbon dioxide, and NADPH. The reaction is a step in the pentose phosphate pathway of glucose metabolism. (From Dorland, 27th ed) EC 1.1.1.43. [NIH]

Phospholipids: Lipids containing one or more phosphate groups, particularly those derived from either glycerol (phosphoglycerides; glycerophospholipids) or sphingosine (sphingolipids). They are polar lipids that are of great importance for the structure and function of cell membranes and are the most abundant of membrane lipids, although not stored in large amounts in the system. [NIH]

Phosphorus: A non-metallic element that is found in the blood, muscles, nerves, bones, and teeth, and is a component of adenosine triphosphate (ATP; the primary energy source for the body's cells.) [NIH]

Phosphorylation: The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. [NIH]

Phototherapy: Treatment of disease by exposure to light, especially by variously concentrated light rays or specific wavelengths. [NIH]

Physical Examination: Systematic and thorough inspection of the patient for physical signs of disease or abnormality. [NIH]

Physiologic: Having to do with the functions of the body. When used in the phrase "physiologic age," it refers to an age assigned by general health, as opposed to calendar age. [NIH]

Pigment: A substance that gives color to tissue. Pigments are responsible for the color of skin, eyes, and hair. [NIH]

Pilot study: The initial study examining a new method or treatment. [NIH]

Piroxicam: 4-Hydroxy-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide. A non-steroidal anti-inflammatory agent that is well established in the treatment of rheumatoid arthritis and osteoarthritis. Its usefulness has also been demonstrated in the treatment of musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. The drug has also been shown to be effective if administered rectally. Gastrointestinal complaints are the most frequently reported side effects. [NIH]

Plants: Multicellular, eukaryotic life forms of the kingdom Plantae. They are characterized by a mainly photosynthetic mode of nutrition; essentially unlimited growth at localized regions of cell divisions (meristems); cellulose within cells providing rigidity; the absence of organs of locomotion; absence of nervous and sensory systems; and an alteration of haploid and diploid generations. [NIH]

Plasma: The clear, yellowish, fluid part of the blood that carries the blood cells. The proteins that form blood clots are in plasma. [NIH]

Plastids: Self-replicating cytoplasmic organelles of plant and algal cells that contain pigments and may synthesize and accumulate various substances. Plastids are used in phylogenetic studies. [NIH]

Plumbism: Disease caused by the gradual accumulation of a significant body burden of

lead. [NIH]

Pneumonia: Inflammation of the lungs. [NIH]

Poisoning: A condition or physical state produced by the ingestion, injection or inhalation of, or exposure to a deleterious agent. [NIH]

Pollen: The male fertilizing element of flowering plants analogous to sperm in animals. It is released from the anthers as yellow dust, to be carried by insect or other vectors, including wind, to the ovary (stigma) of other flowers to produce the embryo enclosed by the seed. The pollens of many plants are allergenic. [NIH]

Polymorphic: Occurring in several or many forms; appearing in different forms at different stages of development. [EU]

Polymorphism: The occurrence together of two or more distinct forms in the same population. [NIH]

Polypeptide: A peptide which on hydrolysis yields more than two amino acids; called tripeptides, tetrapeptides, etc. according to the number of amino acids contained. [EU]

Postoperative: After surgery. [NIH]

Potential: An overall effect of two drugs taken together which is greater than the sum of the effects of each drug taken alone. [NIH]

Practice Guidelines: Directions or principles presenting current or future rules of policy for the health care practitioner to assist him in patient care decisions regarding diagnosis, therapy, or related clinical circumstances. The guidelines may be developed by government agencies at any level, institutions, professional societies, governing boards, or by the convening of expert panels. The guidelines form a basis for the evaluation of all aspects of health care and delivery. [NIH]

Prenatal: Existing or occurring before birth, with reference to the fetus. [EU]

Prevalence: The total number of cases of a given disease in a specified population at a designated time. It is differentiated from incidence, which refers to the number of new cases in the population at a given time. [NIH]

Progeny: The offspring produced in any generation. [NIH]

Progression: Increase in the size of a tumor or spread of cancer in the body. [NIH]

Progressive: Advancing; going forward; going from bad to worse; increasing in scope or severity. [EU]

Prone: Having the front portion of the body downwards. [NIH]

Prostaglandin: Any of a group of components derived from unsaturated 20-carbon fatty acids, primarily arachidonic acid, via the cyclooxygenase pathway that are extremely potent mediators of a diverse group of physiologic processes. The abbreviation for prostaglandin is PG; specific compounds are designated by adding one of the letters A through I to indicate the type of substituents found on the hydrocarbon skeleton and a subscript (1, 2 or 3) to indicate the number of double bonds in the hydrocarbon skeleton e.g., PGE₂. The predominant naturally occurring prostaglandins all have two double bonds and are synthesized from arachidonic acid (5,8,11,14-eicosatetraenoic acid) by the pathway shown in the illustration. The 1 series and 3 series are produced by the same pathway with fatty acids having one fewer double bond (8,11,14-eicosatrienoic acid) or one more double bond (5,8,11,14,17-eicosapentaenoic acid) than arachidonic acid. The subscript α or β indicates the configuration at C-9 (α denotes a substituent below the plane of the ring, β , above the plane). The naturally occurring PGF's have the α configuration, e.g., PGF₂ α . All of the prostaglandins act by binding to specific cell-surface receptors causing an increase in the

level of the intracellular second messenger cyclic AMP (and in some cases cyclic GMP also). The effect produced by the cyclic AMP increase depends on the specific cell type. In some cases there is also a positive feedback effect. Increased cyclic AMP increases prostaglandin synthesis leading to further increases in cyclic AMP. [EU]

Protease: Proteinase (= any enzyme that catalyses the splitting of interior peptide bonds in a protein). [EU]

Protein C: A vitamin-K dependent zymogen present in the blood, which, upon activation by thrombin and thrombomodulin exerts anticoagulant properties by inactivating factors Va and VIIIa at the rate-limiting steps of thrombin formation. [NIH]

Protein S: The vitamin K-dependent cofactor of activated protein C. Together with protein C, it inhibits the action of factors VIIIa and Va. A deficiency in protein S can lead to recurrent venous and arterial thrombosis. [NIH]

Proteins: Polymers of amino acids linked by peptide bonds. The specific sequence of amino acids determines the shape and function of the protein. [NIH]

Proteolytic: 1. Pertaining to, characterized by, or promoting proteolysis. 2. An enzyme that promotes proteolysis (= the splitting of proteins by hydrolysis of the peptide bonds with formation of smaller polypeptides). [EU]

Protocol: The detailed plan for a clinical trial that states the trial's rationale, purpose, drug or vaccine dosages, length of study, routes of administration, who may participate, and other aspects of trial design. [NIH]

Protons: Stable elementary particles having the smallest known positive charge, found in the nuclei of all elements. The proton mass is less than that of a neutron. A proton is the nucleus of the light hydrogen atom, i.e., the hydrogen ion. [NIH]

Protozoa: A subkingdom consisting of unicellular organisms that are the simplest in the animal kingdom. Most are free living. They range in size from submicroscopic to macroscopic. Protozoa are divided into seven phyla: Sarcomastigophora, Labyrinthomorpha, Apicomplexa, Microspora, Asctospora, Myxozoa, and Ciliophora. [NIH]

Protozoan: 1. Any individual of the protozoa; protozoon. 2. Of or pertaining to the protozoa; protozoal. [EU]

Proxy: A person authorized to decide or act for another person, for example, a person having durable power of attorney. [NIH]

Psychiatric: Pertaining to or within the purview of psychiatry. [EU]

Psychiatry: The medical science that deals with the origin, diagnosis, prevention, and treatment of mental disorders. [NIH]

Psychic: Pertaining to the psyche or to the mind; mental. [EU]

Psychosis: A mental disorder characterized by gross impairment in reality testing as evidenced by delusions, hallucinations, markedly incoherent speech, or disorganized and agitated behaviour without apparent awareness on the part of the patient of the incomprehensibility of his behaviour; the term is also used in a more general sense to refer to mental disorders in which mental functioning is sufficiently impaired as to interfere grossly with the patient's capacity to meet the ordinary demands of life. Historically, the term has been applied to many conditions, e.g. manic-depressive psychosis, that were first described in psychotic patients, although many patients with the disorder are not judged psychotic. [EU]

Public Health: Branch of medicine concerned with the prevention and control of disease and disability, and the promotion of physical and mental health of the population on the international, national, state, or municipal level. [NIH]

Public Policy: A course or method of action selected, usually by a government, from among alternatives to guide and determine present and future decisions. [NIH]

Pulmonary: Relating to the lungs. [NIH]

Pulmonary Artery: The short wide vessel arising from the conus arteriosus of the right ventricle and conveying unaerated blood to the lungs. [NIH]

Pulmonary Edema: An accumulation of an excessive amount of watery fluid in the lungs, may be caused by acute exposure to dangerous concentrations of irritant gasses. [NIH]

Purines: A series of heterocyclic compounds that are variously substituted in nature and are known also as purine bases. They include adenine and guanine, constituents of nucleic acids, as well as many alkaloids such as caffeine and theophylline. Uric acid is the metabolic end product of purine metabolism. [NIH]

Pyrimidines: A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (cytosine, thymine, and uracil) and form the basic structure of the barbiturates. [NIH]

Pyruvate Kinase: ATP:pyruvate 2-O-phosphotransferase. A phosphotransferase that catalyzes reversibly the phosphorylation of pyruvate to phosphoenolpyruvate in the presence of ATP. It has four isozymes (L, R, M1, and M2). Deficiency of the enzyme results in hemolytic anemia. EC 2.7.1.40. [NIH]

Quinine: An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood. [NIH]

Race: A population within a species which exhibits general similarities within itself, but is both discontinuous and distinct from other populations of that species, though not sufficiently so as to achieve the status of a taxon. [NIH]

Radiation: Emission or propagation of electromagnetic energy (waves/rays), or the waves/rays themselves; a stream of electromagnetic particles (electrons, neutrons, protons, alpha particles) or a mixture of these. The most common source is the sun. [NIH]

Radiation therapy: The use of high-energy radiation from x-rays, gamma rays, neutrons, and other sources to kill cancer cells and shrink tumors. Radiation may come from a machine outside the body (external-beam radiation therapy), or it may come from radioactive material placed in the body in the area near cancer cells (internal radiation therapy, implant radiation, or brachytherapy). Systemic radiation therapy uses a radioactive substance, such as a radiolabeled monoclonal antibody, that circulates throughout the body. Also called radiotherapy. [NIH]

Radioactive: Giving off radiation. [NIH]

Reactive Oxygen Species: Reactive intermediate oxygen species including both radicals and non-radicals. These substances are constantly formed in the human body and have been shown to kill bacteria and inactivate proteins, and have been implicated in a number of diseases. Scientific data exist that link the reactive oxygen species produced by inflammatory phagocytes to cancer development. [NIH]

Receptor: A molecule inside or on the surface of a cell that binds to a specific substance and causes a specific physiologic effect in the cell. [NIH]

Recombinant: A cell or an individual with a new combination of genes not found together in either parent; usually applied to linked genes. [EU]

Recombination: The formation of new combinations of genes as a result of segregation in crosses between genetically different parents; also the rearrangement of linked genes due to crossing-over. [NIH]

Rectum: The last 8 to 10 inches of the large intestine. [NIH]

Recurrence: The return of a sign, symptom, or disease after a remission. [NIH]

Red blood cells: RBCs. Cells that carry oxygen to all parts of the body. Also called erythrocytes. [NIH]

Reductase: Enzyme converting testosterone to dihydrotestosterone. [NIH]

Refer: To send or direct for treatment, aid, information, or decision. [NIH]

Remission: A decrease in or disappearance of signs and symptoms of cancer. In partial remission, some, but not all, signs and symptoms of cancer have disappeared. In complete remission, all signs and symptoms of cancer have disappeared, although there still may be cancer in the body. [NIH]

Renal failure: Progressive renal insufficiency and uremia, due to irreversible and progressive renal glomerular tubular or interstitial disease. [NIH]

Reproductive cells: Egg and sperm cells. Each mature reproductive cell carries a single set of 23 chromosomes. [NIH]

Retina: The ten-layered nervous tissue membrane of the eye. It is continuous with the optic nerve and receives images of external objects and transmits visual impulses to the brain. Its outer surface is in contact with the choroid and the inner surface with the vitreous body. The outer-most layer is pigmented, whereas the inner nine layers are transparent. [NIH]

Retinoblastoma: An eye cancer that most often occurs in children younger than 5 years. It occurs in hereditary and nonhereditary (sporadic) forms. [NIH]

Retroviral vector: RNA from a virus that is used to insert genetic material into cells. [NIH]

Rheumatoid: Resembling rheumatism. [EU]

Rheumatoid arthritis: A form of arthritis, the cause of which is unknown, although infection, hypersensitivity, hormone imbalance and psychologic stress have been suggested as possible causes. [NIH]

Ribavirin: 1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide. A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses. [NIH]

Riboflavin: Nutritional factor found in milk, eggs, malted barley, liver, kidney, heart, and leafy vegetables. The richest natural source is yeast. It occurs in the free form only in the retina of the eye, in whey, and in urine; its principal forms in tissues and cells are as FMN and FAD. [NIH]

Ribonucleic acid: RNA. One of the two nucleic acids found in all cells. The other is deoxyribonucleic acid (DNA). Ribonucleic acid transfers genetic information from DNA to proteins produced by the cell. [NIH]

Ribose: A pentose active in biological systems usually in its D-form. [NIH]

Ribosome: A granule of protein and RNA, synthesized in the nucleolus and found in the cytoplasm of cells. Ribosomes are the main sites of protein synthesis. Messenger RNA attaches to them and there receives molecules of transfer RNA bearing amino acids. [NIH]

Rigidity: Stiffness or inflexibility, chiefly that which is abnormal or morbid; rigor. [EU]

Risk factor: A habit, trait, condition, or genetic alteration that increases a person's chance of developing a disease. [NIH]

Rural Population: The inhabitants of rural areas or of small towns classified as rural. [NIH]

Salicylate: Non-steroidal anti-inflammatory drugs. [NIH]

Salicylic: A tuberculosis drug. [NIH]

Salicylic Acids: Derivatives and salts of salicylic acid. [NIH]

Saliva: The clear, viscous fluid secreted by the salivary glands and mucous glands of the mouth. It contains mucins, water, organic salts, and ptylin. [NIH]

Salivary: The duct that convey saliva to the mouth. [NIH]

Salivary glands: Glands in the mouth that produce saliva. [NIH]

Scatter: The extent to which relative success and failure are divergently manifested in qualitatively different tests. [NIH]

Schizophrenia: A mental disorder characterized by a special type of disintegration of the personality. [NIH]

Sclerosis: A pathological process consisting of hardening or fibrosis of an anatomical structure, often a vessel or a nerve. [NIH]

Screening: Checking for disease when there are no symptoms. [NIH]

Secretion: 1. The process of elaborating a specific product as a result of the activity of a gland; this activity may range from separating a specific substance of the blood to the elaboration of a new chemical substance. 2. Any substance produced by secretion. [EU]

Selenium: An element with the atomic symbol Se, atomic number 34, and atomic weight 78.96. It is an essential micronutrient for mammals and other animals but is toxic in large amounts. Selenium protects intracellular structures against oxidative damage. It is an essential component of glutathione peroxidase. [NIH]

Sequencing: The determination of the order of nucleotides in a DNA or RNA chain. [NIH]

Serum: The clear liquid part of the blood that remains after blood cells and clotting proteins have been removed. [NIH]

Sex Distribution: The number of males and females in a given population. The distribution may refer to how many men or women or what proportion of either in the group. The population is usually patients with a specific disease but the concept is not restricted to humans and is not restricted to medicine. [NIH]

Shunt: A surgically created diversion of fluid (e.g., blood or cerebrospinal fluid) from one area of the body to another area of the body. [NIH]

Sickle Cell Trait: The condition of being heterozygous for hemoglobin S. [NIH]

Side effect: A consequence other than the one(s) for which an agent or measure is used, as the adverse effects produced by a drug, especially on a tissue or organ system other than the one sought to be benefited by its administration. [EU]

Signs and Symptoms: Clinical manifestations that can be either objective when observed by a physician, or subjective when perceived by the patient. [NIH]

Small intestine: The part of the digestive tract that is located between the stomach and the large intestine. [NIH]

Social Work: The use of community resources, individual case work, or group work to promote the adaptive capacities of individuals in relation to their social and economic environments. It includes social service agencies. [NIH]

Sodium: An element that is a member of the alkali group of metals. It has the atomic symbol Na, atomic number 11, and atomic weight 23. With a valence of 1, it has a strong affinity for oxygen and other nonmetallic elements. Sodium provides the chief cation of the extracellular body fluids. Its salts are the most widely used in medicine. (From Dorland, 27th ed) Physiologically the sodium ion plays a major role in blood pressure regulation, maintenance of fluid volume, and electrolyte balance. [NIH]

Soft tissue: Refers to muscle, fat, fibrous tissue, blood vessels, or other supporting tissue of the body. [NIH]

Soma: The body as distinct from the mind; all the body tissue except the germ cells; all the axial body. [NIH]

Somatic: 1. Pertaining to or characteristic of the soma or body. 2. Pertaining to the body wall in contrast to the viscera. [EU]

Somatic cells: All the body cells except the reproductive (germ) cells. [NIH]

Somatic mutations: Alterations in DNA that occur after conception. Somatic mutations can occur in any of the cells of the body except the germ cells (sperm and egg) and therefore are not passed on to children. These alterations can (but do not always) cause cancer or other diseases. [NIH]

Specialist: In medicine, one who concentrates on 1 special branch of medical science. [NIH]

Species: A taxonomic category subordinate to a genus (or subgenus) and superior to a subspecies or variety, composed of individuals possessing common characters distinguishing them from other categories of individuals of the same taxonomic level. In taxonomic nomenclature, species are designated by the genus name followed by a Latin or Latinized adjective or noun. [EU]

Spectrum: A charted band of wavelengths of electromagnetic vibrations obtained by refraction and diffraction. By extension, a measurable range of activity, such as the range of bacteria affected by an antibiotic (antibacterial s.) or the complete range of manifestations of a disease. [EU]

Sperm: The fecundating fluid of the male. [NIH]

Spinal cord: The main trunk or bundle of nerves running down the spine through holes in the spinal bone (the vertebrae) from the brain to the level of the lower back. [NIH]

Spleen: An organ that is part of the lymphatic system. The spleen produces lymphocytes, filters the blood, stores blood cells, and destroys old blood cells. It is located on the left side of the abdomen near the stomach. [NIH]

Sporadic: Neither endemic nor epidemic; occurring occasionally in a random or isolated manner. [EU]

Stillbirth: The birth of a dead fetus or baby. [NIH]

Stomach: An organ of digestion situated in the left upper quadrant of the abdomen between the termination of the esophagus and the beginning of the duodenum. [NIH]

Stool: The waste matter discharged in a bowel movement; feces. [NIH]

Strand: DNA normally exists in the bacterial nucleus in a helix, in which two strands are coiled together. [NIH]

Stroke: Sudden loss of function of part of the brain because of loss of blood flow. Stroke may be caused by a clot (thrombosis) or rupture (hemorrhage) of a blood vessel to the brain. [NIH]

Subacute: Somewhat acute; between acute and chronic. [EU]

Subclinical: Without clinical manifestations; said of the early stage(s) of an infection or other disease or abnormality before symptoms and signs become apparent or detectable by

clinical examination or laboratory tests, or of a very mild form of an infection or other disease or abnormality. [EU]

Subspecies: A category intermediate in rank between species and variety, based on a smaller number of correlated characters than are used to differentiate species and generally conditioned by geographical and/or ecological occurrence. [NIH]

Substance P: An eleven-amino acid neurotransmitter that appears in both the central and peripheral nervous systems. It is involved in transmission of pain, causes rapid contractions of the gastrointestinal smooth muscle, and modulates inflammatory and immune responses. [NIH]

Succimer: A mercaptodicarboxylic acid used as an antidote to heavy metal poisoning because it forms strong chelates with them. [NIH]

Sulfadoxine: A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections. [NIH]

Superoxide: Derivative of molecular oxygen that can damage cells. [NIH]

Superoxide Dismutase: An oxidoreductase that catalyzes the reaction between superoxide anions and hydrogen to yield molecular oxygen and hydrogen peroxide. The enzyme protects the cell against dangerous levels of superoxide. EC 1.15.1.1. [NIH]

Supplementation: Adding nutrients to the diet. [NIH]

Supportive care: Treatment given to prevent, control, or relieve complications and side effects and to improve the comfort and quality of life of people who have cancer. [NIH]

Sympathectomy: The removal or interruption of some part of the sympathetic nervous system for therapeutic or research purposes. [NIH]

Sympathetic Nervous System: The thoracolumbar division of the autonomic nervous system. Sympathetic preganglionic fibers originate in neurons of the intermediolateral column of the spinal cord and project to the paravertebral and prevertebral ganglia, which in turn project to target organs. The sympathetic nervous system mediates the body's response to stressful situations, i.e., the fight or flight reactions. It often acts reciprocally to the parasympathetic system. [NIH]

Systemic: Affecting the entire body. [NIH]

Terminator: A DNA sequence sited at the end of a transcriptional unit that signals the end of transcription. [NIH]

Testosterone: A hormone that promotes the development and maintenance of male sex characteristics. [NIH]

Thalassemia: A group of hereditary hemolytic anemias in which there is decreased synthesis of one or more hemoglobin polypeptide chains. There are several genetic types with clinical pictures ranging from barely detectable hematologic abnormality to severe and fatal anemia. [NIH]

Thrombosis: The formation or presence of a blood clot inside a blood vessel. [NIH]

Thyroid: A gland located near the windpipe (trachea) that produces thyroid hormone, which helps regulate growth and metabolism. [NIH]

Thyroid Gland: A highly vascular endocrine gland consisting of two lobes, one on either side of the trachea, joined by a narrow isthmus; it produces the thyroid hormones which are concerned in regulating the metabolic rate of the body. [NIH]

Thyroid Hormones: Hormones secreted by the thyroid gland. [NIH]

Tissue: A group or layer of cells that are alike in type and work together to perform a specific function. [NIH]

Tonicity: The normal state of muscular tension. [NIH]

Tooth Preparation: Procedures carried out with regard to the teeth or tooth structures preparatory to specified dental therapeutic and surgical measures. [NIH]

Topical: On the surface of the body. [NIH]

Toxic: Having to do with poison or something harmful to the body. Toxic substances usually cause unwanted side effects. [NIH]

Toxicity: The quality of being poisonous, especially the degree of virulence of a toxic microbe or of a poison. [EU]

Toxicology: The science concerned with the detection, chemical composition, and pharmacologic action of toxic substances or poisons and the treatment and prevention of toxic manifestations. [NIH]

Toxins: Specific, characterizable, poisonous chemicals, often proteins, with specific biological properties, including immunogenicity, produced by microbes, higher plants, or animals. [NIH]

Trachea: The cartilaginous and membranous tube descending from the larynx and branching into the right and left main bronchi. [NIH]

Transcription Factors: Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process. [NIH]

Transfection: The uptake of naked or purified DNA into cells, usually eukaryotic. It is analogous to bacterial transformation. [NIH]

Transferases: Transferases are enzymes transferring a group, for example, the methyl group or a glycosyl group, from one compound (generally regarded as donor) to another compound (generally regarded as acceptor). The classification is based on the scheme "donor:acceptor group transferase". (Enzyme Nomenclature, 1992) EC 2. [NIH]

Transfusion: The infusion of components of blood or whole blood into the bloodstream. The blood may be donated from another person, or it may have been taken from the person earlier and stored until needed. [NIH]

Translation: The process whereby the genetic information present in the linear sequence of ribonucleotides in mRNA is converted into a corresponding sequence of amino acids in a protein. It occurs on the ribosome and is unidirectional. [NIH]

Trinucleotide Repeat Expansion: DNA region comprised of a variable number of repetitive, contiguous trinucleotide sequences. The presence of these regions is associated with diseases such as Fragile X Syndrome and myotonic dystrophy. Many chromosome fragile sites (chromosome fragility) contain expanded trinucleotide repeats. [NIH]

Trinucleotide Repeats: Microsatellite repeats consisting of three nucleotides dispersed in the euchromatic arms of chromosomes. [NIH]

Trisomy: The possession of a third chromosome of any one type in an otherwise diploid cell. [NIH]

Tungsten: A metallic element with the atomic symbol W, atomic number 74, and atomic weight 183.85. It is used in many manufacturing applications, including increasing the hardness, toughness, and tensile strength of steel; manufacture of filaments for incandescent light bulbs; and in contact points for automotive and electrical apparatus. [NIH]

Typhoid fever: The most important member of the enteric group of fevers which also includes the paratyphoids. [NIH]

Typhoid fever: The most important member of the enteric group of fevers which also includes the paratyphoids. [NIH]

Ultraviolet radiation: Invisible rays that are part of the energy that comes from the sun. UV radiation can damage the skin and cause melanoma and other types of skin cancer. UV radiation that reaches the earth's surface is made up of two types of rays, called UVA and UVB rays. UVB rays are more likely than UVA rays to cause sunburn, but UVA rays pass deeper into the skin. Scientists have long thought that UVB radiation can cause melanoma and other types of skin cancer. They now think that UVA radiation also may add to skin damage that can lead to skin cancer and cause premature aging. For this reason, skin specialists recommend that people use sunscreens that reflect, absorb, or scatter both kinds of UV radiation. [NIH]

Uracil: An anticancer drug that belongs to the family of drugs called alkylating agents. [NIH]

Uremia: The illness associated with the buildup of urea in the blood because the kidneys are not working effectively. Symptoms include nausea, vomiting, loss of appetite, weakness, and mental confusion. [NIH]

Urethra: The tube through which urine leaves the body. It empties urine from the bladder. [NIH]

Uridine Diphosphate: A uracil nucleotide containing a pyrophosphate group esterified to C5 of the sugar moiety. [NIH]

Urinary: Having to do with urine or the organs of the body that produce and get rid of urine. [NIH]

Urinary tract: The organs of the body that produce and discharge urine. These include the kidneys, ureters, bladder, and urethra. [NIH]

Urinary tract infection: An illness caused by harmful bacteria growing in the urinary tract. [NIH]

Urine: Fluid containing water and waste products. Urine is made by the kidneys, stored in the bladder, and leaves the body through the urethra. [NIH]

Uterus: The small, hollow, pear-shaped organ in a woman's pelvis. This is the organ in which a fetus develops. Also called the womb. [NIH]

Vaccine: A substance or group of substances meant to cause the immune system to respond to a tumor or to microorganisms, such as bacteria or viruses. [NIH]

Vacuoles: Any spaces or cavities within a cell. They may function in digestion, storage, secretion, or excretion. [NIH]

Vascular: Pertaining to blood vessels or indicative of a copious blood supply. [EU]

Vector: Plasmid or other self-replicating DNA molecule that transfers DNA between cells in nature or in recombinant DNA technology. [NIH]

Vein: Vessel-carrying blood from various parts of the body to the heart. [NIH]

Venous: Of or pertaining to the veins. [EU]

Venous blood: Blood that has given up its oxygen to the tissues and carries carbon dioxide back for gas exchange. [NIH]

Venules: The minute vessels that collect blood from the capillary plexuses and join together to form veins. [NIH]

Veterinary Medicine: The medical science concerned with the prevention, diagnosis, and treatment of diseases in animals. [NIH]

Viral: Pertaining to, caused by, or of the nature of virus. [EU]

Viral Hepatitis: Hepatitis caused by a virus. Five different viruses (A, B, C, D, and E) most commonly cause this form of hepatitis. Other rare viruses may also cause hepatitis. [NIH]

Virulence: The degree of pathogenicity within a group or species of microorganisms or viruses as indicated by case fatality rates and/or the ability of the organism to invade the tissues of the host. [NIH]

Virus: Submicroscopic organism that causes infectious disease. In cancer therapy, some viruses may be made into vaccines that help the body build an immune response to, and kill, tumor cells. [NIH]

Viscera: Any of the large interior organs in any one of the three great cavities of the body, especially in the abdomen. [NIH]

Viscosity: A physical property of fluids that determines the internal resistance to shear forces. [EU]

Vitro: Descriptive of an event or enzyme reaction under experimental investigation occurring outside a living organism. Parts of an organism or microorganism are used together with artificial substrates and/or conditions. [NIH]

Vivo: Outside of or removed from the body of a living organism. [NIH]

White blood cell: A type of cell in the immune system that helps the body fight infection and disease. White blood cells include lymphocytes, granulocytes, macrophages, and others. [NIH]

Windpipe: A rigid tube, 10 cm long, extending from the cricoid cartilage to the upper border of the fifth thoracic vertebra. [NIH]

Womb: A hollow, thick-walled, muscular organ in which the impregnated ovum is developed into a child. [NIH]

Xenograft: The cells of one species transplanted to another species. [NIH]

Xenon: A noble gas with the atomic symbol Xe, atomic number 54, and atomic weight 131.30. It is found in the earth's atmosphere and has been used as an anesthetic. [NIH]

X-ray: High-energy radiation used in low doses to diagnose diseases and in high doses to treat cancer. [NIH]

Zygote: The fertilized ovum. [NIH]

INDEX

3

3-dimensional, 71, 102, 116

A

Abdomen, 116, 135, 140, 147, 151
 Acatalasia, 116, 122
 Acceptor, 116, 135, 140, 149
 Acetaminophen, 29, 116
 Acetylcysteine, 38, 116
 Acidosis, 116, 134
 Acute renal, 11, 116, 132
 Adaptability, 116, 122, 123
 Adaptation, 58, 116
 Adenine, 65, 116, 144
 Adenosine, 66, 116, 141
 Adenosine Triphosphate, 66, 116, 141
 Adenovirus, 98, 117
 Adjustment, 116, 117
 Adverse Effect, 117, 146
 Aerobic, 117, 137
 Affinity, 117, 127, 147
 Algorithms, 117, 121
 Alkaline, 116, 117, 121
 Alkaloid, 117, 144
 Alleles, 67, 84, 117, 132
 Alpha-1, 80, 84, 117
 Alpha-Thalassemia, 59, 117
 Alternative medicine, 117
 Amino Acids, 67, 71, 77, 117, 124, 140, 142, 143, 145, 149
 Amnion, 117
 Amniotic Fluid, 93, 95, 117
 Ampulla, 118, 128
 Anaemia, 10, 19, 20, 50, 53, 60, 118
 Analgesic, 116, 118, 124, 135, 144
 Analog, 118, 127
 Analogous, 118, 142, 149
 Anaphylatoxins, 118, 125
 Anatomical, 118, 120, 123, 133, 146
 Anemia, 11, 12, 17, 18, 19, 20, 21, 29, 43, 46, 48, 49, 57, 58, 79, 80, 83, 84, 89, 109, 113, 117, 118, 120, 129, 131, 136, 144, 148
 Aneuploidy, 78, 118
 Animal model, 57, 118
 Anions, 118, 134, 148
 Antibacterial, 118, 140, 147
 Antibiotics, 118
 Antibodies, 72, 118, 131, 132
 Antibody, 72, 117, 118, 119, 124, 132, 133, 144

Anticoagulant, 22, 118, 143
 Antidote, 118, 148
 Antigen, 117, 118, 119, 125, 132, 133
 Antigen-Antibody Complex, 119, 125
 Anti-infective, 119, 133, 136
 Anti-inflammatory, 116, 119, 120, 141, 146
 Anti-Inflammatory Agents, 119, 120
 Antimetabolite, 119, 145
 Antioxidant, 56, 119, 129, 140
 Antipyretic, 116, 119, 144
 Antitussive, 119, 127
 Antiviral, 116, 119, 134, 145
 Anuria, 119, 134
 Anus, 119, 124
 Aorta, 119, 122
 Apolipoproteins, 119, 135
 Apoptosis, 21, 66, 75, 119
 Aqueous, 119, 120, 126, 133, 135
 Arginine, 118, 119, 132
 Arterial, 119, 123, 133, 143
 Arteries, 119, 121, 126, 135
 Arterioles, 119, 121
 Ascorbic Acid, 19, 55, 57, 119
 Aspartate, 120, 127
 Aspirin, 12, 29, 35, 109, 120
 Assay, 17, 45, 54, 120
 Asymptomatic, 116, 120
 Atrium, 120, 122
 Atypical, 88, 120

B

Babesiosis, 120, 144
 Bacteria, 64, 72, 76, 118, 119, 120, 125, 128, 131, 132, 137, 140, 144, 147, 150
 Bacterial Physiology, 116, 120
 Bacterium, 120, 125, 132
 Base, 65, 66, 69, 71, 75, 76, 77, 100, 116, 120, 126, 127, 129, 135
 Base Sequence, 76, 120, 129
 Benzo(a)pyrene, 16, 36, 120
 Beta-Thalassemia, 18, 120
 Bewilderment, 120, 125
 Bile, 120, 134, 135
 Bile Pigments, 120, 134
 Bilirubin, 16, 23, 38, 39, 51, 114, 120, 133
 Biochemical, 13, 46, 51, 56, 57, 80, 117, 119, 120, 130, 135, 139
 Biological response modifier, 120, 134
 Biotechnology, 10, 71, 98, 100, 105, 121
 Blackwater Fever, 51, 121

- Bladder, 121, 150
 Blastocyst, 121, 125
 Blood Cell Count, 114, 121, 131
 Blood Coagulation, 121
 Blood Glucose, 121, 131
 Blood Groups, 10, 25, 28, 121
 Blood pressure, 14, 42, 83, 121, 122, 133, 137, 147
 Blood vessel, 87, 121, 122, 123, 132, 136, 147, 148, 150
 Body Burden, 121, 141
 Bone Marrow, 99, 121, 130, 135
 Buccal, 93, 95, 121
- C**
- Calcium, 14, 121, 124, 127
 Carbohydrate, 121, 130
 Carbon Dioxide, 122, 127, 141, 150
 Carcinogen, 120, 122
 Carcinogenic, 16, 122, 134
 Carcinoma, 122
 Cardiopulmonary, 31, 122
 Cardiopulmonary Bypass, 31, 122
 Cardiovascular, 14, 102, 122
 Cardiovascular disease, 14, 102, 122
 Case report, 11, 12, 22, 35, 122
 Catalase, 22, 116, 122
 Cataract, 26, 48, 122
 Causal, 122, 132
 Cause of Death, 122, 127
 Cell Cycle, 74, 75, 122
 Cell Death, 75, 119, 122, 138
 Cell Division, 67, 74, 75, 87, 88, 120, 122, 123, 136, 137, 141
 Cell membrane, 46, 122, 131, 141
 Cell Respiration, 122, 137
 Cell Survival, 42, 122
 Centromere, 67, 70, 123
 Cerebral, 31, 41, 123, 136
 Cerebrospinal, 123, 146
 Cerebrospinal fluid, 123, 146
 Cerebrovascular, 122, 123
 Cerebrum, 123
 Chelation, 58, 123
 Chemotactic Factors, 123, 125
 Chemotherapeutic agent, 29, 123
 Chin, 27, 123, 137
 Cholelithiasis, 21, 33, 123
 Cholesterol, 66, 120, 123, 126, 135
 Cholesterol Esters, 123, 135
 Chromatin, 119, 123, 136
 Chromosomal, 75, 77, 78, 88, 89, 90, 92, 118, 123, 132, 138
 Chromosome Fragility, 123, 149
 Chronic, 12, 14, 31, 46, 48, 52, 59, 115, 123, 124, 133, 134, 135, 147
 Chylomicrons, 123, 135
 Cinchona, 123, 144
 Cirrhosis, 124, 131
 CIS, 124, 130
 Clinical Medicine, 46, 101, 124
 Clinical trial, 98, 99, 102, 105, 124, 140, 143
 Cloning, 121, 124
 Codeine, 124, 127
 Codon, 72, 124
 Coenzyme, 119, 124
 Cofactor, 124, 143
 Collagen, 124, 129
 Colon, 81, 124
 Colonoscopy, 83, 124
 Color blindness, 35, 124
 Complement, 58, 118, 124, 125, 131, 134, 136
 Complementary medicine, 54, 125
 Computational Biology, 105, 125
 Concentric, 125, 139
 Conception, 74, 125, 129, 147
 Confusion, 81, 125, 127, 150
 Congenita, 125, 144
 Conjugated, 16, 125, 126
 Conjugation, 39, 125
 Connective Tissue, 119, 121, 124, 126, 129
 Consciousness, 118, 126, 127
 Constriction, 67, 70, 126
 Consultation, 89, 90, 93, 94, 126
 Contamination, 19, 126, 132
 Contraindications, ii, 126
 Coronary, 122, 126
 Coronary heart disease, 122, 126
 Corpuscle, 126, 128
 Cyanide, 50, 126, 137
 Cysteine, 116, 126
 Cytochrome, 126, 140
 Cytomegalovirus, 16, 17, 30, 126
 Cytoplasm, 64, 65, 66, 72, 119, 122, 126, 128, 131, 136, 139, 145
 Cytosine, 65, 126, 144
 Cytotoxicity, 58, 126
- D**
- De novo, 75, 127
 Death Certificates, 83, 127
 Degenerative, 127, 132, 139
 Deletion, 77, 119, 127
 Dementia, 78, 127
 Demethylation, 34, 127

- Deoxyribonucleic, 65, 127, 145
 Deoxyribonucleic acid, 65, 127, 145
 Deoxyribonucleotides, 127
 Deuterium, 127, 133
 Dextromethorphan, 34, 127
 Diabetes Mellitus, 13, 25, 29, 127, 130, 131
 Digestion, 120, 127, 135, 147, 150
 Dihydrotestosterone, 127, 145
 Diploid, 118, 127, 138, 141, 149
 Direct, iii, 93, 94, 95, 124, 127, 144, 145
 Discrimination, 95, 96, 101, 127
 Disorientation, 125, 127
 Duodenum, 120, 127, 128, 147
 Dysmenorrhea, 127, 141
- E**
- Effector, 124, 127
 Electrolytes, 120, 127, 134
 Electrons, 119, 120, 128, 134, 140, 144
 Embryo, 74, 75, 76, 84, 117, 121, 128, 142
 Endemic, 18, 23, 30, 44, 128, 136, 147
 Endoscope, 128
 Endoscopic, 13, 124, 128, 133
 Endotoxins, 125, 128
 Environmental Health, 104, 105, 128
 Enzymatic, 121, 125, 128
 Epidemiological, 51, 128
 Erythrocyte Indices, 121, 128
 Erythrocyte Membrane, 41, 128
 Erythrocytes, 13, 15, 16, 17, 18, 19, 23, 34, 56, 57, 118, 120, 121, 128, 129, 132, 145
 Ethnic Groups, 24, 45, 89, 92, 128
 Eukaryotic Cells, 128, 139
 Excrete, 119, 128, 134
 Exhaustion, 128, 136
 Extracellular, 126, 128, 129, 147
 Extracellular Matrix, 126, 128, 129
 Eye Color, 76, 128
 Eye Infections, 117, 128
- F**
- Family Planning, 105, 129
 Fat, 121, 126, 129, 134, 135, 147
 Fathers, 84, 129
 Fatigue, 114, 129
 Favism, 23, 50, 54, 56, 57, 59, 129
 Febrile, 53, 129, 136
 Femoral, 122, 129
 Femoral Artery, 122, 129
 Fetus, 92, 93, 95, 99, 129, 142, 147, 150
 Fibroblasts, 20, 36, 129
 Fibrosis, 76, 79, 83, 84, 129, 146
 Fluorescence, 23, 129
 Follicles, 129
 Forearm, 121, 129
 Frameshift, 77, 129
 Frameshift Mutation, 77, 129
- G**
- Gallate, 58, 129
 Ganglia, 129, 138, 148
 Gas, 122, 129, 132, 138, 150, 151
 Gastrin, 129, 132
 Gene Expression, 72, 73, 129, 130
 Gene Products, rev, 129, 130
 Gene Therapy, 97, 98, 99, 100, 117, 130
 Genes, env, 83, 130
 Genetic testing, 86, 90, 91, 92, 93, 94, 95, 96, 101, 130
 Genomics, 102, 130
 Germ Cells, 75, 99, 130, 136, 139, 147
 Germline mutation, 30, 75, 130, 132
 Gland, 130, 140, 146, 148
 Glomerular, 130, 135, 145
 Glucose Intolerance, 127, 130
 Glutamate, 127, 130
 Glutathione Peroxidase, 22, 130, 146
 Glycosylation, 25, 130
 Governing Board, 130, 142
 Gram-negative, 131, 140
 Gram-positive, 131, 140
 Granule, 131, 145
 Granulocytes, 131, 135, 151
 Guanine, 65, 131, 144
- H**
- Haematological, 50, 131
 Haematology, 16, 44, 51, 52, 58, 59, 60, 131
 Haemolysis, 11, 17, 18, 19, 28, 29, 34, 36, 55, 58, 59, 60, 131
 Hair Color, 76, 131
 Hair follicles, 30, 131
 Half-Life, 131, 141
 Haploid, 131, 141
 Haplotypes, 12, 131
 Heart attack, 122, 131
 Hematocrit, 121, 128, 131
 Hemochromatosis, 92, 131
 Hemodialysis, 131, 135
 Hemoglobin, 22, 30, 43, 50, 51, 59, 61, 66, 114, 117, 118, 120, 121, 128, 131, 132, 146, 148
 Hemoglobinopathies, 62, 130, 132
 Hemolysis, 10, 11, 15, 19, 22, 29, 30, 31, 34, 41, 42, 46, 47, 55, 57, 58, 59, 115, 120, 128, 132
 Hemolytic, 10, 11, 12, 17, 18, 29, 36, 43, 48, 58, 114, 129, 132, 144, 148

- Hemophilia, 84, 132
 Hemorrhage, 132, 147
 Hepatitis, 30, 33, 48, 52, 53, 132, 150
 Hepatocytes, 132
 Hepatovirus, 132
 Hereditary, 62, 64, 65, 75, 84, 90, 130, 132, 145, 148
 Hereditary mutation, 75, 130, 132
 Heredity, 24, 25, 36, 38, 41, 42, 43, 67, 129, 130, 132
 Heterogeneity, 25, 28, 37, 38, 117, 132
 Heterozygote, 13, 40, 132
 Histones, 67, 123, 132
 Homologous, 117, 130, 132
 Hormone, 16, 72, 129, 132, 145, 148
 Hydrogen, 43, 56, 116, 120, 121, 122, 127, 130, 132, 133, 135, 137, 140, 143, 148
 Hydrogen Peroxide, 43, 56, 122, 130, 133, 135, 148
 Hydrophobic, 133, 135
 Hyperbilirubinemia, 11, 15, 29, 31, 39, 48, 49, 133, 134
 Hypertension, 122, 133
 Hyperthermia, 35, 133
 Hysteroscopy, 42, 133
- I**
- Immune response, 118, 133, 136, 148, 151
 Immune system, 133, 136, 150, 151
 Impairment, 120, 128, 133, 137, 143
 Implantation, 125, 133
 In situ, 133, 137
 In vitro, 20, 27, 36, 130, 133
 In vivo, 41, 130, 133
 Incubation, 36, 133
 Infancy, 102, 133
 Infection, 10, 16, 17, 30, 34, 121, 123, 126, 128, 133, 135, 138, 145, 147, 151
 Inflammation, 98, 119, 120, 128, 129, 132, 133, 142
 Informed Consent, 93, 96, 101, 133
 Infusion, 134, 149
 Ingestion, 55, 129, 134, 142
 Inhalation, 129, 134, 142
 Initiation, 134, 149
 Interferon, 52, 134
 Interferon-alpha, 52, 134
 Interstitial, 134, 145
 Intracellular, 133, 134, 142, 146
 Intravascular, 11, 34, 55, 134
 Ions, 120, 127, 132, 134
 Iris, 128, 134
 Isozymes, 134, 144
- J**
- Jaundice, 12, 14, 17, 25, 39, 40, 46, 47, 48, 49, 50, 114, 133, 134
- K**
- Karyotype, 69, 134
 Ketoacidosis, 17, 134
 Ketone Bodies, 134
 Ketosis, 30, 134
 Kidney Failure, 78, 134, 135
 Kidney Failure, Acute, 134, 135
 Kidney Failure, Chronic, 135
- L**
- Labile, 124, 135
 Lens, 122, 125, 135
 Lethal, 56, 126, 135
 Leucocyte, 35, 117, 135
 Leukemia, 130, 135
 Levorphanol, 127, 135
 Linkages, 131, 132, 135
 Lipid, 20, 119, 135, 140
 Lipid Peroxidation, 135, 140
 Lipoprotein, 48, 131, 135
 Liver, 73, 109, 116, 120, 124, 126, 127, 131, 132, 135, 145
 Localized, 133, 135, 141
 Locomotion, 135, 141
 Low-density lipoprotein, 135
 Lymphatic, 133, 135, 147
 Lymphatic system, 135, 147
 Lymphocytes, 119, 135, 136, 147, 151
 Lysine, 132, 136
- M**
- Macrophage, 75, 136
 Mafenide, 22, 136
 Major Histocompatibility Complex, 131, 136
 Malaria, 10, 18, 23, 24, 28, 30, 31, 41, 43, 44, 58, 60, 121, 124, 136
 Malaria, Falciparum, 121, 136
 Malaria, Vivax, 136
 Mammography, 83, 136
 Mania, 136
 Manic, 35, 136, 143
 Manic-depressive psychosis, 35, 136, 143
 Medical Records, 83, 96, 136
 MEDLINE, 105, 136
 Medullary, 127, 136
 Meiosis, 74, 136
 Melanocytes, 137
 Melanoma, 30, 137, 150
 Membrane, 22, 41, 65, 117, 122, 125, 128, 131, 137, 139, 141, 144, 145

- Memory, 127, 137
Mental, iv, 9, 35, 88, 90, 92, 104, 106, 123, 125, 127, 129, 136, 137, 143, 146, 150
Mental Retardation, 88, 90, 92, 137
Methylene Blue, 22, 137
Microbe, 137, 149
Microbiology, 116, 120, 137
Microorganism, 124, 137, 140, 151
Microspectrophotometry, 34, 137
Miscarriage, 95, 137
Mitochondria, 65, 66, 78, 84, 85, 137, 139
Mitosis, 74, 119, 137
Molecular, 11, 32, 36, 37, 38, 51, 52, 69, 71, 73, 105, 107, 121, 125, 137, 148
Molecule, 65, 66, 67, 72, 119, 120, 124, 125, 127, 132, 137, 140, 144, 150
Monitor, 32, 137, 139
Monophosphate, 36, 53, 137
Monosomy, 78, 118, 138
Morphological, 128, 137, 138
Morphology, 122, 131, 138
Mosaicism, 75, 138
Mucins, 138, 146
Mucolytic, 116, 138
Mutagen, 120, 138
Mutagenic, 16, 138
Myotonia, 138, 144
Myotonic Dystrophy, 87, 138, 149
- N**
Nausea, 134, 138, 150
NCI, 1, 103, 124, 138, 140
Necrosis, 119, 138
Neonatal, 12, 14, 15, 16, 23, 36, 38, 39, 40, 42, 44, 46, 47, 49, 50, 138
Neonatal period, 16, 138
Neonatal Screening, 14, 44, 138
Nervous System, 87, 129, 138, 148
Neuropathy, 84, 138
Neurotoxicity, 127, 138
Neurotransmitter, 116, 130, 138, 148
Neutrophil, 20, 41, 139
Nuclear, 65, 125, 128, 129, 138, 139
Nuclear Envelope, 65, 139
Nuclear Pore, 139
Nuclei, 125, 128, 130, 132, 137, 139, 143
Nucleic acid, 120, 126, 139, 144, 145
Nucleus, 65, 66, 67, 72, 78, 97, 100, 119, 123, 126, 127, 128, 136, 139, 143, 147
Nurse Practitioners, 93, 139
- O**
Ocular, 51, 139
Oliguria, 134, 135, 139
Opacity, 122, 139
Organelles, 64, 65, 126, 137, 139, 141
Osteoarthritis, 139, 141
Outpatient, 42, 139
Ovaries, 92, 139
Ovary, 139, 142
Overdose, 29, 139
Oxidation, 41, 116, 119, 126, 130, 135, 139, 140
Oxidative Phosphorylation, 66, 140
Oxidative Stress, 20, 140
Oxygenation, 31, 140
Oxygenator, 122, 140
- P**
Pancreas, 131, 140
Parasite, 140
Parasitic, 10, 140
Paternity, 92, 140
Pathogen, 133, 140
Pathologic, 25, 116, 119, 126, 133, 140
Pathologic Processes, 119, 140
PDQ, 103, 140
Pefloxacin, 42, 140
Pelvis, 116, 139, 140, 150
Peptide, 140, 142, 143
Peripheral blood, 134, 140
Peroxide, 20, 140
Phagocytosis, 60, 141
Pharmacologic, 131, 141, 149
Phosphogluconate Dehydrogenase, 56, 141
Phospholipids, 129, 135, 141
Phosphorus, 121, 141
Phosphorylation, 66, 141, 144
Phototherapy, 39, 43, 141
Physical Examination, 90, 141
Physiologic, 131, 141, 142, 144
Pigment, 120, 137, 141
Pilot study, 47, 141
Piroxicam, 42, 141
Plants, 117, 122, 130, 138, 141, 142, 149
Plasma, 65, 118, 122, 123, 130, 131, 134, 141
Plastids, 139, 141
Plumbism, 57, 141
Pneumonia, 35, 126, 142
Poisoning, 34, 137, 138, 142, 148
Pollen, 129, 142
Polymorphic, 13, 142
Polymorphism, 34, 45, 94, 142
Polypeptide, 124, 142, 148
Postoperative, 141, 142

- Potential, 43, 142
Practice Guidelines, 106, 142
Prenatal, 92, 95, 128, 142
Prevalence, 9, 12, 13, 30, 33, 43, 44, 47, 51, 59, 80, 142
Progeny, 125, 142
Progression, 118, 142
Progressive, 79, 124, 127, 135, 138, 139, 142, 145
Prone, 30, 78, 87, 142
Prostaglandin, 142
Protease, 14, 53, 143
Proteolytic, 117, 125, 143
Protocol, 98, 143
Protons, 132, 143, 144
Protozoa, 125, 137, 143
Protozoan, 136, 143
Proxy, 57, 143
Psychiatric, 26, 143
Psychiatry, 26, 35, 143
Psychic, 137, 143
Psychosis, 143
Public Health, 16, 35, 40, 44, 52, 58, 59, 106, 120, 143
Public Policy, 105, 143
Pulmonary, 13, 121, 134, 144
Pulmonary Artery, 121, 144
Pulmonary Edema, 13, 134, 144
Purines, 120, 144
Pyrimidines, 120, 144
Pyruvate Kinase, 24, 144
- Q**
Quinine, 15, 124, 144
- R**
Race, 134, 144
Radiation, 116, 129, 133, 144, 150, 151
Radiation therapy, 116, 144
Radioactive, 121, 131, 133, 139, 144
Reactive Oxygen Species, 144
Receptor, 81, 116, 119, 127, 144
Recombinant, 98, 144, 150
Recombination, 125, 130, 145
Rectum, 119, 124, 129, 145
Recurrence, 136, 145
Red blood cells, 128, 132, 145
Reductase, 24, 145
Refer, 1, 70, 74, 76, 81, 100, 121, 124, 135, 143, 145, 146
Remission, 136, 145
Renal failure, 19, 145
Reproductive cells, 78, 88, 89, 130, 132, 145
Retina, 135, 145
Retinoblastoma, 80, 145
Retroviral vector, 130, 145
Rheumatoid, 141, 145
Rheumatoid arthritis, 141, 145
Ribavirin, 52, 145
Riboflavin, 54, 57, 145
Ribonucleic acid, 72, 145
Ribose, 116, 145
Ribosome, 72, 145, 149
Rigidity, 141, 145
Risk factor, 14, 145
Rural Population, 10, 146
- S**
Salicylate, 146
Salicylic, 146
Salicylic Acids, 146
Saliva, 52, 146
Salivary, 126, 146
Salivary glands, 126, 146
Scatter, 146, 150
Schizophrenia, 85, 146
Sclerosis, 81, 146
Secretion, 53, 138, 146, 150
Selenium, 31, 146
Sequencing, 100, 146
Serum, 23, 48, 115, 118, 124, 135, 146
Sex Distribution, 40, 146
Shunt, 36, 53, 146
Sickle Cell Trait, 14, 23, 47, 146
Side effect, 99, 102, 117, 141, 146, 148, 149
Signs and Symptoms, 86, 87, 92, 145, 146
Small intestine, 123, 127, 132, 146
Social Work, 89, 146
Sodium, 127, 144, 146
Soft tissue, 121, 147
Soma, 147
Somatic, 75, 78, 89, 136, 137, 147
Somatic cells, 75, 78, 89, 136, 137, 147
Somatic mutations, 78, 147
Specialist, 93, 111, 147
Species, 102, 134, 136, 137, 140, 144, 147, 148, 151
Spectrum, 140, 147
Sperm, 74, 75, 78, 87, 88, 89, 92, 99, 123, 130, 132, 142, 145, 147
Spinal cord, 123, 138, 147, 148
Spleen, 113, 126, 135, 147
Sporadic, 60, 145, 147
Stillbirth, 90, 147
Stomach, 129, 132, 134, 138, 146, 147
Stool, 124, 147
Strand, 65, 147

- Stroke, 83, 104, 122, 147
 Subacute, 133, 147
 Subclinical, 133, 147
 Subspecies, 147, 148
 Substance P, 121, 146, 148
 Succimer, 58, 148
 Sulfadoxine, 9, 148
 Superoxide, 22, 148
 Superoxide Dismutase, 22, 148
 Supplementation, 54, 57, 148
 Supportive care, 140, 148
 Sympathectomy, 13, 148
 Sympathetic Nervous System, 148
 Systemic, 119, 121, 133, 140, 144, 148
- T**
 Terminator, 124, 148
 Testosterone, 145, 148
 Thalassemia, 21, 30, 41, 46, 61, 120, 148
 Thrombosis, 143, 147, 148
 Thyroid, 92, 148
 Thyroid Gland, 92, 148
 Thyroid Hormones, 148
 Tonicity, 132, 149
 Tooth Preparation, 116, 149
 Topical, 60, 133, 136, 149
 Toxic, iv, 22, 56, 64, 123, 125, 126, 138, 146, 149
 Toxicity, 20, 36, 98, 149
 Toxicology, 19, 29, 56, 57, 58, 105, 149
 Toxins, 57, 119, 128, 133, 149
 Trachea, 148, 149
 Transcription Factors, 73, 149
 Transfection, 121, 130, 149
 Transferases, 130, 149
 Transfusion, 41, 149
 Translation, 72, 73, 130, 149
 Trinucleotide Repeat Expansion, 87, 149
 Trinucleotide Repeats, 149
 Trisomy, 78, 118, 149
 Tungsten, 137, 149
 Typhoid fever, 16, 52, 149
- U**
 Ultraviolet radiation, 75, 150
 Uracil, 144, 150
 Uremia, 134, 145, 150
 Urethra, 150
 Uridine Diphosphate, 51, 150
 Urinary, 53, 139, 140, 148, 150
 Urinary tract, 140, 148, 150
 Urinary tract infection, 140, 150
 Urine, 113, 119, 121, 134, 135, 139, 145, 150
 Uterus, 92, 133, 139, 150
- V**
 Vaccine, 143, 150
 Vacuoles, 139, 150
 Vascular, 133, 148, 150
 Vector, 97, 98, 150
 Vein, 139, 150
 Venous, 121, 143, 150
 Venous blood, 121, 150
 Venules, 121, 150
 Veterinary Medicine, 105, 150
 Viral, 11, 33, 53, 97, 116, 129, 130, 150
 Viral Hepatitis, 11, 33, 150
 Virulence, 149, 151
 Virus, 97, 134, 145, 150, 151
 Viscera, 147, 151
 Viscosity, 116, 151
 Vitro, 38, 92, 151
 Vivo, 20, 151
- W**
 White blood cell, 75, 118, 135, 136, 139, 151
 Windpipe, 148, 151
 Womb, 150, 151
- X**
 Xenograft, 118, 151
 Xenon, 137, 151
 X-ray, 129, 138, 139, 144, 151
- Z**
 Zygote, 125, 138, 151